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Abstract 
Introduction: Ovarian cancer is one of the most lethal gynaecological cancers in the 
developed world. Development of chemoresistance to platinum-based drugs is a key 
factor for the high morbidity seen in this malignancy. Epithelial ovarian cancer 
(EOC) is the most common form of ovarian cancer, with high-grade serous cancer 
(HGSC) accounting for up to 75% of EOC. The β-subunit of human chorionic 
gonadotropin (hCGβ) is elevated in a number of epithelial cancers, including ovarian 
cancer, and is often associated with aggressive and metastatic disease with poor 
clinical outcomes. Studies have shown evidence of the biological activity of hCGβ in 
epithelial cancer including proliferation, apoptosis, and migration. The level of 
hCGβ has also been shown to be associated in chemoresistance in small-cell lung 
cancer patients.  
Aims and Methods: The aim of this thesis was to investigate the role of hCGβ in 
modulating oncogenic functions and drug resistance in HGSC cell line models. The 
expression levels of the genes encoding hCGβ, CGB, and secreted hCGβ were 
determined by qRT-PCR and ELISA, respectively, in a panel of eight HGSC cell 
lines: A2780, A2780cis, CaOV-3, HEY, OVCAR-3, OV202, PEO-1 and SKOV-3. 
hCGβ was downregulated with two siRNAs or overexpressed using an expression 
plasmid vector in order to determine its role in cell proliferation, migration, adhesion 
and response to platinum-based drugs. The quantitative proteomic technique, 
isobaric tags for relative and absolute quantitation (iTRAQ), was employed to 
determine the mechanism by which hCGβ might be involved in the response of 
HGSC cells to cisplatin. A selected number of proteins found to be dysregulated 
were validated by western blotting. 
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Results and Discussion: All eight HGSC cell lines expressed CGB transcript(s) and 
secreted hCGβ, with SKOV-3 and HEY cells being the highest expressers. HEY 
cells and the pair of cisplatin sensitive/resistant cell lines, A2780 and A2780cis, were 
chosen for functional studies. The effect of hCGβ on cell proliferation was cell type 
dependent, as downregulation of hCGβ significantly decreased proliferation of 
A2780cis and HEY cells, but its effect on A2780 cells seemed to be dependent on 
the siRNA used to downregulate hCGβ. This suggested that the two siRNAs 
targeting hCGβ may have some differences in their actions. Overexpression of hCGβ 
had no effect on proliferation in any cell line, suggesting that a threshold level may 
be reached beyond which hCGβ had no effect. Downregulation of hCGβ increased 
cell adhesion of HEY and A2780cis cells on the various extracellular matrix (ECM) 
proteins, which suggested that hCGβ may be inhibitory to cell adhesion. Cell 
migration was not influenced by hCGβ. 
hCGβ may have a role in the response of HGSC cells to cisplatin, as 
downregulation of hCGβ in A2780cis and HEY cells increased sensitivity to 
cisplatin; however, this effect was not seen in the cisplatin sensitive A2780 cells. 
This suggested that hCGβ may be involved in the response of HGSC cells towards 
cisplatin but only when cells have acquired resistance to cisplatin. An increase in 
drug sensitivity was also observed when cells were treated with carboplatin and 
oxaliplatin, particularly in A2780cis cells. This was not surprising for carboplatin 
which is thought to have a similar mode of action to cisplatin, but unexpected for 
oxaliplatin as it is thought to have a different mode of action. These results suggested 
that hCGβ may be involved in a common mechanism of action for all three drugs.  
iTRAQ and pathway analysis revealed a number of proteins and pathways that 
were differentially regulated when cells were treated with cisplatin following hCGβ 
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downregulation, compared to cisplatin treatment alone. Validation by western 
blotting revealed that the wings apart-like homolog (WAPAL) and sirtuin 1 (SIRT1) 
proteins were both downregulated when cells were treated with cisplatin following 
hCGβ downregulation compared to cisplatin treatment alone; however, this effect 
was dependent on the siRNA used to target hCGβ, indicating that the two siRNAs 
worked by different mechanisms to confer cisplatin sensitivity. A compensatory 
upregulation of the highly homologous LHB gene (encoding the β-subunit of 
luteinising hormone) by one siRNA but not the other provided a plausible 
explanation as to why the two siRNAs had some different effects. Interestingly, one 
of the siRNAs decreased the level of SIRT1 independent of cisplatin treatment, 
suggesting that SIRT1 could be a secondary target of the siRNA and therefore be a 
contributing factor to the increased sensitivity to drug treatment. Downregulation of 
SIRT1 increased cisplatin sensitivity in A2780cis cells but not HEY cells. From this 
result it can be inferred that the increased sensitivity toward cisplatin following 
downregulation of hCGβ was not caused by a decrease in SIRT1 alone.  
Conclusion: This study has demonstrated that hCGβ is potentially involved in cell 
proliferation, adhesion and response to platinum-based drugs in HGSC cells. 
However, further work on the mechanism by which hCGβ regulates cellular 
responsiveness to platinum-based drugs would be needed with the view to 
establishing a targeted therapeutic approach that could have future implications on 
how chemoresistance is managed in ovarian cancer.  
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 Literature Review Chapter 1
 
1.1 Ovarian cancer  
Ovarian cancer is one of the most lethal gynaecological cancers in the developed 
world, and accounts for half of the gynaecological cancer-related deaths of women in 
Australia [1, 2]. The lack of specific symptoms, poor diagnostic methods, diagnosis 
at an advanced stage and development of drug resistance are key factors for the high 
morbidity seen in this malignancy. Ovarian cancer is predominantly diagnosed in 
postmenopausal women with 60% of new diagnoses being in patients 60 years and 
over. Of all ovarian cancer diagnosis, 3-17% are in women aged 40 years and under  
[3]. Within the first 5 years of diagnosis, the survival rate for older women is 
significantly lower than for women diagnosed at 30 years of age or younger [2]. The 
survival rates of patients with ovarian cancer is also linked to the stage of diagnosis 
with 80-90% cure rates for patients with stage I cancer (when the malignancy is 
confined to the ovaries) dropping to 20-30% when patients are diagnosed at an 
advanced stage (III and IV, when the tumour(s) have metastasised beyond the pelvis) 
[4-8]. Unfortunately, only 20-25% of ovarian cancers are detected at stage I [5, 8]. 
 
1.1.1 Familial risk factors 
Between 5 to 15% of ovarian cancers are considered to be caused by hereditary 
germline mutations [8, 9]. Women with a family history of breast and ovarian 
cancer, in particular first degree relatives, have a higher risk of developing ovarian 
cancer [6, 10, 11]. Among the best studied hereditary risk factors contributing to 
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ovarian cancer are germline mutations in the breast cancer type 1 and 2 genes 
(BRCA1 and BRCA2) [10-13]. The lifetime risk of ovarian cancer in the general 
population jumps from 1.8% to 30–65% and 15-30% in carriers of the BRCA1 and 
BRCA2 mutations, respectively [8, 14-16]. Interestingly, the two genes also seem to 
have differential levels of risk based on age, with women carrying BRCA1 mutations 
presenting with disease predominantly before 50 years of age and BRCA2 mutation 
carriers after 50 years [16, 17]. Bilateral prophylactic oophorectomy is a preventative 
procedure chosen by some women who are carriers of a BRCA1 or BRCA2 mutation 
[18, 19].  
Mutations in mismatch repair genes MLH1 and MSH2 which are linked to 
hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome) have also 
been associated with an increased risk (up to 7%) of developing ovarian cancer [8, 
20, 21]. 
 
1.1.2 Protective factors 
The use of oral contraception has been shown to play a protective role in the 
development of ovarian cancer [22, 23]. Studies have also shown that the longer the 
duration of use of the oral contraceptive, the better the protective outcome. In 
addition, oral contraception has been shown to have a long term protective effect 
against ovarian cancer, even after the cessation of use, but only up to 20 years since 
the last use [24-27]. The use of oral contraceptives has also been found to have a 
protective effect in women who are carriers of BRCA1/2 germline mutations who are 
at increased risk of developing ovarian cancer as discussed in section (1.1.1) [28]. 
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Parity (child birth) has been shown to have an inverse effect on the risk of 
developing ovarian cancer [29-32]. 
The protective role of oral contraception and parity supports two theories about 
the development of ovarian cancer: the incessant ovulation theory and the 
gonadotropin theory [33-35]. These two theories will be further discussed in section 
1.2.  
 
1.1.3 Symptoms 
Ovarian cancer has been referred to as the ‘silent killer’ as the disease is 
asymptomatic or symptoms may only occur at an advanced stage of disease [36]. 
However, symptoms can arise at earlier stages of the disease but are often ignored or 
misdiagnosed [37]. These symptoms include abdominal distention, pelvic and 
abdominal pain and fatigue but since these symptoms are non-specific to ovarian 
cancer, the disease can be dismissed or misdiagnosed [38].  
 
1.1.4 Detection 
Ovarian cancer can be detected and diagnosed by transvaginal ultrasound and 
determining the level of serum biomarker CA-125. CA-125 is elevated in 50% of 
patients with stage I ovarian cancer and up to 90% in patients with an advanced stage 
of disease [6]. Though CA-125 has been used for several decades as a biomarker for 
ovarian cancer it has a number of drawbacks:  1. high levels of CA-125 can be 
detected in early pregnancy, during the menstrual cycle and in benign conditions 
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such as endometriosis [39, 40]; 2. elevated levels of CA-125 have also been shown 
in other cancers such as breast [41], gastric [42] and non-Hodgkin lymphoma (NHL) 
[43]; and, 3. twenty percent of ovarian cancer tumours do not express CA-125 [44]. 
CA-125 however has been shown to be a valuable biomarker in monitoring the 
progress of ovarian cancer during treatment and follow-up of recurrent disease [45-
47].  
Alternate or additional biomarker(s) for the detection of ovarian malignancies 
have been studied and one such marker that has been extensively investigated is the 
human epididymis secretory protein 4 (HE4). HE4 has been shown to be superior to 
CA-125 as it is able to better distinguish between benign and malignant pelvic 
masses and can detect malignancies at stage I of the disease [48, 49] which is 
thought to be  due to HE4 being released earlier than CA-125 [50]. The combination 
of HE4 and CA-125 has been shown to be more specific at distinguishing between 
malignant and benign tumours compared to either biomarker alone, leading to the 
development of the Risk of Ovarian Malignancy Algorithm (ROMA) [48, 49]. 
ROMA incorporates HE4 and CA-125 as well as menopausal status, to determine the 
likelihood of finding malignant abnormalities [51, 52].  Although HE4 or ROMA 
has had promising results, studies have also shown it does not outperform CA-125 as 
a predictor of ovarian cancer [53].   
OVA1 is an assay approved by the FDA in 2009 for pre-surgical prediction of 
pelvic malignancies. OVA1 is a multivariate index assay encompassing five 
biomarkers: CA-125, 2-microglobulin, apolipoprotein A1, transthyretin, and 
transferrin [54]. It has been shown to be more sensitive and effective at detecting 
advanced and early stage malignancies in both pre- and postmenopausal women 
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compared to CA-125 alone [55]. Studies have also shown that OVA1 is capable of 
detecting malignancies (up to 76%) missed by standalone CA-125 assay [56]. 
 
1.1.5 Staging 
The Federation of International Gynaecology and Obstetrics (FIGO) staging 
system which is based on surgical and pathological observations is the most 
commonly used staging system, established in 1988 (Rio de Janeiro). Since its 
establishment, FIGO has undergone revision, with the current version, outlined in 
Table 1-1, approved in 2012 [57, 58]. 
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Table 1-1 FIGO nomenclature for ovarian carcinomas 
Stage Description 
Stage I Tumour confined to ovaries or fallopian tube(s) 
IA: Tumour limited to one ovary (capsule intact) or fallopian tube; no 
tumour on ovarian or fallopian tube surface; no malignant cells in the 
ascites or peritoneal washings. 
IB: Tumour limited to both ovaries (capsules intact) and fallopian 
tubes; no tumour on ovarian or fallopian tube surface; no malignant 
cells in the ascites or peritoneal washings. 
IC: Tumour limited to one or both ovaries or fallopian tubes, with any 
of the following: 
IC1: Surgical spill 
IC2: Capsule ruptured before surgery or tumour on ovarian or 
fallopian tube surface. 
IC3: Malignant cells in the ascites or peritoneal washings. 
 
Stage II Tumour involves one or both ovaries or fallopian tubes with pelvic extension 
(below pelvic brim) or primary peritoneal cancer 
IIA: Extension and/or implants on uterus and/or fallopian tubes 
and/or ovaries. 
IIB: Extension to other pelvic intraperitoneal tissues. 
 
Stage III Tumour involves one or both ovaries or fallopian tubes, or primary peritoneal 
cancer, with cytologically or histologically confirmed spread to the 
peritoneum outside the pelvis and/or metastasis to the retroperitoneal lymph 
nodes 
IIIA1: Positive retroperitoneal lymph nodes only (pathologically 
proven): 
IIIA1(i) Metastasis up to 10 mm in greatest dimension. 
IIIA1(ii) Metastasis >10 mm in greatest dimension. 
IIIA2: Microscopic extrapelvic (above the pelvic brim) peritoneal 
involvement with or without positive retroperitoneal lymph nodes. 
IIIB: Macroscopic peritoneal metastasis beyond the pelvis up to 2 cm 
in greatest dimension, with or without metastasis to the 
retroperitoneal lymph nodes. 
IIIC: Macroscopic peritoneal metastasis beyond the pelvis more than 
2 cm in greatest dimension, with or without metastasis to the 
retroperitoneal lymph nodes (includes extension of tumor to capsule 
of liver and spleen without parenchymal involvement of either organ). 
 
Stage IV Distant metastasis excluding peritoneal metastases 
Stage IVA: Pleural effusion with positive cytology. 
Stage IVB: Parenchymal metastases and metastases to extra-
abdominal organs (including inguinal lymph nodes and lymph nodes 
outside of the abdominal cavity). 
Table extracted and adapted from [57, 58] 
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1.1.6 Histological subtypes 
Ninety percent of ovarian cancers are malignant epithelial cancers (EOC) and 
there are five distinguished histological types: high-grade serous ovarian carcinoma 
(HGSC), endometrioid carcinoma (EC), clear-cell carcinoma (CCC), mucinous 
carcinoma (MC), and low-grade serous carcinoma (LGSC). Characteristics of the 
histological subtypes are outlined in Table 1-2. 
  
Chapter 1 
8 
 
Table 1-2 Characteristics of histological subtypes of ovarian cancer 
Classification Incidence Characteristics 
high-grade 
serous carcinoma  
(HGSC) 
60-80% [59] HGSC are the most common and aggressive of 
ovarian cancers accounting for more than two 
thirds of EOC cases and are thought to 
originate from precursor lesions from the 
fimbria of the fallopian tube [60, 61]. Up to 
80% of HGSC present at an advanced stage 
and respond to conventional chemotherapy 
[58, 60]. Though these tumours are generally 
initially responsive to chemotherapy, they 
develop drug resistance resulting in poor 
patient survival outcomes [62].  
low-grade serous 
carcinoma 
(LGSC) 
<5% [60, 63] LGSC are thought to originate from serous or 
adenofibroma cystadenoma [64] and 
borderline tumours as well as the fallopian 
tube [65, 66]. They are often resistant to 
platinum-taxane based chemotherapy [67, 68]. 
mucinous 
carcinoma (MC) 
3% [60, 63, 65] MC consists of a mix of borderline, non-
invasive or invasive carcinomas as well as 
cystadenomas [69]. 80% of MC are 
cystadenomas with low proliferative potential 
[69]. The origin of MC is still under 
speculation and mostly unknown and is 
thought to arise from metastatic 
gastrointestinal tumours [60, 65, 70, 71]. 
endometrioid 
carcinoma (EC) 
10% [60, 63] 
 
EC are thought to arise from atypical 
endometriosis or endometriotic cysts [60, 72, 
73].   
clear-cell 
carcinoma 
(CCC) 
10% [60, 63] 
 
CCC are thought to rise from atypical 
endometriosis or endometriotic cysts [60, 72] 
and do not respond well to platinum-taxane 
based chemotherapy [74, 75]. 
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1.1.7 Aetiology 
Ovarian cancer is a complex disease and the underlying molecular events 
involved in tumorigenesis of the cancer are poorly understood.  However, some of 
the molecular events or pathways that are known to be implicated in the 
development of the different histological subtypes of ovarian cancer are summarised 
in Table 1-3 and are discussed further in this section.  
 
Table 1-3 Dysregulated molecular pathways in the different histological 
subtypes of ovarian cancer 
Histological subtypes Molecular pathway   Reference 
High-grade serous 
carcinoma (HGSC)  
Mutations in TP53 and BRCA1/2 and 
hypermethylation of BRCA1   
[14, 62, 76-
78] 
 
Low-grade serous 
carcinoma (LGSC) 
 
Mutations in BRAF and KRAS  [8, 79, 80] 
 
Mucinous carcinoma  (MC) Mutations in BRAF and KRAS [8, 80, 81] 
 
Endometrioid carcinoma 
(EC) 
Mutations in PTEN, PIK3CA, BRAF, 
KRAS and ARID1A 
[65, 77, 82, 
83] 
 
Clear-Cell carcinoma 
(CCC) 
Mutations in PTEN, PIK3CA and 
ARID1A  
[8, 84] 
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1.1.7.1 TP53 
TP53 is the most common and well-studied tumour suppressor gene in ovarian 
cancer [85] and mutations in TP53 occur in up to 96% of  HGSC [62, 76] but are less 
frequent in the other four histological subtypes [77, 84]. TP53 mutations are also 
more frequent at a later stage of tumour progression, with mutations more prevalent 
in stages III and IV (58%) compared to I and II (27%) which could suggest that 
TP53 mutations occur at a later stage of cancer development [86].  Contrary to this 
notion, the fact that TP53 mutations have been identified in low stage HGSC [86-
88], and in precursor lesions [66, 89] suggests that TP53 mutations may be an early 
event in the development of HGSC.  
 
1.1.7.2 KRAS and BRAF 
Activating mutations in KRAS and BRAF which code for the V-Ki-ras2 Kirsten 
rat sarcoma viral oncogene homolog (KRAS) and proto-oncogene B-RAF (BRAF) 
proteins, respectively, are commonly found in mucinous, endometrioid and LGSC 
compared to HGSC [64, 81, 90, 91]. KRAS and BRAF are upstream regulators of 
mitogen-activated protein kinase (MAPK) and mutations in KRAS and BRAF result 
in constitutive activation of the MAPK pathway [77]. Interestingly, the two 
mutations are mutually exclusive with tumours carrying either a KRAS or a BRAF 
mutation [79].  
 
1.1.7.3 Phosphotidylinositol 3-kinase (PI3-kinase)/AKT pathway 
The phosphatidylinositol 3-kinase (PI3K)/AKT pathway which is involved in a 
number of cellular processes including survival, apoptosis, cell cycle arrest and DNA 
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repair, has been found to be dysregulated in ovarian cancer [92, 93]. Phosphatase and 
tensin homolog (PTEN) is an antagonist of the PI3K pathway and inactivating 
mutations in the PTEN gene occur in 14–21% of endometrioid cancer [77]. Although 
PTEN mutations were initially associated with only endometrioid cancer [90], they 
have since been shown in other histological subtypes including HGSC [62, 76, 94] 
and mucinous cancer [95]. In addition to PTEN, other genes such as PIK3CA and 
AKT2 which are involved in the PI3K pathway have also been shown to be amplified 
in ovarian cancer [96, 97]. PIK3CA which codes for the human p110α subunit of 
PI3K  is amplified in 40% of ovarian cancer [97]. 
 
1.1.7.4 ARID1A 
Somatic mutations in AT-rich interactive domain1A gene (ARID1A) which codes 
for the BAF250a protein have been reported in almost 50% of clear cell carcinoma 
and 30% of endometrioid cancers [82]. BAF250a forms part of the SWI/SNF 
complex which is involved in chromatin remodelling and cellular processes such as 
proliferation, DNA repair and tumour suppression [98]. It is speculated that mutation 
in ARID1A and loss of BAF250a is an early event in the development of the cancer 
from endometriosis as they are detected in preneoplastic lesions [82]. In a study by 
Weigand et al. mutations in ARID1A were not present in HGSC tumours [82]. 
 
1.1.7.5 BRCA1/2 
As discussed in section 1.1.1 carriers of BRCA1/2 mutations have an increased 
risk of ovarian cancer. In addition to inactivating germline mutations, somatic 
mutations in BRCA1/2 have been identified in serous ovarian cancer [62, 76, 99-
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101]. Hypermethylation of the promoter region BRCA1 leading to loss of BRCA1 has 
also been documented in HGSC [62, 76]. 
 
1.2 Site of origin 
The site of origin for ovarian cancer is a controversial and evolving topic of 
research. A widely accepted, but highly disputed, theory is that epithelial ovarian 
cancers arise from the cells of the ovarian surface epithelium (OSE) or ovarian 
epithelial inclusions (OEI) [9, 59, 102]. An explanation behind this train of thought 
is explained by the incessant ovulation theory put forward by Fathalla which 
suggests that the constant rupture and repair of the OSE during ovulation predisposes 
the cells to malignant transformations [33]. In support of this theory, Schildkraut 
et al. found that high levels of TP53 mutations in ovarian cancer tumours were 
associated with higher number of ovulatory cycles [103]. Interestingly, the risk of 
ovarian cancer also seems to be associated with the number of ovulation cycles, 
particularly in women in their 20s [104, 105]. Furthermore, pregnancy and oral 
contraceptives which allows for a break in the ovulation cycle have been found to 
decrease the risk of ovarian cancer [30, 106]. Another theory which suggests that 
EOC cancer may develop from OSE is the gonadotropin hypothesis which suggests 
that high levels of pituitary gonadotropins during ovulation, in particular of follicle 
stimulating hormone (FSH) and luteinising hormone (LH), directly leads to 
malignant transformation of ovarian epithelium [107, 108]. In agreement with this 
theory factors such as multiple pregnancies, breast feeding and oral contraception 
which lead to a reduction of these hormones, seem to play a protective role in 
ovarian cancer [105, 106, 109].  Some studies have shown that fertility treatments 
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which increase the levels of FSH and LH also increase the risk of ovarian cancer  
[30, 110, 111]; however, subsequent studies have shown little or no link between 
fertility treatment and increased risk of ovarian cancer [1, 10, 106, 112].  
One of the main criticisms of the OSE being the site of origin of EOC is that 
EOC cells are morphologically distinct to OSE cells often displaying a Müllerian 
phenotype. This discrepancy has been explained by the suggestion that cells of the 
OSE differentiate into a Müllerian-like phenotype and invaginate into the stroma 
forming small OEI mesothelial cysts before metaplasia into EOC cells [59, 102, 
113].  A major criticism for this explanation is that intermediate precursor lesions 
have been rarely identified [59, 102].  
A more recent and increasingly accepted theory about the site of origin of EOC 
specifically for HGSC is that they arise from fallopian tube [65, 71, 114, 115]. In 
support of this theory samples from prophylactic salpingo-oophorectomy specimens 
from BRCA mutation carriers displayed high levels of dysplasia and early serous 
malignancies often referred to as serous tubal intraepithelial carcinomas (STICs) or 
tubal intraepithelial carcinoma or (TIC) at the fimbriated end of the fallopian tube 
[61, 89]. These precursor lesions contained abnormal immunohistochemical 
expression of p53 and TP53 mutations similar or identical to HGSC [59, 61, 116]. 
STICs also have upregulated levels of cyclin E1, Rsf-1 and fatty acid synthase which 
is also observed in HGSC [66]. Despite this evidence for the origin of serous ovarian 
cancer, a consensus of the origin of ovarian cancer has not been reached perhaps due 
to the diverse nature of the different histological subtypes. 
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1.2.1 Type I and II EOC 
EOC can be classified into two broad tumour groups based on morphological, 
immunohistochemical and molecular characteristics, and subsequent clinical 
presentations: Low-grade-Type I and high-grade-Type II [59, 71, 90, 117]. Type I 
cancers are composed of low-grade serous, mucinous, endometrioid or clear cell 
carcinomas and account for 25% of  EOC [71]. These cancers are often detected at 
an early stage, have a less aggressive growth and a low-malignant potential (LMP). 
They are however less likely to respond to, or are even resistant to, conventional 
platinum-taxane based chemotherapy [81]. Type I tumours are thought to develop 
from serous borderline tumours from OEIs or serous cystadenoma which develop 
into invasive carcinoma [59]. Type II cancers account for 75% of EOC and include 
high-grade serous and endometrioid cancers as well as undifferentiated carcinomas 
[66, 71]. These tumours are poorly differentiated, and are generally diagnosed at a 
late stage (III-IV) [118]. Type II tumours are more aggressive and genetically 
unstable, with greater gene copy number abnormalities compared to type I tumours; 
however, they do generally respond initially to conventional chemotherapy. Type I 
serous cancer have wild-type TP53 and BRCA1/BRCA2 and often present with 
mutations in BRAF, KRAS, PTEN, PIK3CA and ARID1A [66, 81, 119]. Type II in 
particular HGSC, almost always have a mutation in TP53 (up to 96%), and  can also 
have BRCA1 or BRCA2 mutations [76].  
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1.2.2 Clinical management  
The current treatment of ovarian cancer is primary cytoreductive surgery 
(surgical resection or debulking) to remove as much of the macroscopic tumour as 
possible, followed by adjuvant combination chemotherapy consisting of platinum-
based chemotherapeutic agents such as carboplatin, in combination with a taxane 
such as paclitaxel. Optimal cytoreduction has been linked to better patient survival 
[120]. Furthermore, in patients whose tumours cannot be completely removed, it is 
thought that cytoreduction improves the ability of chemotherapeutic agents to 
penetrate remaining tumour deposits. In some cases, neoadjuvant chemotherapy is 
employed before interval cytoreduction, when extensive metastasis has occurred 
and/or primary debulking is not possible due to poor health of the patient [118, 121]. 
However, studies have reported conflicting results of the benefit of neoadjuvant 
therapy over primary cytoreductive surgery; van der Burg et al. showed that 
neoadjuvant therapy was more beneficial [122] while others have shown patients are 
no better or even worse off with neoadjuvant therapy compared to primary 
cytoreduction [120, 123]. Despite the arguments for neoadjuvant or primary 
cytoreduction followed by adjuvant therapy, it is clear that optimal cytoreduction is a 
primary prognostic factor for overall patient survival [122, 123]. 
Genotyping patients either at germline or somatic levels has given rise to 
personalised treatment that is specific to a patient. One example is a new line of 
treatment that has been approved in patients who carry BRCA1/2 mutations. Tumour 
cells that carry these mutations are unable to repair double stranded breaks (DSBs) in 
the DNA by homologous recombination. The enzyme poly(ADP-ribose) polymerase 
is involved in the repair of single stranded breaks (SSBs) in DNA by excision repair.  
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PARP inhibitors prevent the repair of SSBs, thus leading to DSBs. In this case DSBs 
cannot be repaired by the mutant BRCA proteins, thus leading to synthetic lethality 
and subsequent cell death [124]. Following a Phase II study in platinum-sensitive 
relapsed HGSC patients, the FDA approved (in December 2014) the first PARP 
inhibitor Lynparza (olaparib) in patients with advanced disease carrying BRCA 
mutations. 
 
1.3 Human chorionic gonadotropin  
Human chorionic gonadotropin (hCG) is a gonadotropic hormone important in 
the maintenance of early pregnancy, in particular rescue of the corpus luteum which 
produces progesterone required for the maintenance of pregnancy. hCG is 
predominantly produced by the syncytiotrophoblasts of the placenta. Levels of 
hormone can be detected in the maternal serum 8-10 days after ovulation near the 
time of implantation of a fertilised egg. After 7 weeks of gestation, progesterone 
production by the placenta takes over the function of the corpus luteum [125]. 
Though the main function of hCG in pregnancy seems to be the rescue of the corpus 
luteum, there is increasing evidence that hCG may be involved in cellular 
differentiation and angiogenesis [126, 127].  Shi et al., proposed  that hCG may be 
involved in the differentiation of cytotrophoblast into syncytiotrophoblasts by 
showing that the addition of exogenous hCG to cytotrophoblasts in culture resulted 
in the cells beginning to merge into multinucleated cells and increased cadherin 
production which indicate differentiation into syncytiotrophoblasts [126].  Berndt 
et al. showed that exogenous hCG could be involved in endometrial angiogenesis 
which could also be important in pregnancy [127]. They found that hCG increased 
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proliferation of endothelial cells (HUVEC) and endometrial epithelial cells (EEC) 
(isolated from the endometrium of fertile women) as well as increased the VEGF 
production in EEC. In addition, the ex vivo aortic ring assay (with rat aortic rings 
cultured in collagen) and in vivo mouse matrigel plug assay also showed increased 
angiogenesis by increased microvessel outgrowth and haemoglobin respectively in 
the presence of exogenous hCG [127]. 
 
1.3.1 Structure of hCG 
hCG is a heterodimeric glycoprotein consisting of  non-covalently linked α- and 
β-subunits. It has a total molecular mass of 36 kDa composed of 237 amino acids, 
92 amino acids in the α-subunit and 145 amino acids in the β-subunit [128, 129].  
hCG belongs to the gonadotropin-glycoprotein family which includes FSH, LH and 
thyroid-stimulating hormone (TSH). Interestingly all four hormones share the same 
α-subunit but differ in their β-subunit resulting in different and specific biological 
roles [130]. Both the α- and β-subunits are required for hCG to interact with its 
extracellular receptor [131]; however, it is the β-subunit which is responsible for 
specific hormone activity [132]. FSH and TSH have specific cellular receptors; 
however LH and hCG interact with the same receptor known as the luteinising 
hormone/chorionic gonadotropin receptor (LHCGR) (Figure 1.1). The β-subunit of 
hCG (hCGβ) is highly homologous to the β-subunit of LH (LHβ), sharing 82% 
sequence homology. LHβ is composed of 121 amino acids whereas hCGβ has 145 
amino acids [133, 134]. The major difference between hCGβ and LHβ is the 
additional 24 amino acids at the carboxyl terminal of hCGβ [134]. The glycosylation 
sites within these extra amino acids are thought to contribute to the longer half-life 
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and higher biological potency of hCG compared to LH (hours compared to minutes) 
[133, 135-138].   
 
Figure 1.1 α- and β subunits of the gonadotropin-glycoprotein family 
The follicle stimulating hormone (FSH), luteinising hormone (LH), thyroid 
stimulating hormone (TSH) and human chorionic gonadotropin (hCG) share a 
common α-subunit but each has a unique β-subunit. FSH and TSH interact with 
different cellular receptors, FSHR and TSHR receptively, but LH and hCG share 
a common LHCGR receptor. 
 
Although LH and hCG bind to the same receptor, share a high sequence 
homology and promote progesterone production, they are important in different 
biological settings. LH, which is secreted from the anterior pituitary gland, is 
predominantly involved in the menstrual cycle regulating follicular maturation and 
induction of ovulation; whereas the main role of hCG is the maintenance of 
pregnancy [133].  
hCG is heavily glycosylated with 25–30% of the protein’s molecular weight 
composed of both N- and O-linked oligosaccharides [132, 139]. The α-subunit 
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contains two N-linked glycans whereas the β-subunit contains two N-linked glycans 
and four additional O-linked glycans. The position on the sugar residues is depicted 
in Figure 1.2. The degree of glycosylation has been found to not only affect protein 
stability but also the biological activity of the hormone [140, 141]. 
 
Figure 1.2  Amino acid sequence of hCG α-subunit and β-subunit 
Numbers indicate amino acid residue positions and N and O indicate the 
positions of N- and O-linked oligosaccharides. 
Image extracted from Cole[139] 
 
hCG also bears resemblances to the proteins of the cysteine knot family which 
includes transforming growth factor β (TGF-β), neuronal growth factor (NGF) and 
platelet-derived growth factor beta (PDGFB) due to the presence of cysteine knot 
disulphide bonds [132, 142]. The structural similarity of hCG to the cysteine knot 
family is thought to contribute to its biological activity which may be independent of 
the presence of the α-subunit and binding to LHCG receptor (for further discussion, 
see section 1.5). 
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1.3.2 Isoforms of hCGβ 
So far in this thesis, hCG has been discussed as a single molecule, however it 
occurs in at least four known physiological isoforms which include hCG, 
hyperglycosylated (h-hCG), free hCGβ and pituitary hCG [133, 143]. These different 
isoforms seem to have different functions which are summarised in Table 1-4. As 
this thesis will focus on hCGβ, its function will be discussed in detail in sections 1.4 
and 1.5. 
Table 1-4 Isoforms of human gonadotropin 
Isoform Produced  by Function 
hCG villous 
syncytiotrophoblast cells 
-Rescue of the corpus luteum and 
progesterone production [144, 145] 
-Maintenance of pregnancy [133, 
145, 146] 
-Foetal growth and development 
[146] 
-Angiogenesis of uterine vasculature 
[147-150] 
hyperglycosylated hCG 
(h-HCG) 
cytotrophoblast cells 
and choriocarcinoma 
cells  
-Normal function: 
Implantation of pregnancy e.g. 
invasion of cytotrophoblast/ 
trophoblast  [151, 152] 
 
-Choriocarcinoma: 
Antiapoptotic and growth of 
choriocarcinoma cells [153]   
free β-subunit non-trophoblastic 
malignancies 
-Proliferation, anti-apoptotic and 
migration [154-156]  
 
pituitary hCG 
 
anterior pituitary -Generally unknown role however 
like LH maybe be involved in the 
menstrual cycle [143] 
Table adapted from Cole et al. [143] 
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In addition to these isoforms, hCG can also be detected in a shorter 
proteolytically degraded form consisting of nicked-hCGβ and the core fragment of 
hCGβ (hCGβcf) which can be detected in the placenta, blood and urine [157]. 
 
1.3.3 Expression of hCG subunits 
The expression of the α- and β-subunits is thought to be controlled by different 
regulatory pathways due to imbalance of expression of the two subunits: specifically 
the α-subunit is found to be produced in excess compared to the β-subunit [158]. The 
α-subunit is encoded by a single gene located on chromosome 6q12-q21; however, 
the β-subunit of hCG (hCGβ) is encoded by multiple genes arranged in a gene 
cluster of six nonallelic genes located on chromosome 19q13.3 organised in tandem 
and inverted pairs along with the LHB gene which codes for the β-subunit of 
luteinising hormone (Figure 1.3) [130, 159]. These genes share 89-99% nucleotide 
sequence identity [160] and have been thought to have evolved from the ancestral 
LHB gene [161]. CGB1 and CGB2 are considered to be psueudogenes and though 
their gene transcripts have been detected in both the placenta [162] and pituitary 
[163] their function and protein product remains to be identified. 
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Figure 1.3 Gene cluster on chromosome 19q13.3 encoding the β-subunit of 
human chorionic gonadotropin  
CGB6/7 are type I genes coding for hCGβ with an arginine, methionine and 
alanine at positions 2, 4, and 117 respectively and CGB3/9, CGB5, and CGB8 
are type II genes coding for hCGβ with a lysine, proline and aspartic acid at 
positions 2, 4, and 117 respectively. CGB1 and CGB2 are pseudogenes.  
Image extracted and adapted from Jameson et al. [164]and Aldaz-Carroll [165] 
 
 
Two structurally different isoforms (types I and II) of hCGβ are expressed which 
differ in a single amino acid at position 117: type I hCGβ is encoded by CGB6/7 
(alleles) and has an alanine at position 117, and type II hCGβ  encoded by CGB3/9 
(alleles), CGB5, and CGB8 has an aspartic acid at this position. In addition to the 
difference in the amino acid at position 117, type I gene products have an arginine 
and methionine at positions 2 and 4, respectively whereas, type II gene products 
have a lysine and proline at positions 2 and 4 respectively (Figure 1.3) [165]. 
Expression of the two isoforms seems to be tissue-specific with type I genes 
expressed in normal nontrophoblastic tissues and type II genes expressed in the 
normal trophoblastic tissue and non-trophoblastic malignant tumours [166, 167]. 
Type I genes have also been shown to be expressed in renal cell carcinoma which is 
a non-trophoblastic tumour [168]. However it should be noted that a general tissue 
Chapter 1 
23 
 
specific pattern of gene expression cannot be made.  For example Dirnhofer et al. 
also found that CGB7, CGB5, CGB3, CGB8 and CGB1/2 were expressed in the 
pituitary [163]; and  Bo and Boime found that all six CGB genes were expressed in 
the placenta albeit at varying levels: CGB5> CGB3 = CGB8>CGB7, CGB1/2 [162].   
1.4 hCG and cancer 
Elevated expression of hCGβ is common in trophoblastic cancers and germline 
tumours and monitoring the levels of hCGβ as a biomarker for prognosis, relapse 
and therapeutic response has been well established in these cancers [134, 169-171]. 
hCGβ is expressed by a number of non-trophoblastic epithelial cancers e.g. in 
bladder [172, 173], cervical [174] and pancreatic [175] cancers and is often 
associated with aggressive disease and poor survival outcomes [134]. Interestingly, it 
is the monomeric β-subunit (hCGβ) and not the intact dimer which is predominantly 
expressed by epithelial cancers [134, 176]. Often the presence of hCGβ is a hallmark 
of aggressive and metastatic disease and is associated with poor clinical outcome 
[177, 178]. High hCGβ levels have also been associated with tumours which are 
resistant to radiotherapy [179] and chemotherapy [180]. Expression of hCGβ has 
been well documented in ovarian cancer and is summarised in (Table 1-5).    
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Table 1-5 Detection of hCG/hCGβ in serum, ascites or tumour tissue from 
ovarian cancer patients 
% Expression 
(cohort size) 
Detected 
in 
Comments 
33% (N=173) Serum Strong association between high levels of hCGβ 
and poor survival. Patients with high levels of 
hCGβ had poorer survival rates - 19% compared 
to 65% in patients with normal levels of hCGβ 
[181]. 
29% (N=146) Serum The frequency of hCGβ elevation correlated 
with the stage of disease with 12% in stage I and 
82% in stage IV [182]. 
100% (N=15) Tissue High levels of hCGβ transcript in ovarian cancer 
tissue compared to almost no expression in 
normal tissue [183]. 
41% (N=27) Serum 
and 
ascites 
The ratio of hCG/hCGβ levels was found to be 
elevated in serum and ascites fluids of patients 
with ovarian cancer [184].  
36% (N=73) Serum High levels of hCGβ correlated with poor 
survival outcome of patients [185].  
67% (N=123) 
68% (N=156) 
Serum  
Tissue 
Higher levels of hCG were detected in malignant 
tumours compared to benign tumours. In 
mucinous carcinomas expression of hCG was 
significantly higher at stage III compared to 
stage I  [186]. 
 
Survival studies have shown a negative correlation between high levels of hCGβ 
and survival in patients with ovarian cancer [181, 182]. In one study Vartiainen and 
colleagues showed that the frequency at which hCGβ was elevated in patients with 
ovarian cancer correlated with the stage of the disease and poor survival outcomes. 
They found that elevated hCGβ occurred at a frequency of 82% in patients with 
stage IV disease compared to 12% with stage I [182].  Another study also by 
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Vartiainen et al. found that the combination of hCGβ and p53 expression levels was 
a strong prognostic marker in patients with serous ovarian cancer (Figure 1.4). They 
found that the five-year survival for patients with either elevated serum hCGβ levels 
or aberrant p53 expression was 44% but only 14% in patients who had both elevated 
hCGβ levels as well as aberrant p53 expression. The five-year survival outcome for 
patients with normal hCGβ and p53 expression was 82% [181].  
 
Figure 1.4 Overall disease-specific survival in 167 patients with serous 
ovarian carcinoma in relation to serum hCGβ and p53 tissue expression 
Figure extracted from Vartiainen et al. [181] 
The value of hCGβ as a tracker of disease progression in ovarian cancer is not 
well established but Grossman et al. showed that the ratio of hCG/hCGβ correlated 
with tumour burden in a 47 year old patient with ovarian cancer who had undergone 
surgical invention as well as chemotherapy (Figure 1.5) [184]. 
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Figure 1.5 Serial expression of hCG/hCGβ serum concentration in a 47 year 
old woman with ovarian cancer 
During chemotherapy without clinical response (0-12 weeks) hCG/hCGβ levels 
were elevated. At 12 weeks when the tumour was surgically removed (arrow) 
levels dropped, followed by an increase as the tumour began to relapse.  
Figure extracted from Grossman et al. [184] 
 
1.5 Evidence to support biological activity of hCGβ 
Since the free β-subunit of hCG cannot interact with the LHCG receptor it was 
originally thought to have no functional biological role; however, a number of 
studies have shown evidence of its biological activity in epithelial cancer including 
proliferation, apoptosis and malignant transformation and this is further discussed in 
sections 1.5.1 to 1.5.4. 
 
1.5.1 hCGβ and cell proliferation 
Gillot et al. observed that exogenous hCGβ could promote proliferation of 
bladder cancer cell lines T24, SCaBER, RT112 and 5637 in a dose dependent 
manner shown by the tetrazolium salt reduction assay (MTT) [154]. T24 cells 
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produced the least amount of secreted hCGβ but showed the highest proliferative 
response to exogenous hCGβ. This group also showed that the proliferative effect of 
hCGβ could be reversed with the addition of anti-hCGβ anti-serum in a dose 
dependent manner and that the anti-serum could only inhibit cell growth in bladder 
cancer cell lines that produced endogenous hCGβ [154].  
 
1.5.2 hCGβ and cell apoptosis 
hCGβ has been shown to be involved in preventing apoptosis in some cancer cell 
lines [155, 187]. Janowaska et al. showed that downregulation of hCGβ in the 
cervical carcinoma cell line HeLa, caused an increase in the population of cells 
undergoing apoptosis (shown by cell cycle analysis) [187].  Butler et al. found more 
evidence in support of the anti-apoptotic role of hCGβ by showing that exogenous 
hCGβ reversed the apoptotic effects of TGF-β1 in a dose dependent manner in 
bladder cancer cell lines [155]. They proposed that due to the structural similarity 
between hCGβ and TGFβ (discussed in section 1.3.1), hCGβ may be competing with 
dimeric TGFβ for the TGFβ receptor. This is a plausible theory, given that it has 
been found that like some members of the cysteine knot family, hCGβ can form 
homo-dimers which are required for receptor interaction [188]. Therefore, even if 
hCGβ cannot interact with the LHCG receptor, it may be able to participate in 
cellular processes by binding an alternate receptor. 
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1.5.3 hCGβ and cell migration and invasion 
Wu et al. showed that overexpression of hCGβ in prostate carcinoma cell lines 
caused a change in cellular morphology which increased their migratory 
characteristics [156]. The cells’ morphology changed from rounded cells to more 
elongated shapes with increased cellular protrusions, decreased E-cadherin 
expression and increased migration and invasion through matrigel. A successive 
paper also from Wu and colleagues, showed that activation of ERK1/2 and 
subsequent upregulation of matrix metalloproteinase-2 (MMP-2) were the 
mechanism by which hCGβ induced invasion and migration in a prostate cell line 
model DU145 [189]. They also demonstrated that hCGβ could increase motility of 
the human glioblastoma cell line U87MG by the same mechanism [190]. 
 
1.5.4 hCGβ and malignant transformation 
Whether hCGβ is a driver of cancer progression or can actually transform normal 
cells into malignant cells was studied by Guo et al. [191]. This study showed that 
overexpression of hCGβ in OSE cells caused an increase in proliferation, anchorage 
independent growth and a decrease in apoptosis by mechanisms that increased pro-
survival proteins such as Bcl-XL, as well as a decrease in the pro-apoptotic protein 
phospho-Bad. They also found that xenografts of these transformed cells were 
tumorigenic in nude mice. 
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1.6 Platinum-based chemotherapeutics in ovarian cancer 
Cis-platinum(II) diammine dichloride (cisplatin) was the first platinum-based 
chemotherapeutic drug approved by the FDA in 1978. Though cisplatin has been a 
successful cytotoxic agent, it has a number of toxic side effects which include oto-, 
neuro- and nephrotoxicity. Cyclobutane-1,1-dicarboxylic acid platinum(II) 
(carboplatin) is a second generation platinum anti-cancer drug introduced in 1989 
and is more stable and has fewer side effects compared cisplatin [192, 193]. 
However, resistance and cross-resistance of cisplatin and carboplatin is common and 
has led to the development of a third generation of platinum-therapeutics, out of 
which, oxaliplatin has proven to be the most successful [192]. The chemical structure 
of cisplatin, carboplatin and oxaliplatin is depicted in Table 1-6. Despite their 
molecular differences, the primary target of platinum drugs is thought to be DNA, 
resulting in cytotoxicity (discussed in detail in section 1.6.2).  
The use of cisplatin in conjunction with cyclophosphamide and later paclitaxel 
showed that these combinations improved patient survival outcomes compared to 
cisplatin treatment alone [194, 195]. The cisplatin-paclitaxel combination was then 
replaced with carboplatin-paclitaxel combination and is now accepted as standard for 
the treatment of ovarian cancer, in particular advanced ovarian cancer [196].  
Interestingly, the International Collaborative Ovarian Neoplasm (ICON) 3 trial 
showed that the addition of paclitaxel did not improve the benefit of using 
carboplatin as a single agent treatment [197].  
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Table 1-6  Chemical structure of cisplatin, carboplatin and oxaliplatin 
Drug Structure 
Cisplatin 
(cis-dichlorodiammineplatinum(II)) 
 
Carboplatin  
(cis-diammine(1,1-
cyclobutanedicarboxylato)platinum(II)) 
 
Oxaliplatin 
 ([1R,2R]-1,2-cyclohexanediamine-N,N′)oxalate(2-)-
O,O′platinum(II)) 
 
Structures extracted from Turner and Mascorda [198] 
 
1.6.1 Uptake of platinum-based drugs 
Though cisplatin has been widely used for a number of decades, the actual 
mechanism by which it enters cells is yet to be fully understood. It was initially 
thought that the drug might enter cells through passive diffusion but the fact that the 
side effects (nephrotoxicity, ototoxicity) seem to be specific to certain cell types 
implies that there may be specific drug transporters, perhaps expressed by specific 
cell and/or tissue types responsible for cisplatin transport [199]. Furthermore, studies 
have found a link between lowered cisplatin accumulation and resistance which 
cannot be explained by mere diffusion of this drug [200]. Indeed, there is increasing 
literature that suggests that cisplatin is transported across cell membranes by active 
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means through membrane transporters. Some of the transporters include the copper 
transporters 1 and 2 (CTR1 and CTR2) [201, 202], the P-type copper-transporting 
ATPases (ATP7A and ATP7B) [203, 204], multidrug extrusion transporter 1 
(MATE1) [199] and the  multidrug resistance-associated protein  2 (MRP2) [205].  
 
1.6.2 Mechanism of action of platinum-based drugs 
Cisplatin, carboplatin and oxaliplatin are administered as prodrugs and are 
activated inside the cell by aquation (hydrolysis ), which is initiated by the low 
chloride environment [206]. Two water molecules replace two chloride ions, 
bidendate cyclobutanedicarboxylate and bidentate oxalate ions, on cisplatin, 
carboplatin and oxaliplatin respectively [198]. 
Hydrolysis of the drugs is important for their biological activity, as once they are 
aquated, the drugs become positively charged and can interact with nucleophilic 
DNA, RNA and proteins; but preferentially bind to the N-7 position on the imidazole 
ring of purines, guanosine and adenosine of DNA, forming monoadducts and intra-, 
inter- and DNA-protein cross links (Figure 1.6) [192, 207]. The DNA-adducts cause 
distortion of the DNA helix which leads to interference with DNA replication and 
transcription and subsequently leads to apoptosis [208-210]. 
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Figure 1.6 DNA-adducts formed by platinum-based chemotherapeutics 
Image extracted from Rabik and Dolan [192] 
 
About 90% of cisplatin-DNA adducts are 1,2- or 1,3-intrastrand cross links 
[206]. Carboplatin is thought to be therapeutically equivalent to cisplatin and forms 
similar DNA adducts to cisplatin which could explain their similar mechanism of 
action as well as cross-resistance [192, 211]. However, a higher concentration of 
carboplatin is required compared to cisplatin to produce equivalent anti-tumour 
effects due to the higher stability and lower DNA interaction of carboplatin [211]. 
Oxaliplatin is as potent (and sometimes more potent) as cisplatin. Despite having 
similar, but fewer DNA adducts, oxaliplatin causes the same number of DNA strand 
breaks as does cisplatin [212-214]. Oxaliplatin has a different mechanism of action 
and no reported cases of cross-resistance to cisplatin which is possibly due to the 
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difference in the way the DNA is distorted by its bulky 1,2-diaminocyclohexane 
(DACH) ring [214].  
It is thought that the 1,2-intra strand crosslinks caused by cisplatin is the major 
driver of apoptosis. It is believed that the High-Mobility Group Protein (HMGB) 
family are able to bind to these DNA-lesions, preventing DNA replication and 
transcription as well as preventing the lesions from being repaired, leading to the 
activation of pro-apoptotic signals [192, 215]. Apoptosis is also thought to be 
induced by activation of the endoplasmic reticulum (ER)-stress pathway. 
 
1.6.3 Platinum-Resistance 
The initial response rate to platinum therapy in patients with ovarian cancer is 
70-80%; however, development of resistance to the drug is common with patients 
relapsing within two years of initial treatment resulting in a 5-year patient survival 
rate of only 15–20% [216-219]. Resistance is multifactorial and includes drug 
inactivation, reduced drug accumulation, increased DNA repair and tolerance to 
DNA damage, as well as failure to induce apoptosis (Figure 1.7) [192, 219].  
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Figure 1.7 Mechanisms of platinum-based (cisplatin) drug resistance  
Platinum resistance, in particular to cisplatin (pt), is multifactorial involving a 
number of mechanisms. Cisplatin can either be exported out of the cells through 
efflux pumps, have reduced accumulation due to mutations or low expression of 
entry pumps/ transporters, and once inside the cells the drug can be inactivated 
by thiol containing proteins and the damaged DNA can be repaired and/or 
tolerated leading to failure to activate cisplatin-adduct induced apoptosis. 
 
1.6.3.1 Drug inactivation by thiol containing proteins 
Cisplatin has a tendency to react with thiol containing proteins forming insoluble 
sulphides and limiting its reactivity with DNA. Increased levels of thiol containing 
proteins/peptides, e.g. glutathione (GSH), metallothionein and thioredoxin, have 
been correlated with increased cisplatin resistance [192, 220-222]. Enzymes 
involved in the regulation of GSH levels such as gamma-glutamylcysteine 
synthetase and gamma-glutamyl transpeptidase have been shown to be upregulated 
in cisplatin-resistant ovarian cancer cell lines [223]. Ishikawa and Ali-Osman 
showed that in L1210 leukemia cells, cisplatin formed a complex with GSH which 
was subsequently expelled from the cells by the ATP-dependent glutathione 
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transporter pumps (GS-X pump), providing another perspective on how GSH and 
glutathione transporters may be associated with cisplatin resistance [224]. 
Interestingly, GSH has been shown to also reduce the toxic effects of cisplatin. In 
fact, one study found that administering GSH in conjunction with cisplatin in 
patients with ovarian cancer reduced the toxic effects of cisplatin and improved their 
overall quality of life; however, the effect of administered GSH on cisplatin 
sensitivity was not considered [225].  
 
1.6.3.2 Reduced drug accumulation 
Studies have shown a correlation between reduced sensitivity to cisplatin and 
reduced intracellular levels of cisplatin which could be due to reduced influx or 
increased efflux of the drug [226]. As previously mentioned (section 1.6.1), cisplatin 
transport into and out of the cell can be regulated through heavy metal transporters, 
e.g. the CTR 1/2 copper transporters [199]. It is therefore plausible that irregularities 
in these transporters could result in reduced drug accumulation and resistance to 
platinum compounds. A study by Larson et al. using an isogenic pair of CTR1(+/+) 
and CTR1(-/-) mouse embryonic fibroblasts showed that deletion of this copper 
transporter reduced intracellular accumulation of cisplatin and increased cell survival 
[202]. The same group also showed that increased exposure of CTR1 (+/+) fibroblast 
cells to cisplatin significantly reduced CTR1 expression. In addition, they showed 
that CTR1 (-/-) cells not only had reduced intracellular levels of cisplatin, but also 
less carboplatin and oxaliplatin; however, the effect on oxaliplatin levels was less 
than that of cisplatin. This result demonstrated that oxaliplatin was less dependent on 
the CTR1 transporter, suggesting that its mode of intracellular transport is different 
from that of cisplatin. These results were in agreement with Holzer et al. who 
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reported that CTR1(-/-) embryonic fibroblasts cells accumulated lower levels of 
cisplatin and carboplatin and were also less sensitive to the drugs compared to the 
wild-type CTR1 (+/+) cells. Interestingly, they showed that accumulation of 
oxaliplatin in CTR1(-/-) cells was also lower compared to CTR1 (+/+) cells but this 
was only evident at low concentration of oxaliplatin and not at high concentrations 
of the drug; suggestive of additional means by which oxaliplatin enters the cell 
[227]. Lee et al. showed that high expression of CTR1 in tumour tissue from patients 
with ovarian cancer was associated with higher sensitivity to platinum-based 
treatment and improved survival [228]. 
CTR2 like CTR1 is a copper transporter; however, its cellular distribution is 
different from CTR1. CTR1 is predominantly a plasma membrane protein whereas 
CTR2 is expressed in late endosomes and lysosomes, as well as on the plasma 
membrane [229, 230]. Interestingly, the links between CTR2 and CTR1 expression 
and cisplatin sensitivity are different. Lee et al. showed that patients with ovarian 
cancer who had low expression levels of CTR1 along with high expression levels of 
CTR2 were resistant to platinum-based therapy and had poor survival outcomes 
[228]. Furthermore, in vitro studies have shown that downregulation of CTR2 in 
mouse embryonic fibroblasts with either CTR1 (+/+) or CTR1 (-/-) showed increased 
sensitivity to cisplatin and carboplatin and drug accumulation independent of CTR1 
expression [201]. Blair et al. also showed in a panel of six ovarian carcinoma cell 
line models, a positive correlation between CTR2 expression and IC50 levels for 
cisplatin (indication of drug sensitivity) [201]. 
The copper-transporting P-type adenosine triphosphate proteins ATP7A and 
ATP7B which regulate copper efflux, are elevated in some ovarian cancers resulting 
in a negative correlation with cisplatin sensitivity [204, 220, 231]. Katano et al. 
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observed that the expression of either ATP7A or ATP7B was increased in cisplatin 
resistant (A2780/CP, 2008/C13*5.25, and IGROV-1/CP) cell lines compared to their 
cisplatin-sensitive parental line (A2780, 2008, and IGROV-1) and was associated 
with reduced intracellular cisplatin accumulation, formation of fewer DNA adducts 
and reduced sensitivity to cisplatin [203]. The ATP-binding cassette (ABC) 
transporters e.g. ABCB1 which codes for the multi-drug efflux pump MDR1 
P-glycoprotein (MDR1 or P-gp), has been associated with chemoresistance [232]. 
In vitro work by Yang et al. showed that the cisplatin-resistant ovarian cancer 
SKOV3/CIS cell line expressed low levels of MDR1 mRNA which they attributed to 
the increase in the levels of the micro RNA miR-130a [233]. Ren et al. on the other 
hand showed that MDR1 was not involved in cisplatin-resistance in cisplatin-
resistant A2780 cells [234].  Patch et al. reported that promoter fusion and 
translocation in the 5’ region of ABCB1 was observed in 8% of HGSC patient with 
recurrence, resulting in upregulation of MDR1; however, authors of this study 
attributed MDR1 expression to resistance to paclitaxel which was part of the 
combination treatment for HGSC [62]. Expression of another member of the ABC 
transporters which has also been implicated with cisplatin resistance in cell lines is 
the multidrug resistance protein 2 (MRP2, ABCC2) or the canalicular multiple 
organic anion transporter (cMOAT) [235, 236]. However, studies in patients with 
ovarian cancer, found that MRP2 expression was not associated with response to 
platinum-based chemotherapy, progress-free survival or overall survival time [237-
239]. Interestingly, MRP2 can be localised in the cytoplasmic or nuclear member 
and Surowiak et al. observed that cisplatin resistance in patients with ovarian 
carcinoma could be attributed its nuclear localisation [240]. 
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1.6.3.3 Defects in DNA damage repair, increased DNA repair and tolerance to 
DNA damage 
Platinum-resistant cancer cells have been shown to evade activation of pro-
apoptotic pathways by employing a number of different mechanisms to overcome 
DNA damage induced by platinum-based compounds. These mechanisms which 
include defects in the DNA damage repair pathways, increased DNA repair and 
tolerance to DNA damage are discussed further in this section. 
Formation of DNA adducts has been shown to lead to cell cycle arrest and in the 
case of cisplatin, this is thought to occur predominantly in the S and G2 phases of the 
cell cycle. This break in the cell cycle is thought to give cells a chance to repair DNA 
damage and prevent activation of the DNA-damage induced apoptosis pathway [241, 
242]. 
Mismatch repair (MMR) proteins are important mediators of DNA repair, cell 
cycle arrest and activation of apoptosis, failing repair of damaged DNA. MMR 
proteins are important in the recognition of cisplatin induced DNA adducts, and 
mutations or aberrations in expression levels of some of the genes/proteins 
associated with the MMR system have been linked to cisplatin resistance [208, 214, 
220, 241, 243]. For example, loss of MutS protein homologue 2 (MSH2) and MutL 
protein homologue 1 (MLH1), which are inducers of cisplatin-induced cell cycle 
arrest and apoptosis, have been associated with cisplatin resistance in ovarian cancer 
[220, 244, 245].  Interestingly, the lack of cross-resistance between cisplatin and 
oxaliplatin is proposed to be due to the MMR system not being able to recognise 
oxaliplatin-DNA adducts [246].  
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Nucleotide excision repair (NER) is another mechanism through which some 
cancers can repair cisplatin-DNA adducts and is an important determinant of 
cisplatin sensitivity. NER has also been implicated in the activation of apoptosis 
induced by cisplatin [242, 247]. Patients with ovarian cancer who are resistant to 
cisplatin have been shown to have elevated levels of the DNA repair genes XP 
complementation group (XPA, XPG) and excision repair cross-complementation 
group I (ERCCI) which are involved in NER [192, 248-252]. Saldivar et al. observed 
allelic variations of the XPA and XPG genes in ovarian tumours which were linked to 
a poor response to cisplatin treatment [253].  Elevated levels of the ERCC1 gene 
which encodes the excision repair cross-complementation group 1 (ECCR1) in 
tumour samples have been linked to clinical resistance or poor survival in a number 
of tumours including colorectal [254], non-small-cell lung [255], and ovarian cancer 
[252, 256, 257]. Steffensen et al. observed that expression levels of ECCR1 
negatively correlated with patient response to platinum-based therapy but also noted 
that it was not an indicator of patient survival in ovarian cancer [257]. Studies have 
also shown that single nucleotide polymorphisms in ECCR1 can be a predictor of 
how well patients with ovarian cancer respond to platinum-based chemotherapy, but 
is not a predictor of overall survival [258-260].   
Though the NER system has been shown to have a preferential affinity for the 
less common 1,3 intrastrand cross links compared to the more common 1,2 
intrastrand cross links formed by cisplatin, the 1,2 cross links seemed to be more 
rapidly repaired [261]. A plausible explanation for these conflicting observations is 
that trans-lesion DNA replication or repair of damaged DNA is facilitated by high 
mobility group proteins (e.g. HMGB1), which have an affinity for 1,2 intrastrand 
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cross links and induce MMR opposite the 1,2 intrastrand which in turn facilitates 
DNA repair by NER [261, 262].  
BRCA1/2 genes are often deregulated through somatic or germline mutations in 
EOC and are involved in homologous recombination DNA repair. BRCA1/2 
mutations in ovarian tumours have been linked to high sensitivity towards cisplatin 
[263]. However, even in BRCA1/2 mutant carriers, the occurrence of platinum 
resistance is common. Though PARP inhibitors have proven to be useful in this 
group of patients, reversion of BRCA2 to wild-type has been shown, leading to 
disease relapse and poor patient outcomes [62, 264, 265].  
Epigenetic changes which include DNA methylation, histone modification, and 
posttranslational gene regulation by micro-RNAs (miRNAs), which can regulate 
gene expression independent of DNA sequence, have been associated with platinum-
resistance [266, 267]. For example, studies have shown hypermethylation of 
promoter regions of the DNA damage repair proteins BRCA1 and MLH1, leading to 
the loss of expression of these genes, is associated with platinum-resistance ovarian 
cancer [62, 268-271]. 
Tolerance of cisplatin-DNA damage has been observed in cisplatin-resistant 
ovarian cancer cell lines compared to the parental cisplatin sensitive cell lines [221, 
272]. The theory behind DNA damage tolerance is that adducts formed by cisplatin 
can be bypassed by DNA replicative enzymes during DNA replication.  
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1.6.3.1 Failure of apoptotic pathway 
Apoptosis induced by DNA damage is central to the cytotoxic effects of 
platinum-based drugs. A network of pathways is involved in regulating apoptosis 
and interception of one, or more of these pathways can be a mechanism employed by 
cancer cells to evade cell death. Apoptosis can be triggered through the intrinsic or 
extrinsic pathway [273, 274]. The intrinsic pathway involves disruption of the 
mitochondrial membrane and an array of protein regulators such the B-cell 
lymphoma-2 (BCL-2) family proteins, BCL-2-associated X protein (BAX), caspases, 
and PI3K/AKT pathway. The extrinsic pathway is triggered by binding of ligand to 
the death receptors, e.g. the TRAIL receptor, leading to activation of molecules 
involved in apoptosis such as caspases [273, 274]. 
A key player in the intrinsic pathway is the tumour suppressor p53 which is 
mutated in almost 38-50% of cancers [275], which could confer inherent resistance 
to cisplatin induced apoptosis [276]. Loss of p53 function however, does not 
exclusively render cells resistant to cisplatin [219, 220]. Aurora kinase A is elevated 
in a number of cancers and in vitro data suggests that it is involved in the 
destabilisation and degradation of p53 leading to the loss of wild-type p53 and is a 
proposed mechanism of cisplatin resistance [277]. Dysregulation of PIK3/AKT 
pathway, as discussed in section 1.1.7.3, has also been linked to cisplatin resistance 
in a range of cancers including ovarian cancer [220, 274].   
 
1.6.4 hCGβ and resistance to chemotherapy 
The link between elevated levels of hCGβ and poor survival outcomes in patients 
with cancer is well studied [278]; however, its link to chemoresistance is still not 
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determined. Both patient studies and in vivo data exist to suggest that hCGβ may 
have a role in chemoresistance. Szturmowicz et al. aimed to determine whether the 
level of hCGβ in the serum of patients with  small-cell lung cancer could be used a  
prognostic factor or used to reclassify the cancer into different subtypes [180]. They 
found that serum levels of hCGβ was elevated in 21 of 156 patients (14%) which 
correlated with poor survival outcomes (5% compared to 21% 2-year survival). What 
was interesting about their data is that 73% of patients with normal levels of hCGβ 
responded to chemotherapy, compared to 48% of patients with elevated hCGβ levels. 
This data suggests that hCGβ could be involved in resistance to chemotherapy.  
A study by Berman et al. used xenografts of tumours established from patients with 
small cell lung cancer which had differing responsiveness to the chemotherapeutic 
drug cyclophosphamide. One chemosensitive xenograft (HX78) which was never 
exposed to cyclophosphamide was made resistant by repeated exposures to the drug 
[279]. They found that when the xenografts were maintained in culture the 
cyclophosphamide resistant (HX78Cy) line produced up to five times more  hCGβ 
(detected in the media by radioimmune assay) compared to the parental 
chemosensitive line (HX78) [280]. This suggests that the levels of secreted hCGβ 
could be linked to chemoresistance. 
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1.7 Hypothesis and aims 
Given that hCGβ is expressed by a number of epithelial cancers including 
ovarian cancer and evidence suggests that it has a biological role in some cancer cell 
line models, we sought to study the role of hCGβ in cellular processes in ovarian 
cancer cell lines.   
Central hypothesis: hCGβ is expressed in HGSC cell lines and has a role in 
proliferation, migration, adhesion and sensitivity to platinum-based drugs. 
Aim 1: Characterise the expression of CGB and secreted hCGβ levels in HGSC cell 
line models. 
Aim 2: Determine the role of hCGβ on proliferation, migration and adhesion of 
HGSC cell lines. 
Aim 3: Determine the role of hCGβ in sensitivity of HGSC cell lines to the platinum-
based drugs cisplatin, carboplatin and oxaliplatin.  
Aim 4: Determine the mechanism by which hCGβ may regulate sensitivity of HGSC 
cells to cisplatin treatment by detecting global protein changes using the quantitative 
proteomic technique isobaric tags for relative and absolute quantitation (iTRAQ). 
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 Material and Methods Chapter 2
 
2.1 Chemicals and Reagents 
A list of chemicals and reagents used in this thesis are outlined in Table 2-1. 
Table 2-1 List of chemicals and reagents 
Item Catalogue  # Manufacturer 
Ampicillin Sodium Salt  A9518-5G Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Agar 214010 Bacto Laboratories  Pty. 
Ltd., Mt Pritchard, NSW, 
Australia 
β-mercaptoethanol M3148-25ML 
 
Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
3(N-Morpholino) 
propanesulfonic acid 
(MOPS)  
M1254-1KG 
 
Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Bromophenol blue 114391-25G Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Carboplatin C2538-100MG Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Cell Gibco Cell Dissociation 
Buffer enzyme-free, PBS  
13151-014 Life Technologies 
Corporation, Mulgrave, 
VIC, Australia 
CellTiter 96® AQueous One G3581 Promega, Alexandria NSW, 
Australia 
Cisplatin 4319H Hospira Australia Pty Ltd 
VIC , Australia 
Cytosine beta-D-
arabinofuranoside  
C1768-100MG Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Dimethyl Sulfoxide (DMSO)  67-68-5 
 
Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
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RNase-Free DNase Set   79254 Qiagen Pty. Ltd., 
Chadstone, VIC, Australia  
Dulbecco’s Phosphate buffered 
saline (PBS)  
21600-010 Life Technologies 
Corporation, Mulgrave, 
VIC, Australia 
Ethanol, absolute  E7023-500ML Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Ethylene glycol-bis(β-aminoethyl 
ether)-N,N,N′,N′-tetraacetic acid 
tetrasodium salt (EGTA) 
E8145-10G Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Ethylenediaminetetraacetic acid 
(EDTA) 
0105-5009 
 
Astral Scientific Pty. Ltd., 
Caringbah, NSW, Australia 
Fetal Bovine Serum (FBS)  FBS500-S AusgeneX Pty. Ltd., 
Oxenford, QLD, Australia 
Glycerol  
 
15524 Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Glycine  
 
VWRC10119CU-
5KG 
Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Hybond-C-Extra Nitrocellulose 
Membrane 
RPN303E 
 
Crown Scientific Pty. Ltd., 
Minto, NSW, Australia 
Methanol  5005-10L Thermo Fisher Scientific 
Australia Pty. Ltd., 
Scoresby, VIC, Australia 
NuPAGE Novex 4-12% Bis-Tris 
gels  
Gel NP0321BOX 
 
Life Technologies 
Corporation, Mulgrave, 
VIC, Australia 
Opti-MEM® Reduced Serum 
Medium  
31985-062 Life Technologies 
Corporation, Mulgrave, 
VIC, Australia 
Oxaliplatin O9512-5MG Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Ponceau S P7170-1L 
 
Bio-Rad Laboratories Pty. 
Ltd., Gladesville, NSW, 
Australia 
Propan-2-ol (isopropanol) 425-2.5L 
 
Thermo Fisher Scientific 
Australia Pty. Ltd., 
Scoresby, VIC, Australia 
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Ribonuclease A (RNaseA)  R6513-10MG 
 
Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
RPMI 1640 R0278-50ML 
 
Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
SeeBlue® Plus2 Pre-stained 
Protein Standard 
LC5925 Thermo Fisher Scientific 
Australia Pty. Ltd., 
Scoresby, VIC, Australia 
Sodium dodecyl sulfate (SDS) 
 
L3771-500G Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Sodium chloride BIOSB0476-5kg Astral Scientific Pty. Ltd., 
Caringbah, NSW, Australia 
Sucrose S0389-1KG Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Sodium fluoride 201154-5G Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Sodium orthovanadate S6508-10G Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Triton® X-100 T9284-500ML Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Tryptone  211705 Bacto Laboratories  Pty. 
Ltd., Mt Pritchard, NSW, 
Australia  
Trypsin-EDTA T4049 
 
Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Tween-20 P5927-500ML Sigma-Aldrich Pty. Ltd., 
Castle Hill, NSW, Australia 
Yeast extract 212750 Bacto Laboratories  Pty. 
Ltd., Mt Pritchard, NSW, 
Australia 
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2.2 Commercial kits 
A list of commercial kits used in this thesis is outlined in Table 2-2. 
Table 2-2 List of commercial kits 
Kit Catalogue # Manufacturer 
10X Gene Expression Master Mix  
 
4369016 Life Technologies 
Corporation, Mulgrave, 
VIC, Australia 
MycoAlert
TM
 Mycoplasma 
Detection Kit 
LT07-318  Lonza, North Sydney, 
NSW, Australia 
Cell Line Nucleofector® Kit L  VCA-1005  Lonza, North Sydney, 
NSW, Australia 
Cell Line Nucleofector® Kit V  VCA-100V Lonza, North Sydney, 
NSW, Australia 
ECM Cell Adhesion Array Kit, 
colorimetric 
ECM540 Merck Millipore, 
Bayswater, VIC, Australia 
Chorionic Gonadotropin beta 
Human ELISA kit  
ab108638  Abcam, Melbourne, VIC, 
Australia 
PureYield™ Plasmid Midiprep 
System 
A2495 Promega, Alexandria, 
NSW, Australia 
Pierce® BCA Protein Assay  
 
23227 
 
Thermo Fisher Scientific 
Australia Pty. Ltd., 
Scoresby, VIC, Australia 
RNeasy Kit 74034  Qiagen Pty. Ltd., 
Chadstone, VIC, Australia 
Super Signal® West Dura Stable 
chemiluminescent substrate 
PIE34075 
 
Thermo Fisher Scientific 
Australia Pty. Ltd., 
Scoresby, VIC, Australia 
Super Signal® West Pico Stable 
chemiluminescent substrate 
PIE34080 
 
Thermo Fisher Scientific 
Australia Pty. Ltd., 
Scoresby, VIC, Australia 
SuperSignal™ West Femto 
Maximum Sensitivity Substrate 
34095 Thermo Fisher Scientific 
Australia Pty. Ltd., 
Scoresby, VIC, Australia 
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Superscript III Reverse 
Transcription Kit 
18080-400 
 
Life Technologies 
Corporation, Mulgrave, 
VIC, Australia 
X-tremeGENE 9 DNA Transfection 
Reagent 
06365787001 Roche Products Pty. Ltd., 
Dee Why, NSW, Australia 
 
 
 
2.3 Routine equipment  
A list of equipment used routinely in this thesis is outlined in Table 2-3. 
Table 2-3 List of Equipment 
Equipment Manufacturer 
ABI 7900 HT Fast real-time PCR  Life Technologies/Applied Biosystems, 
USA 
epMotion 5070  Eppendorf, Hamburg, Germany 
 
Fijifilm LAS-4000 imaging system  Fijifilm Australia, Brookvale, NSW, 
Australia 
Incucyte™ FLR Kinetic Imaging System  
 
Essen Bioscience, MI , USA 
Moxi Z  Gene Target Solutions Pty Ltd., Dural, 
NSW, Australia 
NanoDrop ND-1000 spectrophotometer  NanoDrop Technologies, Wilmington 
DE, USA 
Veritas
TM
 Microplate  Promega Corporation, Alexandria, NSW, 
Australia 
Victor Multilabel Plate Reader  Perkin Elmer, Australia 
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2.4 Cell lines 
All cell lines used were classified as human serous epithelial ovarian cancer cells 
at the commencement of this thesis. OVCAR-3 and SKOV-3 cells were purchased 
from The American Type Culture Collection (ATCC, VA, USA). PEO1 cells were 
obtained from Dr S. P. Langdon (Cancer Research UK Centre, University of 
Edinburgh, Edinburg, UK).  HEY and CaOV-3 cells were a gift from 
Prof A. DeFazio (Westmead Millenium Institute, Sydney, Australia).  A2780 and 
A2780cis cells were a gift from Ms R. Harvey (Bill Walsh Cancer Laboratory, 
Kolling Institute of Medical Research, Australia). OV202 cells were a gift from 
Dr K. Kalli and Dr C. Conover (Mayo Clinic, Rochester, MN, USA).  Characteristics 
and origin of the cell lines are outlined in Table 2-4.  
 
During the course of this thesis, Domcke and colleagues published data 
identifying the  preferred cell lines to use as models of high-grade serous ovarian 
cancer (HGSC) based on genomic data [281]. All preferred models, such as 
OVCAR-3 and CaOV-3, for study were TP53 mutants.  While A2780, HEY and 
SKOV-3 appeared as less preferred models for the study of HGSC.  In agreement 
with Domcke et al., Ince and colleagues published a paper in June this year, also 
indicating that the SKOV-3 and A2780 cell lines may not be preferable models for 
studying HGSC [282]. Substantial work had already been undertaken using these 
cell lines for this thesis and extensive data on these lines is reported. This is true not 
only for this thesis, but in the ovarian cancer literature where these cell lines are 
amongst those most frequently published in studies of HGSC. The A2780 / A2780cis 
pair are still regarded as excellent matched lines for studying developed drugged 
resistance. OV202 and PEO1 were not reported by Domcke and colleagues [281]. 
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Table 2-4  Histology, origin and TP53 status of experimental cell lines  
Cell line Histology Origin TP53 status 
A2780 Undifferentiated carcinoma Tumour [283] Wild-type  [281, 
282] 
A2780cis Cisplatin resistant cells derived from A2780 cells Tumour [284] Wild-type 
CaOV-3 Serous adenocarcinoma Unknown [285] Mutant [281, 
286] 
OV202 Serous epithelial ovarian cancer Tumour [287] unknown 
OVCAR-3 Poorly differentiated papillary epithelial ovarian cancer Ascites [288] Mutant [281] 
SKOV-3 Serous adenocarcinoma Ascites [289, 290] Null [282, 286] 
PEO1 Poorly differentiated serous adenocarcinoma Ascites [291] Mutant [292] 
HEY Moderately differentiated papillary cystadenocarcinoma Xenograft of a peritoneal deposit [293] Wild-type [294] 
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2.5 Cell line maintenance 
2.5.1 Cell line culturing conditions 
All cell lines were grown in culture media composed of RPMI 1640 media 
supplemented with 10% foetal bovine serum (FBS). They were maintained in a 
humidified incubator at 37°C and 5% CO2   and routinely cultured in 10 mL of culture 
media in T75 flasks unless stated otherwise. 
 
2.5.2 Passaging cell lines 
Cells were passaged when 80% confluent by washing them in 5 mL of 
phosphate-buffered saline (PBS) and incubating them in 2 mL of 0.25% 
trypsin/EDTA for 3 min at 37°C to detach the cells from the flask. Once detached, 
5 mL of culture media was added to the flask to neutralise the trypsin and the cell 
suspension transferred to a 15 mL tube and centrifuged at 300 x g for 3 min. The 
supernatant was discarded and the cell pellet was resuspended in fresh culture media 
and replated in T75 flasks.  PBS, trypsin/EDTA and culture media were warmed up 
to 37°C in a water bath prior to use. The cell lines were passaged twice weekly and 
the splitting ratio range is outlined in Table 2-5.  
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Table 2-5 Split ratio range for cell lines 
Cell line Split ratio range 
A2780 1:20-1:30 
A2780cis 1:20-1:30 
CaOV-3 1:3-1:5 
HEY 1:5-1:10 
OVCAR-3 1:3-1:5 
OV202 1:3-1:5 
PEO-1 1:5-1:10 
SKOV-3 1:3-1:5 
 
2.5.3 Routine cell counting 
On a routine basis cell number concentrations were determined using a 
haemocytometer or automatically counted using the Moxi Z. 
 
2.5.4 Cryopreservation of cell lines 
All cell lines were cryopreserved in liquid nitrogen. Cells growing in flasks were 
trypsinised, pelleted by centrifugation and resuspended in an appropriate amount of 
culture media containing 10% (v/v) of dimethyl sulfoxide (DMSO) to yield a cell 
concentration of 1 x 10
6
 cells / mL. One mL of the cell suspension was aliquoted into 
a 2 mL cryrovial. Prior to long term storage, the cells in cryrovials were stored 
at -80°C in cell freezers containing isopropanol for at least 24 h before being 
transferred to liquid nitrogen tanks for long term storage. Cells were cultured from 
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liquid nitrogen stocks by defrosting them in a water bath at 37°C, resuspending the 
cells in culture media, pelleting the cells by centrifugation at 300 x g for 3 min, then 
resuspending them in fresh media before plating them into culture flasks. 
 
2.5.5 Mycoplasma testing 
One mL of conditioned media from cultured cells was routinely monitored for 
mycoplasma using the MycoAlet™ Mycoplasma detection kit. This assay relies on 
the conversion of ATP to ADP (by enzymes produced by Mycoplasma) giving a 
luminescent signal which was read on the Veritas
TM
 Microplate luminometer.   
 
2.5.6 Cell typing 
Authenticity of the cell lines was determined by CellBank Australia (Children’s 
Medical Research Institute, Westmead, Australia) using an AmpFLSTR® 
Identifiler® PCR Amplification Kit. 
 
2.6 Gene expression 
2.6.1  RNA isolation  
Total RNA was extracted using the RNeasy kit including a DNA digestion step 
as per the manufacturer’s protocol. Briefly, culture media was removed from the 
cells and the proprietary RNA extraction buffer added directly to the cells. The RNA 
was precipitated with 70% ethanol, transferred to an RNA extraction column, 
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cleaned through a series of wash and centrifugation steps and finally eluted from the 
column with 30 μL of RNase and RNase-free water. DNA was digested on the 
column in the middle of the wash steps with DNase I in buffer RDD according to the 
manufacturer’s protocol. RNA was stored at -80°C. 
 
2.6.2 RNA and DNA quantification  
The quality and quantity of RNA and DNA was determined by measuring 
absorbance at wavelengths 260 and 280 nm using the NanoDrop ND-1000 
spectrophotometer.  Two μL of the RNA sample was quantified and a ratio of 
1.8-2.1 of A260/A280 was deemed acceptable to carry out qRT-PCR.    
 
2.6.3 Complementary DNA synthesis 
RNA was reverse transcribed into complementary DNA using the SuperScript® 
III First-Strand Synthesis System with oligo(dT) primers according to the 
manufacturer’s protocol.  Briefly, 0.2-5 ng of RNA was mixed with 1 μL of 
oligo(dT) and 1 μL annealing buffer and made up to 8 μL with RNase free water. 
The annealing reaction mix was incubated in a thermal cycler at 65°C for 5 min and 
rapidly cooled on ice for at least 1 minute. Ten μL of 2x First-Strand reaction mix 
and 2 μL SuperScript®III/RNAseOUT Enzyme was added to the annealing reaction 
mix and incubated for 50 min at 50°C followed by termination at 85°C for 5 min. 
The cDNA was then diluted 1:5 or 1:10 with RNase free water and stored at -20°C. 
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2.6.4 Quantitative RT- realtime PCR 
Gene expression was determined by quantitative real-time reverse transcriptase 
PCR (qRT-PCR) using TaqMan gene expression assays.  The efficiency of the PCR 
reaction for each assay was initially determined to be ~90% by absolute quantitation 
from a standard curve. The qRT-PCR reaction mix consisted of 10 μL of 2x reaction 
Master mix, 1 μL of 20x Taqman gene expression probe (Table 2-6 for probe details) 
and 5 μL of cDNA made up to 20 μL in RNase free water. Twenty μL of the reaction 
mix was pipetted in triplicate for each sample (cDNA) into a 96 well plate using the 
epMotion 5070 automated pipetting system.  Five μl half reactions were prepared 
when a 384 well plate format was used. The PCR reaction was conducted on the 
ABI 7900 HT machine with an amplification program of 95°C for 10 min, followed 
by 40 cycles of 95°C for 15 sec and 60°C for 1 min.   
 
Relative gene expression was determined by delta-delta Ct analysis against the 
HMBS (hydroxymethylbilane synthase) reference gene using RQ Manager Software 
(Life Technologies). 
 
Table 2-6 TaqMan Probes 
Assay ID Gene Symbol Gene name 
Hs00361224_gH CGB c horionic gonadotropin, beta polypeptide  
Hs00751207_s1 LHB luteinizing hormone beta polypeptide 
 Hs00609297_m1* HMBS hydroxymethylbilane synthase 
All TaqMan probes were obtained from Life Technologies Australia Pty Ltd, 
Mulgrave, VIC, Australia. *endogenous reference gene 
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2.7 Protein expression 
2.7.1 Detection of secreted hCGβ protein using enzyme-linked immunosorbent 
assay (ELISA) 
The level of hCGβ secreted by the cell lines was determined using the Chorionic 
Gonadotropin beta Human ELISA kit which detects free hCGβ according to the 
manufacturer’s protocol. Briefly, 50 μL of conditioned media and hCGβ standards 
were incubated overnight at 4ºC in ELISA well strips coated with anti-hCGβ capture 
antibodies. Excess sample was aspirated from the strips and the wells washed five 
times with 300 µL of deionized water. One hundred and fifty μL of anti-Chorionic 
Gonadotropin beta HRP conjugate was added and incubated for 30 min. The strips 
were then washed five times with 300 µL of deionized water and 100 μl TMB 
substrate added and incubated for 20 min. One hundred µL stop solution was then 
added to terminate the reaction. The absorbance was read at 450 nm on a 
spectrophotometer microplate reader Victor Multilabel Plate Reader. The 
concentration of protein was calculated based on the standard curve (range 0.25 
ng/mL - 50 ng/mL). Refer to Appendix A, Supplementary Figure 1 for standard 
curve. 
 
2.7.2 Western blotting 
Protein expression from cell lysates was determined using western blotting. Cells 
growing in either flasks or well plates were washed in cold PBS and directly lysed in 
Laemmli buffer.  Lysates were transferred to 1.5 mL Eppendorf tubes and sonicated 
with a probe for 30 sec to shred the DNA. The lysates were boiled at 95°C for 5 min 
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and 10-20 μL of the lysates were run against the SeeBlue® Plus protein protein 
standard (range 4-250 kDa) on precast 4-12% NuPAGE® Novex Bis-Tris gels for 1 
h at 180 V in MOPS SDS buffer. Protein from the gel was transferred onto a 
nitrocellulose membrane for 90-120 min at 100V in cold blotting buffer. The 
membranes were then blocked in blocking buffer for at least 30 min, followed by 
incubation with primary antibody overnight at 4°C.  Unbound primary antibody was 
washed off in wash buffer (3 x 10 min washes) and probed with Horseradish 
Peroxidase coupled (HRP) secondary antibodies in blocking buffer for 1 h before a 
final wash (3 x 10 min washes). Refer to Table 2-7 for composition of buffers used 
for western blotting and Table 2-8 for the antibodies used to probe proteins of 
interest. Bands were detected using chemiluminescence Super Signal ECL Pico, 
Dura or Femto reagent (in order of increasing sensitivity) on the Fujifilm LAS-4000 
imaging system. The intensity of the bands was quantitated using Multi Gauge 3.0 
software (Fujifilm Australia, Brookvale, NSW, Australia). 
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Table 2-7 Composition of buffers used for western blotting 
Laemmli buffer Running buffer Blotting buffer Blocking buffer Wash buffer 
SDS              6% w/v Tris   50 mM Tris  25 mM Tris pH 7.4    40 mM Tris pH 7.4  20 mM 
Sucrose       40% w/v Glycine  384 mM Glycine  152 mM Skim milk 5% NaCl  150 mM 
Tris, pH 6.8  20 mM SDS 0.1% Methanol  20% v/v Tween-20  0.1% Tween-20  0.1% 
Bromophenol blue  0.15% w/v         
β-mercaptoethanol  5% v/v         
 
Table 2-8 List of antibodies for western blotting 
Antibody Catalogue  # and source Produced in Molecular weight (kDa) Dilution 
Anti-WAPL ab109537, Abcam Rabbit 133 1:50 000  
Anti-LIM Kinase 1 ab108507, Abcam Rabbit 73 1:1000 
Anti-SIRT1 ab32441, Abcam Rabbit 83 and  110 (ubiquitinated) 1:5000 
Anti-hCGβ SAB4500168-100UG,  Sigma-Aldrich Rabbit 17 1:1000 
Anti-GAPDH  2118, Cell Signalling Rabbit 39 1:10 000 
Secondary Anti-rabbit 
IgG – HRP linked 
NA934V, GE Healthcare Life Sciences Donkey Secondary Antibody 1:2500 
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2.8 siRNA downregulation using nucleofection 
RNA interference (siRNA) was used to downregulate gene expression. In order 
to minimise off target effects, two siRNA targeting two different regions of the gene 
were used.  siRNAs used are outlined in Table 2-9. 
Table 2-9 List of siRNA used for nucleofection 
siRNA Catalogue # Sequence of probe Target gene 
HS_CGB_4 
FlexiTube siRNA 
SI00344162 CACCACCATCTGTGCCGGCTA CGB 
HS_CGB_5 
FlexiTube siRNA 
SI03057607 CACCATGACCCGCGTGCTGCA CGB 
Hs_CGB_7 FlexiTube 
siRNA 
SI03114580 TCCCTAGCACTGACGACTGA CGB 
Hs_SIRT1_2 
FlexiTube siRNA 
SI00098441  SIRT1 
Hs_SIRT1_3 
FlexiTube siRNA 
SI00098448  SIRT1 
AllStars SI03650318    non-
silencing 
control 
All siRNAs were sourced from Qiagen Pty. Ltd., Chadstone, VIC, Australia. Note: 
siRNA against CGB do not discriminate against the different CGB genes. 
Transfection was conducted by nucleofection using the Amaxa Nucleofector 
system which is based on cell electroporation. Briefly, cells at 80% confluency were 
harvested, counted, pelleted and resuspended in 100 μL of the proprietary 
transfection solution containing 7.5 μl of 20 μM of siRNA. Cells were then 
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electroporated using a specific program tailored to the cell type being transfected. 
The cell number, transfection solution and electroporation program for nucleofection 
of different cell lines is outlined in Table 2-10.  
The level of downregulation of the gene transcript was determined 24 h post 
transfection by qRT-PCR (refer to section 2.6) and at the protein level 48 h post 
transfection, using either ELISA or western blotting (refer to sections 2.7.1 and 
2.7.2, respectively). 
Table 2-10 Transfection conditions using the Amaxa Nucleofector system 
Cell line Cell number Solution Program 
HEY 1.5 x 10
6
 V U-023 
A2780 3 x 10
6
 L T-020 
A2780cis 3 x 10
6
 L T-020 
 
The protocol to transfect HEY cells using the Amaxa nucleofection system had to 
be optimised as Lonza did not provide an existing protocol. Optimisation involved 
transfecting the cells with a green fluorescent protein (GFP) vector provided in the 
optimisation kit using a range of programs to achieve the highest GFP expression 
while maintaining cell viability.  
HEY cells were passaged and grown to 80% confluence 2 days prior to 
transfection. Cells were harvested and 1.5 x 10
6
 cells transfected with 2 μg of 
pmaxGFP vector (part of kit) in 100 μL of Solution V using the following programs:  
A-020, T-020, T-030, X-001 and X-005. Cells were then seeded into 6 well plates 
and observed using a florescent microscope 24 h after transfection. 
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Cell viability was unaffected by the different programs used to transfect the HEY 
cells using nucleofection; however, GFP expression did vary and the T-020 
programme showed the highest level of GFP expression (Figure 2.1). The T-020 
program was used for subsequent transfections of HEY cells.  
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Program Fluorescence Phase-contrast 
 
 
A-020 
  
 
 
T-030 
  
 
 
X-003 
  
 
 
T-020 
  
 
 
X-005 
  
Figure 2.1 Optimisation of transfection of HEY cells using Amaxa 
nucleofection  
Expression of GFP vector vs cell viability 24h post transfection using the 
following programs: A-020, T-020, T-030, X-001, X-005. T-020 highlighted in 
green provided the optimum transfection efficiency.  
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2.9 hCGβ overexpression 
hCGβ was transiently overexpressed in cells using plasmid DNA. 
2.9.1 Plasmid preparation 
2.9.1.1 Bacterial culture 
The pCI-neo-hCG plasmid containing an hCGβ insert cloned into the XbaI and 
XhoI sites was purchased from Addgene in E.coli bacterial cells (Catalogue #16574, 
Addgene MA, USA).  The hCGβ insert (534 base pairs)  was generated from human 
placental cDNA amplified using the 5'−TGTGCTCTAGATCATGACCAAGG-
ATGGAGATGTTCCAG−3' and 5'−GCACAGTCTAGATTATTGTGGGAGGAT-
CGGG−3 primers and sequenced and cloned in the pCI-neo vector by Clontech, Palo 
Alto, California [295].  pC1-neo control vector also in E.coli were a gift from Dr S. 
Firth (Hormones and Cancer Laboratory, Kolling Institute of Medical Research, 
Australia).  The stocks were  struck out on Lysogeny broth (LB) agar plates (1% w/v 
NaCl and Tryptone, 0.5% w/v yeast extract, 1% w/v agar,  pH 7.5) containing 0.1 
mg/mL ampicillin and grown overnight at 37°C. A single colony was then picked 
and grown in 5 mL of LB broth (1% w/v NaCl and Tryptone, 0.5% w/v yeast extract, 
pH 7.5) containing 0.1mg/mL ampicillin overnight at 37°C in an orbital shaker.  
 
2.9.1.2 Glycerol stock of bacterial strains 
1 mL of the bacterial culture was pelleted, resuspended in 1 mL of LB broth 
containing 10% glycerol (v/v) and stocked at -80°C.  
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2.9.1.3 Plasmid extraction and DNA quantification 
Fifty to 100 mL of LB broth was inoculated with the bacterial stocks containing 
plasmids and grown overnight at 37°C in an orbital shaker. Plasmid DNA was 
extracted from the bacteria using a PureYield™ Plasmid Midiprep System according 
to the manufacturer’s protocol. Briefly, bacterial cells were pelleted and cells lysed 
with proprietary reagents provided in the kit. DNA was then extracted and purified 
through a column system and a series of wash (using proprietary reagents provided 
in the kit) and centrifugation steps. Finally, DNA was eluted from the column with 
300 μL of Nuclease-Free Water and quantified using the NanoDrop™ 
spectrophotometer (section 2.6.2). 
 
2.9.2 Plasmid transfection 
One μg of pCI-neo-hCG and pCI-neo control plasmids were transfected into cell 
lines using a non-lipid based X-tremeGENE 9 DNA Transfection Reagent. 
Two  x  10
5 
of  HEY cells and 4 x 10
5
 of A2780 and A2780cis cells were plated in 
six well plates in 2 mL of culture media and after 18-24 h, transfection was carried 
out according to the manufacturer’s protocol. Three μL transfection reagent, 97 μL 
Opti-MEM® I reduced serum medium and 1 μg of plasmid DNA were mixed and 
incubated for 15 min at room temperature (RT). The reaction mix was added to the 6 
well plate containing cells and overexpression of intracellular hCGβ and secreted 
hCGβ was determined at 48 h using western blotting and ELISA respectively.  
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2.10 Statistical analysis 
Statistical analysis was performed using SPSS Statistics software v 22 (IBM 
Australia Ltd., St Leonards, NSW, Australia). Statistical significance was determined 
using the following models: 
• t-test to compare two sample means 
• one-way analysis of variance (ANOVA) with LSD Post Hoc test to compare 
means of three or more samples 
• two-way ANOVA to compare multiple levels of two factors with multiple 
observations at each level  
• repeated measures ANOVA when comparing dose or time response curves  
Data was presented as the mean ± Standard error of the mean (S.E.M) from at 
least three independent experiments.  A P value of less than 0.05 was considered to 
be significant. 
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 Expression of hCGβ and its role in prolifera-Chapter 3
tion, adhesion and migration 
 
3.1 Introduction 
Presence of the β-subunit of hCG (hCGβ) has been reported in serum, malignant 
ascites, cyst fluid and tumour tissue from women with ovarian cancer [181, 183-185, 
296].  Studies conducted by Ind et al. and Vartianen et al. showed that high serum 
levels of hCGβ corresponded to poor survival rate of patients with ovarian cancer 
[181, 185]. 
The fact that free hCGβ cannot bind to the receptor LHCGR without being 
associated with its α-subunit has led to the suggestion that it does not have a 
biological function and that it may be just a biological marker in epithelial cancers. 
Contrary to this idea, studies have shown that hCGβ may have effects on biological 
functions such as proliferation and migration in non-trophoblastic epithelial cancers 
distinct from the intact hCG heterodimer (Chapter 1, section 1.5). In this chapter, the 
expression of both CGB gene transcript and secreted hCGβ protein was determined 
in eight commonly studied HGSC cell lines. The role of hCGβ in proliferation, 
adhesion and migration was determined by transiently down regulating hCGβ by 
siRNA transfection, as well as overexpression of this protein. 
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3.2 Materials and Methods 
Refer to Chapter 2, section 2.5 for details on how cells were grown, harvested 
and counted. 
 
3.2.1 Expression of CCA and CGB transcripts in HGSC cells 
Cells were grown until 80% confluent in six well plates in culture media before 
total RNA was extracted and the CCA and CGB transcript levels (encoding  hCGβ 
and hCGα proteins) determined by qRT-PCR. Methodological details of RNA 
isolation, cDNA preparation and determination of the levels of hCGβ transcript by 
qRT-PCR are described in Chapter 2, section 2.6. 
 
3.2.2 Determining secreted hCGβ protein levels in conditioned media  
SKOV-3, HEY, OV202, PEO-1, A2780, A2780cis, CaOV-3 and OVCAR-3 cells 
were grown until 80% confluent in T25 flasks and serum starved for 18-24 h in 4 mL 
of RPMI containing 0.1% bovine serum albumin (BSA). Fifty μL of conditioned 
medium from each cell line was then assayed using the Chorionic Gonadotropin beta 
Human ELISA kit described in Chapter 2, section 2.7.1. 
 
3.2.3 Downregulation and overexpression of hCGβ 
hCGβ was downregulated or overexpressed in HEY, A2780 and A2780cis 
according to the protocols described  in Chapter 2, sections 2.8 and 2.9 respectively.  
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3.2.4 Proliferation assay 
Given that hCGβ has been shown to increase cell proliferation in bladder cancer 
cells and normal ovarian surface epithelial cells [155, 191], the effect of 
manipulating hCGβ levels on proliferation of three HGSC cell lines HEY, A2780 
and A2780cis was studied.  
 
3.2.4.1 Effect of hCGβ downregulation and overexpression on cell proliferation 
Twenty-four hours post transfection with siRNA or plasmid, 1 x 10
5
 A2780 and 
A2780cis cells (in 5 mL culture media) and HEY (in 10 mL of culture media) were 
seeded into a T25 or T75 flask respectively. Cells were allowed to grow for 3 and 6 
days with culture media replenished every 2 days. After day 3 or day 6, cells were 
harvested, resuspended in 0.5-2 mL of culture media and the cell number determined 
using a Coulter counter (Ac·T diff Analyzer, Beckman Coulter, Sydney, NSW 
Australia). 
 
3.2.4.2 Effect of exogenous hCGβ downregulation on cell proliferation 
determined by MTS viability assay 
The effect of exogenous recombinant hCGβ on cell proliferation was determined 
using the colorimetric CellTiter 96® AQueous One Solution (MTS) cell viability 
assay over 4 days. Recombinant hCGβ expressed in Pichia pastoris was purchased 
from Sigma-Aldrich. The MTS assay is based on the MTT (3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide) assay and works on the principle of viable 
cells converting the active component, a tetrazolium compound called 3-(4,5-
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dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) [297], from a yellow colour to soluble formazan which is a deep 
brown/maroon colour. The absorbance of formazan is measured at 490 nm and is 
proportional to the number of viable cells. 
Compared to cell counts, the MTS assay can underestimate changes in cell 
number therefore changes in proliferation can go undetected. Furthermore, RPMI 
media has been shown to reduce MTS which can diminish the results of the 
assay[298]. However the assay has an advantage over cell counts used in section 
3.2.4.1 as it allows for higher throughput and the effect of a range of hCGβ 
concentrations could be tested at one time. HEY, A2780 and A2780cis cells were 
seeded in triplicate in 100 μl of culture media into a 96-well plate (Table 3-1 for 
seeding densities). Six hours after seeding, cells were treated with 100 μl culture 
media containing hCGβ in 0.1% BSA at 10 X, 25 X and 50 X the basal endogenous 
concentration of  hCGβ expressed by the individual cell lines (Table 3-1 summarises 
the concentrations of hCGβ used). The culture media of untreated cells contained 
0.1% BSA as a vehicle control. The cells were incubated for 4 days at 37 ºC and 5% 
CO2.  After 4 days, the percentage of viable cells was determined by the addition of 
the MTS reagent to each well at a dilution of 1:5. After an incubation period of 1-2 h 
for HEY cells and 2-3 h for A2780 and A2780cis cells at 37 ºC and 5% CO2, the 
absorbance was measured at 490 nm on the Wallac Victor 1420 Multilabel Counter. 
The background absorbance from blank wells was subtracted from the wells that 
contained cells. The percentage of viable cells indicative of proliferation was 
calculated as follows:  
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% 𝑣𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 ℎ𝐶𝐺𝛽 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
 × 100 
 
Prior to performing the MTS cell viability assay, the optimal cell number 
required to produce a reading above the blank reading at 490 nm, was determined. 
Cells were seeded at a density of 0.5- 5 x10
3
 cells per well in triplicate in a 96 well 
plate and allowed to grow for 96 h (marking the end of the viability assay) at which 
point the MTS reagent was added. The aim was to achieve a cell number that would 
give an absorbance reading between 0.1 and 0.5 within 1- 4 h. 
 
Table 3-1 Seeding density of cell lines and concentration of hCGβ for cell 
proliferation assay  
Cell line Seeding density  
/  per well 
Concentration of hCGβ (ng/mL) 
  Basal level 10 X 25 X 50 X 
HEY 1 x 10
3
 4 40 100 200 
A2780 2.5  x  10
3
 0.9 9 22.5 45 
A2780cis 2.5  x  10
3
 0.6 6 15 30 
Note: Basal levels were determined in section 3.2.2. 
3.2.5 Wound healing assay 
The wound healing assay was used to determine cell migration 48 h after siRNA 
or plasmid transfection. HEY cells were seeded at 5 x 10
4
 in 250 μL of culture media 
in 96-well plates and allowed to form a confluent layer overnight at 37°C in 5% 
Chapter 3 
71 
 
CO2. Once the confluent layer was formed, 150μl of condition media was removed 
from individual wells and reserved in a separate 96-well plate. A scratch was then 
made to the confluent layer using the Incucyte WoundMaker (Essen Bioscience) 
tool. Loosened cells were washed off with 200 μL of warm PBS (twice). The 
remaining cells were replenished with the conditioned media with 5 μM of the cell 
proliferation inhibitor cytosine β-D-arabinofuranoside. Note that the conditioned 
media was used in order to take into account secreted levels of hCGβ. The plate was 
placed into an Incucyte™ FLR Kinetic Imaging System and the Incucyte™ software 
was programmed to generate phase-contrast photographs of the scratched region at 
3 h time intervals for up to 48 h. The Incucyte™ software was then used to 
automatically determine the percentage of wound closure in individual wells, at a 
given time point relative to the size of the wound at time zero. 
 
3.2.6 Cell adhesion assay 
Cell adhesion was studied in HEY and A2780cis cells using the ECM Cell 
adhesion Array colorimetric kit according to the manufacturer’s protocol.  The kit 
consisted of 12 x 8-well strips percolated with an extracellular matrix (ECM) 
protein: Collagen I (ColI), Collagen II (ColII), Collagen IV (ColIV), Fibronectin 
(FN), Laminin (LN), Tenascin (TN), Vitronectin (VN) and BSA as a negative 
control, as well as Assay, Cell Stain, and Extraction buffers.   
Forty-eight hours after siRNA or plasmid transfection, cells growing in a T25 
flask were harvested and resuspended into a single cell suspension before being 
plated onto the ECM matrix proteins. Specifically, cells were washed with warm 
PBS and detached from the flask by incubating them with 4 mL of Cell Gibco Cell 
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Dissociation Buffer enzyme-free PBS for 20 min at RT. Cell clumps were broken by 
gently pipetting the cells up and down with a 5 mL pipette and the cell suspension 
was transferred to a 15 mL centrifuge tube and cells pelleted by centrifugation at 
300 x g for 3 min. The pellet was washed in 2 mL of warm PBS to remove residual 
serum proteins from the growth media and re-pelleted by centrifugation. This wash 
step was repeated once more before the cells were resuspended in the Assay buffer, 
counted and diluted in an appropriate volume of Assay buffer to attain a density of 
5x10
5
 and 1x10
6
 cells/mL of HEY and A2780cis cells, respectively. One hundred μl 
of the cell suspension was added (in duplicate) to ECM coated wells and incubated at 
37°C in 5% CO2 for 1 and 2 h for HEY and A2780cis cells, respectively. After the 
cells had adhered, the Assay buffer was gently aspirated and unattached cells were 
washed off with 200 μL of Assay buffer (repeated one more time).  
The remaining attached cells were fixed and stained for 5 min at RT with 100 μL 
of Cell Stain solution. Excess stain was washed off with 200 μL of deionised water 
(repeated four times) and wells were left to air dry. The cell-bound stain was 
solubilised by the addition of 100 μL of Extraction buffer to each well and placed on 
a shaker for 5 min. Absorbance at 560 nm was measured with the Victor Multilabel 
Plate Reader. The absorbance readings, which were proportional to the amount of 
cells that had attached to the matrix, were plotted on a bar graph. 
Prior to the adhesion assay, the ideal cell number to form a confluent layer and 
time required for the cells to adhere to the ECM surfaces were optimised. Cell 
suspensions of 0.5-2 x 10
5 
of HEY and A2780cis cells were prepared in Assay buffer 
as described in the above section and incubated on the ECM matrix proteins to attain 
a confluent layer within 1-2 h on at least one matrix protein. An optimum cell 
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number of 5 x 10
4
 and 2 x 10
5
 and incubation times of 1 and 2 h were determined for 
HEY and A2780cis cells, respectively.  
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3.3 Results 
3.3.1 Expression of CGB transcript and secreted hCGβ in HGSC cell lines 
All eight HGSC cell lines: SKOV-3, HEY, OV202, PEO-1, A2780, A2780cis, 
CaOV-3 and OVCAR-3 expressed hCGβ at both the transcript and protein levels to 
varying degrees (Figure 3.1). qRT-PCR data normalised to cDNA from SKOV-3 
cells showed that HEY cells expressed the highest level of CGB, followed by 
SKOV-3 cells. OV202, PEO1, A2780, A2780cis, CaOV3 and OCAR-3 cells 
expressed considerably lower levels of CGB compared to HEY and SKOV-3 cells 
(Figure 3.1 A). Notably, the A2780cis cells had much lower CGB expression than 
the parental A2780 cell line. 
The level of basal secreted hCGβ determined by ELISA (Figure 3.1 B) from 
conditioned media revealed a similar relative expression pattern to the transcript 
levels, specifically SKOV-3 (13.80 ± 0.82 ng/mL)  and HEY (3.94 ± 0.34 ng/mL) 
cell lines produced significantly higher levels of hCGβ compared to OV202 
(0.12 ±0.01 ng/mL), PEO1 (1.39 ± 0.57 ng/mL), A2780 (0.95 ± 0.19 ng/mL), 
A2780cis (0.40 ± 0.02 ng/mL), CaOV-3 (0.23 ± 0.03 ng/mL) and OVCAR-3 
(0.15 ± 0.02 ng/mL) cell lines. There were however some notable differences in 
protein expression levels compared to transcript levels. SKOV-3 cells produced 
significantly higher levels (more than 4 times) hCGβ protein compared to HEY cells, 
whereas HEY cells expressed 1.4 times more CGB transcript compared to SKOV-3 
cells. Although OV202 cells expressed at least 2 times higher levels of CGB 
transcript compared to PEO1, A2780 and A2780cis cells, they secreted lower levels 
of hCGβ protein.  
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Figure 3.1 Expression of CGB transcript and secreted hCGβ in HGSC cell 
lines 
Expression of CGB and hCGβ in 8 HGSC cell lines (A) CGB transcript level 
relative to HMBS, determined by qRT-PCR normalised to CGB/HMBS 
expression in SKOV-3 cells. (B) Secreted hCGβ protein levels determined by 
ELISA. Data are expressed as mean ± SEM; (N=3). * P < 0.05, ** P < 0.005. 
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3.3.2 Expression of CGA in HGSC cell lines 
Analysis of expression of CGA was also carried out in the eight HGSC cell lines 
to determine if the cells could potentially produce whole hCG protein that would 
require the presence of both subunits. All cell lines expressed some level of CGA 
(Figure 3.2). Expression levels of CGA in the cell lines were normalised to levels in 
A2780 cells. CGA expression for CaOV-3 cells is not shown on the graph as they 
expressed 660 times more CGA compared to A2780 cells. 
 
Figure 3.2 Expression of CGA in HGSC cell lines normalised to expression 
in A2780 cells 
Expression of CGA transcript level relative to HMBS, determined by qRT-PCR 
normalised to CGA/HMBS expression in A2780 cells. Data are expressed as 
mean ± SEM; (N=3). The relative expression value for CaOV-3 cells (not 
shown) was 660 ± 328. 
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The degree of expression of CGA and CGB transcripts in the cell lines was 
different. The expression level of CGA transcript in the order of highest to lowest 
expression level was: CaOV-3> A2780> A2780cis> HEY> OVCAR-3> PEO1> 
SKOV-3> OV202 whereas the expression level of the CGB in the order of highest to 
lowest expression level was SKOV-3> HEY> OV202> PEO1> A2780> A2780cis> 
CaOV-3> OVCAR-3.  The most striking differences were that: 1. CaOV-3 cells 
which expressed one of the lowest levels of CGB, expressed the highest level of 
CGA; 2. SKOV-3 cells which expressed the second highest level of CGB expressed 
almost no CGA, and 3. HEY cells which expressed the highest level of CGB and 
higher levels compared to the A2780 and A2780cis cells expressed lower amounts of 
CGA compared to A2780 and A2780cis cells. Interestingly, A2780 expressed higher 
levels of both the CGA and CGB transcript compared to A2780cis cells. 
 
3.3.3 Downregulation of hCGβ 
Twenty-four hours after siRNA transfection, an average reduction of 50-60% in 
CGB transcript was achieved in HEY, A2780 and A2780cis cells using either of two 
hCGβ targeting siRNAs: CGB_4 and CGB_5 (Figure 3.3 A). CGB_4 siRNA caused 
a reduction of 65, 55 and 60% of CGB in HEY, A2780 and A2780cis cells, 
respectively.  A reduction of 55, 60, and 60% of CGB in HEY, A2780 and A2780cis 
cells, respectively was achieved with the CGB_5 siRNA.  
The secreted hCGβ level in conditioned media was determined in HEY cells 48 h 
post transfection using ELISA, and indicated a 50% downregulation of hCGβ with 
both CGB_4 and CGB_5 siRNAs (Figure 3.3 B). Due to limited cell number after 
siRNA transfection, the level of secreted hCGβ in A2780 and A2780cis was below 
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the detectable thresh-hold of the ELISA assay (as reflected in Figure 3.1 B) hence 
hCGβ downregulation at the protein level could not be determined. Each transfection 
yielded 1.5 x 10
6
 of A2780 and A2780cis cells and ~ 6 x 10
6
 cells were needed to 
produce secreted hCGβ protein levels which could be detected by the ELISA kit.   
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Figure 3.3  Downregulation of CGB and secreted hCGβ 
CGB transcript level (A) in HEY, A2780 and A2780cis cells  determined 24 h 
post transfection by qRT-PCR and secreted hCGβ protein level (B) in HEY cells, 
determined 48 h post transfection by ELISA on conditioned media. Secreted 
hCGβ could not be detected in conditioned media from A2780 and A2780cis 
cells, likely due to the small number of cells used for these assays. siRNAs: non-
silencing control, CGB_4 and CGB_5.  Data normalised to negative non-
silencing control siRNA and expressed as mean ± S.E.M; N=3. 
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3.3.4 Effect of hCGβ downregulation on cell proliferation 
Cell proliferation was determined following hCGβ downregulation at 3 and 6 
days in HEY, A2780 and A2780cis cells. A general trend of reduction of cell 
proliferation was observed when hCGβ was downregulated (Figure 3.4).  
In HEY cells (Figure 3.4 A), there was a significant reduction in cell proliferation 
following siRNA treatment (ANOVA; P = 0.013), and the post hoc test revealed that 
both CGB_4 and CGB_5 siRNAs caused a significant reduction in proliferation 
(P = 0.026 and P = 0.005, respectively). Specifically, a reduction in cell number of 
25 and 10% was observed using the CGB_4 siRNA at day 3 and 6 respectively, and 
a 10% reduction was observed at both day 3 and 6 using the CGB_5 siRNA. 
In A2780 cells (Figure 3.4 B), a statistically significant difference in cell 
proliferation was observed with siRNA treatment (P = 0.01) however, the post hoc 
test revealed that this reduction was statistically significant only when the CGB_5 
siRNA was used (ANOVA; P = 0.004). Specifically, a reduction in cell number of 
40 and 30% at day 3 and 6 respectively was observed using the CGB_5 siRNA. 
In A2780cis cells (Figure 3.4 C) there was a significant reduction in cell 
proliferation following siRNA treatment (ANOVA; P = 0.01) and the post hoc test 
revealed that both CGB_4 and CGB_5 siRNAs showed a significant reduction in 
proliferation (P = 0.004 and P = 0.016, respectively). Specifically, a reduction in cell 
number of 50 and 25% was observed using the CGB_4 siRNA at day 3 and 6, and 40 
and 20% at day 3 and 6 respectively using the CGB_5 siRNA.   
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Figure 3.4 Effect of downregulation of hCGβ on cell proliferation 
Effect of down regulating hCGβ on proliferation of HEY (A), A2780 (B) and 
A2780cis (C) cells. siRNAs: negative control non-silencing ( ),CGB_4( ), and 
CGB_5 ( ) . Results expressed as mean ± S.E.M; N=3. A significant reduction 
in cell proliferation following hCGβ downregulation was observed in HEY 
(P = 0.013) and A2780cis (P = 0.01) using ANOVA. 
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3.3.5 Effect of hCGβ downregulation on cell adhesion  
The effect of downregulation of hCGβ on cell adhesion to plates coated with 
different matrix proteins was examined in A2780cis and HEY cells. A2780cis did 
not attach to any of the collagen matrixes hence these matrixes were omitted from 
further examination. A general increase in cell adhesion was observed in both HEY 
and, more notably, in A2780cis cells when hCGβ was downregulated (Figure 3.5). In 
both HEY and A2780cis cells there was no significant difference in cell adhesion 
between the different ECM matrixes. However, when cell adhesion was analysed 
across all seven matrixes there was a significant difference (P < 0.0005) when hCGβ 
was downregulated in HEY cells with either CGB_4 or CGB_5 siRNAs. 
When the data were normalised to the non-silencing negative control siRNA the 
differences were more clear than the raw data (Figure 3.6). Cell adhesion increased 
by 10% on Fibronectin, Laminin and Vitronectin and by 20% on Tenascin in 
A2780cis when hCGβ was downregulated (Figure 3.6 A). However, the observed 
increase was not statistically significant due to high variation between experimental 
runs which could have been due to the high variability in the number of cells that 
attached to the ECM surfaces between experimental runs and the level of stain taken 
up by the cells. Statistical analyses were performed using t-test, comparing adhesion 
between cells treated with non-silencing control siRNA and CGB_4 or CGB_5 
siRNA. It is possible that increasing the number of replicates may have reached 
statistically significant differences. The increase in cell adhesion observed in HEY 
cells (Figure 3.6 B) when hCGβ levels were decreased was more noticeable 
compared to A2780cis cells but varied between the CGB_4 and CGB_5 siRNA. 
When CGB_4 was used to downregulate hCGβ the increase in cell adhesion was as 
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follows: 10% on Collagen I, 30% on Collagen II and IV, Fibronectin, Laminin, and 
Vitronectin, and a 50% increase on Tenasin. When CGB_5 was used the increase in 
adhesion was as follows: 40% on Collagen I and II, 80% on Collagen and Tenasin, 
50% on Fibronectin and Laminin and 60% on Vitronectin. As was the case for 
A2780cis cells, these increases did not reach statistical significance.  
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Figure 3.5 Effect of hCGβ downregulation on cell adhesion 
Effect of downregulation of hCGβ on cell adhesion to extracellular matrix 
proteins of A2780cis (A) and HEY (B) cell lines, 48 h post siRNA transfection. 
siRNAs: non-silencing control ( ),CGB_4( ),CGB_5( ). Collagen I (Col I), 
Collagen II (Col II), Collagen 1 (Col  IV),  Fibronectin (FN), Laminin (LN), 
Tenasin (TN), Vitronectin (VN). Results are expressed as mean ± S.E.M; N=3. 
Statistical test: two-way ANOVA. When cell adhesion was analysed across all 
seven matrixes in HEY cells there was a significant difference (P < 0.0005) 
when hCGβ was downregulated with either CGB_4 or CGB_5 siRNAs. 
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Figure 3.6 Effect of hCGβ on cell adhesion: data normalised to non-
silencing negative control 
Effect of downregulation of hCGβ, on cell adhesion to extracellular matrix 
proteins of A2780cis (A) and HEY (B) cell lines, 48 h post siRNA transfection. 
Data normalised to cells treated with negative control non-silencing siRNA. 
siRNAs: non-silencing control ( ),CGB_4 ( ) , CGB_5( ).Collagen I (Col I), 
Collagen II (Col II), Collagen 1 (Col  IV),  Fibronectin (FN), Laminin (LN), 
Tenasin (TN), Vitronectin (VN). Results expressed as mean ± S.E.M; N=3. Red 
dotted line indicates 100%. 
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3.3.6 Effect of hCGβ downregulation on cell migration  
Migration was measured by the rate of closure of a wound made in the cell 
monolayer. A2780 and A2780cis did not migrate or migrated to a maximum wound 
closure of 20% during the 48 h period of the assay, after which time they started 
dying (Figure 3.7 and Figure 3.8, respectively). Due to this limited ability for A2780 
and A2780cis cells to migrate despite hCGβ downregulation, migration was studied 
only in HEY cells.  
 
0 h 
 
24 h 
 
48 h 
Figure 3.7 Wound closure in A2780 cells over 48 h 
Representative images from the Incucyte of wound closure in A2780 cells at 0 h, 
24 h and 48 h. Outline of the wound depicted by dashed orange line. 
0 h 24 h 48 h 
Figure 3.8 Wound closure in A2780cis cells over 48 h  
Representative images from the Incucyte of wound closure in A2780cis cells at 0 
h, 24 h and 48 h. At 48 h cells can be seen to be lifting off the plate forming 
patches in the confluent layer (indicated by green arrows). Outline of the wound 
depicted by dashed orange line.  
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In HEY cells, downregulation of hCGβ did not seem to affect cell migration (Figure 
3.9).   
Control non-silencing siRNA 
 
 
0 h 
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15 h 
CGB_4 siRNA 
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15 h 
Figure 3.9 Wound closure in HEY cells over 15 h following hCGβ 
downregulation 
Representative images from the Incucyte of wound closure in HEY cells at 0 h, 
6 h and 15 h, 24 h post siRNA transfection. Outline of the wound depicted by 
dashed orange line. 
 
However, a small increase in migration, 4-5% at 10 h, was seen as a result of 
downregulation of hCGβ following quantitation of wound closure (Figure 3.10). 
However, this effect did not reach statistical significance. 
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Figure 3.10 Effect of hCGβ downregulation on cell migration in HEY cells 
Effect of hCGβ downregulation on migration of HEY cells, 48 h post siRNA 
transfection. siRNAs: non-silencing control, CGB_4, CGB_5. Results are 
expressed as mean ± S.E.M; N=4. 
 
3.3.7 Overexpression of hCGβ 
hCGβ was overexpressed in HEY, A2780 and A2780cis cells in order to 
determine if increasing its levels would result in the opposite effect of 
downregulation with regards to proliferation. The effect of hCGβ overexpression on 
cell migration was also studied in HEY cells. Protein expression of hCGβ was 
examined in whole cell lysates and conditioned media 48 h post transfection with an 
empty vector (pCI-neo) or the vector containing hCGβ insert (pC1-neo+ hCGβ). 
Intercellular hCGβ was successfully transiently expressed in all three cell lines at 
levels which could be detected by western blot (Figure 3.11 A).  There was an 
apparent 3, 4 and 6 fold increase in hCGβ in A2780, A2780cis and HEY cells 
respectively (Figure 3.11 B). The ImageJ program used to quantify the intensity of 
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the bands will give a reading regardless of whether a band is visible to the naked eye, 
therefore the extent of overexpression is probably underestimated and it should be 
noted an hCGβ band is visible only after protein is overexpressed. Background 
corrections were made by measuring a region of the blot that contained no bands and 
subtracting it from measured bands. When the level of secreted hCGβ was measured 
it was found that hCGβ was dramatically increased from 0 ng/mL to 51.84 ng/mL, 
53.84 ng/mL and 47.02ng/mL in A2780, A2780cis and HEY cells respectively 
(Figure 3.11 C).   
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Figure 3.11 Overexpression of hCGβ 
Expression of hCGβ 48 h post transfection in A2780, A2780cis and HEY cells 
(A) Western blot showing expression of hCGβ protein in cell lysates. (B) 
Measured intensity of bands on western blot and normalised to cells treated with 
empty pC1-neo vector. (C)  Secreted hCGβ measured by ELISA. Plasmid 
vectors:  pC1-neo (E), pC1-neo with hCGβ insert (β). Results expressed as mean 
± S.E.M; N=3. 
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3.3.8 Effect of overexpression of hCGβ on cell proliferation 
No significant effect on cell proliferation was observed in A2780, A2780cis and 
HEY cells when hCGβ was overexpressed (Figure 3.12).  
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Figure 3.12 Effect of hCGβ overexpression on cell proliferation 
Effect of hCGβ overexpression on proliferation of A2780(A), A2780cis (B) and 
HEY (C) cells. Plasmid vectors: pCI-neo( ) or pCI-neo with hCGβ insert( ). 
Results expressed as mean ± S.E.M; N=3.  
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It was possible that the large growth surface area used for the proliferation study 
(i.e. T75 flask for HEY cells and T25 flasks for A2780 and A2780cis cells) and the 
presence of serum proteins in the media could have diminished any effects of 
increased hCGβ.  Therefore, to test the effect of cells growing over a smaller growth 
surface and in serum free conditions the experiment was repeated using 6 and 
12 well plates for HEY and A2780 and A2780cis cells, respectively in serum free 
media. Specifically, 24 h post hCGβ transfection, 1 x 105 cells were plated in 6 or 
12 well plates, incubated for 6 hours at 37°C in 5% CO2 after which the media was 
changed to serum free media (RPMI media containing 0.1% BSA). Cells were then 
allowed to grow for 4 days. A longer period could not be pursued as the cells were 
almost 100% confluent by the end of this time period. It was found that a decrease in 
surface area and serum starvation did not influence proliferation of any of the three 
cell lines transiently transfected with hCGβ (Figure 3.13).  
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Figure 3.13 Effect of hCGβ overexpression and serum starvation on cell 
proliferation in a 6 and 12 well format  
Effect of hCGβ overexpression on proliferation of A2780, A2780cis and HEY 
cells under serum starved conditions in a 6 or 12-well plate in 4 days. Plasmid 
vectors: pCI-neo ( ) or pCI-neo with hCGβ insert ( ). Results are expressed as 
mean ± S.E.M; N=3. 
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3.3.9 Effect of hCGβ overexpression on migration of HEY cells 
Overexpression of hCGβ had no effect on migration of HEY cells over a 21 h 
period (Figure 3.14). Representative images are shown at time points 0 and 21 h 
(Figure 3.15). 
 
Figure 3.14 Effect of hCGβ overexpression on migration of HEY cells 
Migration of HEY cells over a period of 21 h, 48 h after transfection. Plasmid 
vectors: Empty vector pCI-neo, pCI-neo with hCGβ insert. Results are expressed 
as mean ± S.E.M; N=4.  
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pC1-neo 
 
0 h 
 
 
21 h 
pCI-neo with hCG-β insert 
 
0 h 
 
21 h 
Figure 3.15 Wound closure in HEY after overexpression of hCGβ 
Representative images from the Incucyte of wound closure in HEY cells at 0 h 
and 21 h time points. 48 h post transfection. Plasmid vectors: pCI-neo plasmid 
and pCI-neo with hCGβ insert.  
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3.3.10 Effect of exogenous hCGβ on cell proliferation 
The effect of exogenous recombinant hCGβ on proliferation of HEY, A2780 and 
A2780cis cells was studied using the MTS cell viability assay. Exogenous hCGβ did 
not have a significant effect on cell proliferation (Figure 3.16) when delivered at 10, 
25 and 50 times the concentration of basal hCGβ levels expressed by the cells (Table 
3-1). 
 
Figure 3.16 Effect of exogenous hCGβ on cell proliferation 
Effect of exogenous hCGβ on proliferation of HEY, A2780, A2780cis cells 
when applied at 10 X, 25 X and 50 X the basal endogenous expression of hCGβ 
which was 4, 0.9 and 0.6 ng/mL for HEY, A2780 and A2780cis cells , 
respectively. Untreated cells received 0.1% BSA in RPMI media as the vehicle 
control. Proliferation was measured 4 days after treatment using the MTS cell 
viability assay. 
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3.4 Discussion 
3.4.1 Basal expression of CGB and secreted hCGβ 
All eight HGSC cell lines expressed CGB and secreted hCGβ protein to varying 
degrees with SKOV-3 and HEY cells being the highest expressers. The fact that 
hCGβ was expressed in the HGSC cell lines agreed with patient data showing that 
hCGβ is expressed in ovarian cancer [181, 183, 186]. Though the level of hCGβ 
secreted by the OVCAR-3 cells was below the lowest standard (0.25 ng/mL) in 
assay, the absorbance was above the blank (media only) and 0 ng/mL standard hence 
it can be inferred that hCGβ was secreted by the cells. 
 
3.4.2 Downregulation of hCGβ 
Three cell line models – HEY, A2780 and A2780cis cells – expressing a varied 
range of CGB/hCGβ, were selected for functional studies. HEY cells were chosen as 
they expressed the highest level of hCGβ and the pair of cisplatin-sensitive and 
resistant cells, A2780 and A2780cis, respectively were chosen for drug response 
studies (investigated in Chapter 4). hCGβ was successfully downregulated in A2780, 
A2780cis and HEY cells by 50-60% at the transcript level (Figure 3.3 A). A higher 
level of downregulation was unable to be achieved, despite increasing the amount of 
siRNA to the highest recommended amount (10 nM). A further increase in the 
amount of siRNA was not considered as it may have resulted in off-target effects. 
There are a number of reasons that may explain why a more efficient level of hCGβ 
downregulation could not be achieved. As mentioned in Chapter 1 section 1.3.3, 
hCGβ is encoded by 6 different genes. Therefore it is possible that the siRNAs are 
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differentially targeting the different CGB genes so that the reduction observed is a 
result of preferentially targeting one gene or a subset of the genes. siRNA binding 
could also be dependent on the which CGB gene is being expressed by the cells. If 
indeed only one or a subset of the genes were targeted, it is possible that other 
untargeted CGB genes could increase their expression in order to compensate for the 
loss of the other gene. The Taqman assay used to measure CGB downregulation does 
not distinguish between the different CGB genes and therefore cannot produce a 
representation of each individual gene product. We cannot therefore determine 
which gene(s) are targeted or if there is a compensatory effect. This theory could be 
tested by using primers that specifically target each transcript. In Chapter 4 section 
4.3.8, it was shown that CGB_4 and CGB_5 siRNA differentially targeted the LHB 
gene which encodes for the highly homologous LHβ protein. 
It could be argued that even if the different CGB genes are targeted it is the 
protein product which is of functional importance. This is a valid argument; 
however, hCGβ poses another challenging scenario as hCGβ can be either of two 
different protein products depending on the gene expressed. The two protein 
products differ in particular by a single amino acid at position 117: type I genes 
(CGB7) encodes hCGβ with an alanine at position 117, whereas type II genes 
(CGB3, CGB5 and CGB8) encode a protein product with an aspartic acid at position 
117.  Therefore if it is assumed that a higher level of gene knockdown could not be 
achieved due to the inability of the siRNAs to target all CGB transcripts then the 
protein product (type I or type II hCGβ) may be of importance. Differential 
expression of type I and type II genes can be detected using nested PCR which can 
detect single nucleotide gene products [165].  To date, there is no antibody assay that 
is capable of distinguishing between the two hCGβ protein products. However, 
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Aldaz-Carol et al. published a paper in 2015, suggesting they have designed a 
specific antibody for type II hCGβ [165].  
The expression of the α-subunit and β-subunit in HEY, A2780 and A2780cis 
cells shows the potential that these cells have to produce the heterodimeric hCG 
protein.  This has to be addressed as it would mean effects observed in functional 
studies involving hCGβ downregulation or overexpression cannot be attributed to, or 
distinguished from, either whole hCG or free hCGβ. However, a number of studies 
have investigated hCGβ on its own without regard to expression of the whole protein 
[156, 187, 191].  
The α-subunit of hCG has been shown to be biologically activate in endometrial 
stromal cells [299-301]. Specifically Blithe and colleagues found that the free α-
subunit could act synergistically with progesterone to regulate the differentiation of 
human endometrial cells in vitro [299, 300]. In an attempt to study the effect of 
hCGβ while discounting the presence of hCGα  we used exogenous recombinant 
hCGβ in experiments to determine its effect on cell proliferation (Figure 3.16). It 
was found that exogenous hCGβ did not influence cell proliferation. The drawback 
of the recombinant hCGβ is that its biological activity was unknown.  Furthermore, it 
was produced in yeast cells which may result in varied glycosylation and therefore 
different stability and activity of the protein compared to the product from 
mammalian cells. Therefore, downregulation or overexpression of hCGβ was the 
best approach to ensure that hCGβ produced by the cells had any biological 
importance.  
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3.4.3 Role of hCGβ in cell proliferation 
Downregulation of hCGβ with both CGB_4 and CGB_5 siRNAs significantly 
decreased cell proliferation in HEY and A2780cis cells (Figure 3.4 A and C 
respectively). However, only the use of CGB_5 siRNA caused a significant decrease 
in cell proliferation of A2780 cells.  These data suggest that the role of hCGβ in cell 
proliferation is cell type dependent which could be in part due to potential 
differences in the mechanism of action of the two siRNAs in different cell lines. The 
pro-proliferative role of hCGβ in HEY and A2780cis cells agrees with data shown 
Gillot et al. and Guo et al. [154, 191]. Gillot et al.  showed that exogenous hCGβ 
could increase cell growth of bladder cancer cell lines [154] and Guo et al. showed 
that overexpression of hCGβ in ovarian surface epithelial cells caused an increase in 
cell proliferation [191]. Since downregulation of hCGβ had a negative effect on cell 
proliferation in HEY and A2780cis cells it was expected that overexpression of 
hCGβ would have the opposite effect. However, overexpression of hCGβ seemed to 
have no measurable effect on cell proliferation in these cells (Figure 3.12). A 
possible explanation for this result is that increased expression of hCGβ beyond an 
endogenous threshold level could not further influence cell proliferation. The 
influence of exogenous hCGβ on cell proliferation was also investigated in the 
current study and results showed that exogenous hCGβ did not influence cell 
proliferation (Figure 3.16). This data is contrary to Gillot’s data that showed that 
exogenous hCGβ could increase cell growth of bladder cancer cell lines [154]. This 
could be due to the different hCGβ preparations and sources. The recombinant hCGβ 
sourced from Sigma that was used in the current study had not been confirmed to 
have biological activity; although Butler et al. showed hCGβ from Sigma had 
biological activity [155]. Given that the actual product number was not stated in this 
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paper, it is possible that the product used in our study is different and may be 
biologically less potent or inactive. 
 
3.4.4 Role of hCGβ on cell migration 
hCGβ did not have a significant effect on migration of HEY cells irrespective of 
whether it was downregulated or overexpressed (Figure 3.10 and Figure 3.14). This 
result is contrary to findings by Wu et al. who showed that overexpression of hCGβ 
in prostate carcinoma cell lines increased cell migration [156]. It is possible that the 
migratory effect of hCGβ is cell type dependent or that HEY cells express levels of 
hCGβ that are so high (Figure 3.1) that downregulation of 50-60% or overexpression 
of up to 6 fold did not have an overall impact on cell migration.  
As mentioned in section 3.3.6, A2780 and A2780cis cells did not migrate 
substantially within a 48h period; however, a 20% difference in wound closure was 
observed which could be attributed to cell spreading; as cells seemed to be more 
rounded at time zero perhaps due to the scratching and wash steps, compared to later 
time points which showed cells to be more spread out. 
 
3.4.5 Role of hCGβ on cell adhesion 
The effect of hCGβ on cell adhesion of extracellular matrixes has not been 
studied before; however the effect of hCGβ on anchorage independent growth has 
been reported by Guo et al. [191]. Specifically, Guo’s study showed that 
overexpression of hCGβ in ovarian surface epithelial cells increased their growth 
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potential in soft agar. Interestingly, our results showed that downregulation of hCGβ 
caused a general increased trend in cell adhesion of HEY cells on collagen I, II and 
IV, fibronectin, vitronectin, tenascin, and laminin (Figure 3.6 B) and A2780cis cells 
on fibronectin, vitronectin, tenascin, and laminin (Figure 3.6 B). Although cell 
adhesion and anchorage independent growth are two different assays each indicative 
of different cellular functions, they are related, as anchorage independent growth 
demonstrates that cells are capable of growing without having to attach to a surface 
which is characteristic of  anchorage dependent cells. 
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3.5 Conclusions 
All eight HGSC cell lines expressed CGB transcript and secreted hCGβ protein to 
varying degrees with SKOV-3 and HEY cells being the highest expressers. All cells 
also expressed CGA at varying levels with CaOV-3 expressing almost 700 times the 
amount of A2780 cells which were the next highest expresser of CGA. Expression of 
both the α- and β- subunits of hCG by the cells suggests the whole protein could 
potentially be expressed; however, specific commercial antibodies targeting hCGβ 
alone were not available hence the best means of studying the role of hCGβ was to 
overexpress and downregulate the gene, the means by which the role of hCGβ has 
been investigated in previously published studies.  
Downregulation of hCGβ significantly decreased proliferation of A2780cis and 
HEY cells suggesting that hCGβ may have a role in cell proliferation. The influence 
of hCGβ downregulation on cell proliferation of A2780 cells seemed to be 
dependent on siRNA used to downregulate hCGβ; suggesting that the two siRNA 
used to target hCGβ may be functioning by different mechanisms. hCGβ may play a 
role in cell adhesion, as downregulation of hCGβ caused a general increased trend in 
cell adhesion of HEY cells on collagen I, II and IV, fibronectin, vitronectin, tenascin, 
and laminin and A2780cis cells on fibronectin, vitronectin, tenascin, and laminin. 
Migration of HEY cells was not influenced by hCGβ. The effect of hCGβ on the 
response of HGSC cell lines and differences in the actions of CGB_4 and CGB_5 
siRNA are investigated in the next chapter.   
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 Role of hCGβ in the response to cisplatin and Chapter 4
other platinum-based drugs 
 
4.1 Introduction 
The role of hCGβ in the response of HGSC cell lines to chemotherapeutic drugs, 
in particular cisplatin, carboplatin and oxaliplatin, were investigated in this chapter.  
Two published studies have suggested that hCGβ could be involved in resistance of 
cancer cells to chemotherapy: 1. Szturmowicz et al. observed that patients with 
small-cell lung cancer who were resistant to chemotherapy and had poor outcomes, 
had elevated serum levels of hCGβ [180] and 2. Berman et al. found that xenografts 
of small cell bronchial carcinoma which expressed hCGβ were resistant to the 
chemotherapeutic drug cyclophosphamide [280]. Despite these observational studies, 
no further work has been published to determine the direct role hCGβ may play in 
the response of cancer cells to chemotherapy. Furthermore, the suggestion that hCGβ 
has an anti-apoptotic role in bladder and cervical cancer cells [155, 187], raises the 
possibility that hCGβ may have a role in determining how cells respond to an 
apoptotic chemotherapeutic agent. 
In order to investigate whether hCGβ plays a role in chemosensitivity (or 
chemoresistance) in HGSC cells, hCGβ was downregulated in three HGSC cell lines 
(HEY, A2780 and A2780cis) and the response to cisplatin determined. In addition, 
sensitivity to other platinum-based drugs, oxaliplatin and carboplatin, and the 
microtubule targeting agent paclitaxel was investigated. hCGβ was also 
overexpressed in the cisplatin sensitive and resistant cell lines A2780 and A2780cis 
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cells respectively, to determine whether high levels of hCGβ could confer decreased 
sensitivity of the cells to cisplatin.  
 
4.2 Materials and Methods 
hCGβ was downregulated (using siRNAs) or overexpressed (using a plasmid 
construct) in A2780, A2780cis and HEY cells as outlined in Chapter 2, sections 2.8 
and 2.9, respectively. 
 
4.2.1 Sensitivity of cells to chemotherapeutics  
The response of cells to drug treatment was studied using cell viability and 
clonogenic (survival) assays. Both assays reflect how cells respond to drug 
treatment, but work on different principles. The cell viability assay (also known as 
the cytotoxic assay) is a 3 day colorimetric assay and measures cell viability after 
drug treatment. The clonogenic assay measures the ability of cells to survive and 
form colonies (defined as ≥ 50 cells) after the drug has been withdrawn. The 
clonogenic assay is a longer assay compared to the viability assay, spanning up to 
2 weeks.   
 
 
4.2.1.1 MTS cell viability assay  
The MTS cell viability assay (described in Chapter 3, section 3.2.4.2 ) was used 
to determine the relative number of viable cells remaining 72 h after drug treatment. 
The protocol for this assay was based on the methods described by Persons et al., 
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[302] and O’Toole et al., [303] with a few modifications. Twenty-four hours after 
siRNA or plasmid transfection, HEY, A2780 and A2780cis cells were harvested, 
counted and seeded in triplicate in 100 μl of culture media into a 96-well plate. The 
seeding density for HEY cells was 1 x 10
3 
cells /well and 2.5 x10
3
 cells/well for 
A2780 and A2780cis cells. Eighteen to 24 h after seeding, the cells were treated with 
100 μl of cisplatin, carboplatin, oxaliplatin or paclitaxel in culture media and 
incubated for 72 h at 37 ºC and 5% CO2. Table 4-1 lists the final concentration range 
for each drug used to treat the cells.  Wells were set up for blank reading which 
contained culture media only. After 72 h of drug treatment, the percentage of viable 
cells was determined as per the protocol described in Chapter 3, section 3.2.4.2. 
Briefly, the MTS reagent was added to each well and incubated for a period of 1-2 h 
for HEY cells and 2-3 h for A2780 and A2780cis cells at 37 ºC and 5% CO2 and the 
absorbance was measured at 490 nm on the Wallac Victor 1420 Multilabel Counter. 
The background absorbance from blank wells was subtracted from the wells that 
contained cells. The percentage of viable cells was then calculated. The IC50 was 
calculated using GraphPad Prism version 6.04 software (GraphPad software, 
California, USA).  
Prior to performing the MTS assay the optimum drug concentration range was 
determined by treating the cells with 0.125-50 μM cisplatin, 3.12-300 μM 
carboplatin, 2.5-100 nM oxaliplatin and 2.5-100 nM paclitaxel.  From the drug 
concentration range a maximum dose which killed more than 80% cells (20% viable) 
and a minimum dose at which cells were unaffected by the drug were chosen, along 
with several drug doses in the middle of this range (Table 4-1).  
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Table 4-1 Drug concentration range analysed for cell viability assay 
Drug  Range for HEY Range for A2780 Range for A2780cis 
Cisplatin 0.4-6 μM  0.4-12 μM  0.4-12 μM  
Carboplatin 5-150 μM  Not tested 5-150 μM  
Oxaliplatin 1-50 nM Not tested 1-50 nM 
Taxol 1-50 nM Not tested 1-50 nM 
 
4.2.1.2 Clonogenic assay 
The clonogenic cell survival assay was based on a paper by Gan et al. with a few 
variations [304]. Twenty-four hours after siRNA or plasmid transfection, HEY, 
A2780 and A2780cis cells were harvested, counted and plated into 6 well plates at a 
seeding density of 120 cells/well in 1 mL of culture media and allowed to adhere for 
5-6 h at 37 ºC and 5% CO2 before being treated with cisplatin, carboplatin, 
oxaliplatin and paclitaxel in 500 μl culture media (Table 4-2 for drug concentration 
range). Seventy-two hours following drug treatment, the medium was replaced with 
1.5 mL drug free culture media and HEY cells and A2780 and A2780cis cells were 
allowed to form colonies over 3 or 8 days, respectively. Media was topped up with 
1 mL of fresh media every 3 days. Colonies were then fixed with 0.5% crystal violet 
in 20% methanol for 5 min and excess stain washed off with water. The stained 
plates were dried and colonies manually counted. The following equations were used 
to calculate the plating efficiency and the surviving fraction: 
𝐏𝐥𝐚𝐭𝐢𝐧𝐠 𝐞𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐜𝐲 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑖𝑛 𝑑𝑟𝑢𝑔 𝑓𝑟𝑒𝑒 𝑚𝑒𝑑𝑖𝑎
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑
 
𝐒𝐮𝐫𝐯𝐢𝐯𝐢𝐧𝐠 𝐟𝐫𝐚𝐜𝐭𝐢𝐨𝐧 =
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠
(𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑠𝑒𝑒𝑑𝑒𝑑 × 𝑝𝑙𝑎𝑡𝑖𝑛𝑔 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦)
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The IC50 was calculated using GraphPad Prism version 6.04 software. 
Table 4-2 Drug concentration range for clonogenic assays 
Drug  Range for HEY Range for A2780 Range for A2780cis 
Cisplatin 0.25-4 μM 0.13-2 μM 0.5-8 μM 
Carboplatin 0.56-25 μM Not tested 3.75-60 μM 
Oxaliplatin 0.63-1 μM Not tested 0.63-1 μM 
Paclitaxel 0.31-5 nM Not tested 0.31-5 nM 
 
Prior to the clonogenic assay the number of cells and the time required for cells 
to form colonies was optimised by seeding between 50-500 cells/well into 6 well 
plates and incubating the plates for 5-14 days at 37 ºC and 5% CO2, until colonies 
could be visualised and were not touching each other.  It was found that the optimum 
density was 120 cells/well for HEY, A2780 and A2780cis cells. The number of days 
required to form colonies was 6 days for HEY and 11 days for A2780 and A2780cis 
cells.   
The drug concentration range was also optimised prior to the clonogenic assay. 
The highest drug concentration used to treat the cells started at IC50 concentration 
based on the cell viability assay from which 2-fold dilutions were made. The 
IC50 concentrations were chosen as it was assumed that the seeding density for the 
clonogenic assay ( ≥10 times less than that used in the viability assay) would require 
considerably less drug to kill cells. The IC50 concentration was an adequate dose to 
prevent colony formation. 
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4.3 Results 
4.3.1 Sensitivity of cells to cisplatin determined by cell viability assay 
The response of A2780,  A2780cis and HEY cells to cisplatin, determined by the 
cell viability (MTS) assay, showed that A2780 cells were the most sensitive to 
cisplatin, followed by HEY cells and, as expected, A2780cis was the most resistant 
cell line (Figure 4.1).  
 
  
Figure 4.1 Response of A2780, A2780cis and HEY cells to cisplatin 
treatment 
Response of A2780, A2780cis and HEY cells to 72 h treatment with cisplatin, 
determined by the cell viability (MTS) assay. Data are expressed as 
mean ± S.E.M; (N=3). The IC50 (μM) for cisplatin for all three cell lines is 
marked on graph. 
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The derived IC50 concentrations showed that A2780cis cells had a significantly 
higher IC50 for cisplatin compared to A2780 cells (6.4 times higher) and HEY cells 
(2.5 times higher). HEY cells had an IC50 cisplatin concentration which was 2.5 
times greater than that of A2780 cells (Table 4-3). 
 
Table 4-3 IC50 concentration of cisplatin derived from the cell viability 
assay for A2780, A2780cis and HEY cells 
Cell line IC50  [μM] 
A2780 1.43  ± 0.04 ** 
A2780cis 9.23 ± 0.63  
HEY 3.5 ± 0.40 **,  #  
IC50 concentration of cisplatin derived from the cell viability (MTS) assay for 
A2780, A2780cis and HEY cells. Data are expressed as mean ± S.E.M; (N=3). ** P 
< 0.005 when samples were compared to A2780cis; # P < 0.05 when samples were 
compared to A2780.  
 
 
4.3.2 Sensitivity of cells to cisplatin relative to expression of secreted hCGβ  
A relationship between the level of CGB expression and hCGβ secreted by the 
cells and their sensitivity to cisplatin (expressed as IC50 concentrations derived from 
the cell viability assay) could not be established (Figure 4.2). The parental cisplatin 
sensitive A2780 cells expressed 3.5 times more CGB and 2 times more secreted 
hCGβ compared to the cisplatin resistant A2780cis cells and were more sensitive to 
cisplatin. HEY cells expressed 55 and 10 times more CGB and secreted hCGβ 
respectively compared to A2780cis cells and were more sensitive to cisplatin. In 
contrast, HEY cells expressed higher levels of CGB and hCGβ compared (16 and 4 
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times more, respectively) to A2780 cells but were less sensitive (up to 2.5 times) to 
cisplatin.  
 
  
Figure 4.2 Cisplatin sensitivity relative to the expression of CGB and 
secreted hCGβ 
IC50 of cisplatin (μM) for A2780, A2780cis and HEY cells derived from the cell 
viability (MTS) assay, relative to CGB/HMBS (arbitrary units) and secreted 
hCGβ (ng/mL) levels. Data are expressed as mean ± S.E.M; (N=3). 
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4.3.3 Effect of hCGβ downregulation on cell viability following cisplatin 
treatment  
Downregulation of hCGβ had different effects on the response of the cisplatin 
sensitive A2780 cells and cisplatin resistant A2780cis cells to cisplatin treatment 
(Figure 4.3). The degree of hCGβ downregulation was previously shown in 
Chapter 3, Figure 3.3. In A2780 cells, reducing the level of hCGβ by ~60% did not 
affect the response to cisplatin (Figure 4.3 A). In contrast, downregulation of hCGβ 
by ~60 % significantly increased the sensitivity of A2780cis cells to cisplatin (Figure 
4.3 B). An increase in sensitivity to cisplatin after hCGβ downregulation was also 
observed in HEY cells (Figure 4.3 C).  
Although both hCGβ targeting siRNAs (CGB_4 and CGB_5) downregulated 
hCGβ to similar levels and both caused increased sensitivity to cisplatin in HEY and 
A780cis cells, it was evident that the CGB_5 siRNA had a greater effect on how 
cells responded to cisplatin, suggesting that the two siRNAs did not function in an 
identical manner. 
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Figure 4.3 Effect of hCGβ downregulation on cell viability following 
cisplatin treatment  
Viability of A2780 (A), A2780cis (B) and HEY (C) cells after cisplatin 
treatment, 48h post transfection with non-silencing control ( ), 
CGB_4 ( ) or CGB_5( ) siRNAs. The MTS viability assay was used to 
determine cell viability. Data are expressed as mean ± S.E.M; (N=3). 
** P < 0.005, *** P < 0.0005. 
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4.3.4 Effect of hCGβ downregulation on cell viability following paclitaxel 
treatment 
As A2780 cells did not show any difference in sensitivity towards cisplatin 
following hCGβ downregulation, from here on drug sensitivity studies following 
hCGβ downregulation were followed only in HEY and A2780cis cells. 
Downregulating hCGβ in A2780cis and HEY cells had no significant effect on their 
sensitivity towards paclitaxel (Figure 4.4). Refer to Appendix B Supplementary 
Table 1 for IC50 concentrations for Paclitaxel. 
A 
 
B 
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D 
 
Figure 4.4 Effect of hCGβ downregulation on cell viability following 
paclitaxel treatment 
Viability of HEY (A and B) A2780cis (C and D) cells in response to paclitaxel, 
48h post transfection with non-silencing control ( ), CGB_4 ( ) and 
CGB_5 ( ) siRNAs. The MTS assay was used to determine cell viability. 
Data are expressed as mean ± S.E.M (N=3). 
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4.3.5 Effect of hCGβ downregulation on cell viability following treatment with 
carboplatin and oxaliplatin  
The response of A2780cis and HEY cells to other platinum-based drugs, 
carboplatin and oxaliplatin, was studied to determine whether the increase in 
sensitivity to cisplatin seen when hCGβ was downregulated, was also seen for these 
drugs. In A2780cis cells, downregulation with both CGB_4 and CGB_5 siRNAs 
showed a statistically significant increase in sensitivity to both carboplatin and 
oxaliplatin (Figure 4.5).  Although these trends were reflected in HEY cells, only 
downregulation with CGB_4 showed a statistically significant increase in sensitivity 
to carboplatin (Figure 4.6).  Refer to Appendix B, Supplementary Table 1 for IC50 
concentrations for carboplatin and oxaliplatin. 
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Figure 4.5 Effect of hCGβ downregulation on cell viability of A2780cis cells 
following treatment with oxaliplatin and carboplatin   
Viability of A2780cis cells following treatment with: Carboplatin (A and B), 
Oxaliplatin (C and D), 48 h post transfection with non-silencing control ( ), 
CGB_4 ( ) and CGB_5 ( ) siRNAs. The MTS assay was used to 
determine cell viability. Data are expressed as mean ± S.E.M; (N=3). *P < 0.05, 
***P < 0.0005. 
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Figure 4.6  Effect of hCGβ downregulation on cell viability of HEY cells 
following treatment with oxaliplatin and carboplatin   
Viability of HEY cells following treatment with: Carboplatin (A and B), 
Oxaliplatin (C and D), 48 h post transfection with non-silencing control ( ), 
CGB_4 ( ) and CGB_5 ( ) siRNAs.  The MTS assay was used to 
determine cell viability.  Data are expressed as mean ± S.E.M; (N=3). 
**P < 0.005. 
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4.3.6 Effect of hCGβ downregulation on cell survival following cisplatin, 
carboplatin and oxaliplatin treatment 
The clonogenic assay was used to measure cell survival. Downregulating hCGβ 
significantly decreased cell survival of A2780cis and HEY cells independently of 
any drug treatment. The number of colonies formed relative to the number of cells 
seeded was reduced by ~ 30% in HEY and A2780cis cells (Figure 4.7). Cell survival 
in the context of hCGβ downregulation was not studied in A2780 cells as the use of 
CGB_5 siRNA to downregulate hCGβ almost completely prevented colony 
formation in these cells and therefore subsequent drugs studies could not be pursued. 
 
Figure 4.7 Effect of downregulating hCGβ on the ability of HEY and 
A2780cis cells to form colonies 
The surviving fraction which is indicative of cell survival is expressed as the 
number of cells seeded divided by the number of colonies formed.  Data are 
expressed as mean ± S.E.M; (N=4). * P < 0.05, ** P < 0.005.  
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In A2780cis cells (Figure 4.8) there was a general trend towards decreased cell 
survival following treatment with all three platinum-based drugs independently when 
hCGβ was downregulated. The use of either CGB_4 or CGB_5 siRNA to 
downregulate hCGβ caused a significant increase in cisplatin sensitivity (Figure 4.8 
A and B). Both hCGβ targeting siRNAs also caused a significant increase in 
oxaliplatin sensitivity (Figure 4.8 E and F). The use of CGB_5 siRNA also caused a 
significant increase in carboplatin sensitivity (Figure 4.8 D), but despite CGB_4 
siRNA showing a similar increase in sensitivity towards carboplatin (Figure 4.8 C), 
it did not reach statistical significance (P = 0.079). Refer to Appendix B, 
Supplementary Table 2 for IC50 concentrations for carboplatin and oxaliplatin. 
 
In HEY cells a similar trend in the reduction of cell survival after cisplatin, 
carboplatin or oxaliplatin treatment was observed with downregulation of hCGβ 
(Figure 4.9). However, only the use of CGB_5 siRNA showed a significant increase 
in cisplatin and carboplatin sensitivity (Figure 4.9 B and D). The use of CGB_4 
siRNA also showed a similar trend in increased sensitivity to cisplatin, carboplatin 
and oxaliplatin treatment but these changes were not statistically significant (Figure 
4.9 A, C and E, respectively). Refer to Appendix B, Supplementary Table 2 for IC50 
concentrations for carboplatin and oxaliplatin. 
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Figure 4.8 Effect of hCGβ downregulation on cell survival of A2780cis cells 
after treatment with platinum-based drugs  
The clonogenic assay was used to measure cell survival in response to: Cisplatin 
(A and B, N=6), Carboplatin (C and D, N=4) and Oxaliplatin (C and D, N=4), 
24 h post transfection with a non-silencing control ( ), CGB_4 ( ) or 
CGB_5 ( ) siRNAs. Data are expressed as mean ± S.E.M. * P < 0.05, 
** P < 0.005, *** P < 0.0005. 
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Figure 4.9 Effect of hCGβ downregulation on cell survival of HEY cells 
after treatment with platinum-based drugs. 
The clonogenic assay was used to measure cell survival in response to: Cisplatin 
(A and B, N=4), Carboplatin (C and D, N=3) or Oxaliplatin (C and D, N=3), 
24 h post transfection with a non-silencing control ( ),CGB_4 ( ) or 
CGB_5 ( ) siRNAs. Data are expressed as mean ± S.E.M. *** P < 0.0005. 
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IC50 values for cisplatin, carboplatin and oxaliplatin in A2780cis cells indicated a 
decrease in the amount of drug required to cause a 50% reduction in cell survival 
when hCGβ was downregulated (Figure 4.10 A and B). Downregulation of hCGβ 
with either CGB_4 or CGB_5 siRNAs showed a significant decrease in the IC50 for 
cisplatin and oxaliplatin; however, only CGB_5 significantly decreased the IC50 for 
carboplatin. Despite a general trend in the reduction of IC50 for cisplatin, carboplatin 
and oxaliplatin by both CGB_4 and CGB_5 siRNAs in HEY cells (Figure 4.10 C 
and D), only CGB_5 siRNA caused a significant decrease in the IC50 for cisplatin 
and oxaliplatin in these cells. 
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Figure 4.10 IC50 of cisplatin, carboplatin and oxaliplatin in A2780cis and 
HEY cells after hCGβ downregulation based on survival assays 
IC50 of cisplatin (μM), carboplatin (μM), oxaliplatin (nM) derived from 
clonogenic assays which were used to measure cell survival, in A2780cis (A and 
B) and HEY (C and D) cells,   24h post transfection with a non-silencing control 
( ), CGB_4 ( ) or CGB_5 ( ) siRNAs. Data are expressed as mean ± S.E.M; 
(N=4). * P < 0.05, ** P < 0.005, *** P < 0.0005. 
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4.3.7 Effect of hCGβ downregulation using a third siRNA on cell survival 
following cisplatin, carboplatin and oxaliplatin treatment 
Although the two siRNA targeting hCGβ (CGB_4 and CGB_5) had similar 
levels (~ 60%) of knockdown in HEY and A2780cis cells (Figure 4.11), and showed 
similar trends in terms of cell survival and viability in response to cisplatin and 
carboplatin treatment, there were a few differences that had to be addressed. 
Therefore a third siRNA, CGB_7, targeting CGB was used. This showed a similar 
level of CGB downregulation to CGB_4 and CGB_5 siRNAs (Figure 4.11). 
 
Figure 4.11 Downregulation of CGB in HEY and A2780cis using three 
siRNAs 
CGB downregulation in HEY and A2780cis cells measured by qRT-PCR. 
Expression of CGB gene transcript relative to HMBS, normalised to CGB/HMBS 
expression in the control non-silencing siRNA (C) 24 h post siRNA transfection. 
siRNAs: non-silencing control (C), CGB_4, CGB_5 and CGB_7. Data are 
expressed as mean ± S.E.M. (N=3). Statistical analysis: one sample t-test, 
comparing the different siRNA treatments for each cell line to their respective 
control siRNA * P < 0.05, ** P < 0.005, *** P < 0.0005. 
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Although CGB_7 siRNA showed similar levels of hCGβ downregulation 
(~ 65%) in HEY and A2780cis cells, the resulting response to cisplatin and 
carboplatin in the two cell lines was different (Figure 4.12).  Note that a one sample 
t-test was used for statistical analysis to assess knockdown as the non-silencing 
control siRNA was normalised to 100%. In A2780cis cells, CGB_7 siRNA caused a 
small but significant increase in sensitivity to cisplatin and carboplatin (Figure 4.12 
A and B). The degree by which CGB_7 siRNA increased cisplatin sensitivity in 
A2780cis cells was in between the degrees shown by CGB_4 and CGB_5 siRNA 
(Figure 4.8 A and B). Treatment of HEY cells with CGB_7 siRNA showed no 
change in cisplatin or carboplatin sensitivity in HEY cells (Figure 4.12 C and D). 
This result was contrary to the trend in increased in cisplatin and carboplatin 
sensitivity of caused by treatment of HEY cells with either CGB_4 or CGB_5 
(Figure 4.9 A and B). 
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Figure 4.12 Effect of hCGβ downregulation using CGB_7 siRNA on cell 
survival following cisplatin and carboplatin treatment 
The clonogenic assay was used to measure cell survival of A2780cis (A and B) 
and HEY (C and D) cells in response to treatment with cisplatin and carboplatin, 
24 h post transfection with a non-silencing control ( ) or 
CGB_7 (   ). Data are expressed as mean ± S.E.M. (N=3). * P < 0.05. 
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4.3.8 Investigation of possible compensatory effects of LHβ on hCGβ 
downregulation 
The β-subunit of the luteinising hormone (LHβ) is highly homologous to hCGβ. 
Furthermore, the gene encoding LHβ, LHB, is positioned on the same gene cluster as 
the CGB genes [130]. For these reasons, a compensatory effect by LHB was 
investigated to determine whether functional differences observed by the siRNAs 
targeting hCGβ (in particular CGB_4 and CGB_5) could be due to changes in the 
LHβ levels. Downregulation of CGB by CGB_4 siRNA caused ~ 65 % increase in 
the expression of LHB in HEY cells and a 30 % increase in A2780cis cells (Figure 
4.13); however, statistical significance was reached only for HEY cells.  In contrast, 
downregulation of hCGβ by CGB_5 siRNA caused a significant decrease of LHB 
(~ 20%) in HEY cells and no change in A2780cis cells. CGB_7 caused a slight 
reduction of LHB expression in both cell lines (Figure 4.13 A) but this was not 
statistically significant. Endogenous levels of LHB were also determined and it was 
found that HEY expressed 15 times more LHB compared to A2780cis cells (Figure 
4.13 B). The one sample t-test was used for statistical analysis of LHB expression 
levels following CGB downregulation as the control siRNA was normalised to 
100%. 
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A 
 
B 
 
Figure 4.13 Effect of CGB downregulation on LHB gene expression in HEY 
and A2780cis cells and endogenous expression of LHB  
Effect of CGB downregulation on LHB expression in HEY and A2780cis cells 
(A) and endogenous expression of LHB in HEY and A2780cis cells measured by 
qRT-PCR (B). siRNAs: non-silencing control (C), CGB_4, CGB_7 and CGB_5. 
Data are expressed as mean ± S.E.M; (N=3). Statistical analysis: one sample 
t-test.  Comparing the different siRNA to their respective control siRNA HEY 
cells: * P < 0.05 (applicable to panel A only). 
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4.3.9 Effect of hCGβ overexpression on viability and survival of A2780 and 
A2780cis cells in response to cisplatin treatment 
Downregulation of hCGβ showed different effects in terms of how the cisplatin 
sensitive A2780 cells and cisplatin resistant cells A2780cis responded to cisplatin 
(Figure 4.3 A and B). Specifically, downregulation of hCGβ in A2780 cells did not 
affect how the cells responded to cisplatin; however, it did sensitise A2780cis cells 
to cisplatin. hCGβ was then transiently overexpressed in the two cell lines to 
determine whether an increase in hCGβ would affect response of A2780 cells to 
cisplatin and perhaps show a decrease (opposite to effect seen by downregulation of 
hCGβ) in cisplatin sensitivity in A2780cis. hCGβ was markedly overexpressed 
following plasmid transfection in A2780 and A2780cis cells as shown previously in 
Chapter 3 (Figure 3.11). Despite this increase, the response to cisplatin treatment for 
both cell lines in terms of either cell viability assessed by MTS assay (Figure 4.14) 
or cell survival assessed by clonogenic assays, (Figure 4.15) was unaffected. 
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Figure 4.14 Effect of hCGβ overexpression on cell viability following 
cisplatin treatment  
Viability of cells following hCGβ overexpression and treatment with cisplatin. 
Cells: A2780 (A) and A2780cis (B). Vectors: Empty pCI-neo ( ), pCI-neo 
containing hCGβ insert ( ). Data are expressed as mean ± S.E.M; (N=3). 
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Figure 4.15 Effect of hCGβ overexpression on cell survival following 
cisplatin treatment  
The clonogenic assay was used to measure cell survival of A2780 (A) and 
A2780cis (B) in response to hCGβ overexpression and cisplatin treatment. 
Vectors: Empty pCI-neo ( ), pCI-neo containing hCGβ insert ( ). 
Data are expressed as mean ± S.E.M; (N=3). 
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4.4 Discussion  
4.4.1 Correlation between levels of secreted hCGβ and cisplatin sensitivity 
A clear association between the level of CGB and secreted hCGβ (CGB and 
hCGβ) in HEY, A2780 and A2780cis cells and their sensitivity to cisplatin could not 
be established (Figure 4.2). If only the HEY and A2780 cells were taken into 
consideration it would appear that higher levels of CGB/hCGβ correlate with 
decreased sensitivity to cisplatin, which would agree with the hypothesis that high 
expression of hCGβ may be associated with resistance to chemotherapy. However, 
the question of whether the absolute level of CGB and hCGβ expressed by cells 
could determine sensitivity or resistance to cisplatin arises when the response of 
HEY and A2780 cells to cisplatin is compared to that of A2780cis cells relative to 
the levels of CGB and hCGβ they express. HEY and A2780 cells expressed higher 
levels of CGB and hCGβ compared to A2780cis cells, and if higher levels of CGB 
and hCGβ correlated with decreased sensitivity to cisplatin then HEY and A2780cis 
cells should be less sensitive to cisplatin compared to A2780cis which was not the 
case (Figure 4.2). It should be noted that only three cell lines were used in this 
experiment therefore conclusive correlative data cannot be inferred; however, there 
are a few possible reasons why HEY and A2780 cells are more sensitive to cisplatin 
compared to A2780cis cells that express lower levels of CGB and hCGβ. 1. Cisplatin 
resistance is multifactorial [192], therefore it is likely that the absolute level of CGB 
and hCGβ expression between cell types alone are not able to dictate how cells 
respond to cisplatin. However, it is possible that the relative level of CGB and hCGβ 
in conjunction with unidentified factors determines hCGβ’s role in sensitivity to 
cisplatin (or other platinum-based drugs); 2. Drug resistance in A2780cis is 
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independent of CGB and hCGβ expression and due to other factors e.g. preventing 
drug accumulation and increased DNA repair [250, 305]; and 3. It is possible that 
different isotypes (type I and II) [165] of hCGβ may be expressed at different levels 
in the different cell lines which may play a varied role in cisplatin response. Whether 
type I or II hCGβ have different functions remains to be established. The ELISA and 
gene expression assays used in this study did not have the specificity to determine 
expression of the different isotypes. 
 
4.4.2 Effect of hCGβ downregulation on cell viability following cisplatin and 
paclitaxel treatment 
Downregulation of hCGβ increased the sensitivity of cisplatin resistant A2780cis 
cells to cisplatin but did not affect the sensitivity of cisplatin sensitive A2780 cells to 
cisplatin (Figure 4.3 A and B). From this observation two things can be inferred 
about the role of hCGβ in cisplatin sensitivity: firstly, hCGβ may play a role in how 
cells respond to cisplatin, and secondly, hCGβ’s role in response to cisplatin is more 
important in cells that have acquired resistance (or decreased sensitivity) to cisplatin. 
In agreement with the second proposition, HEY cells which were less sensitive to 
cisplatin compared to A2780 cells, also displayed increased sensitivity to cisplatin as 
a result of decreased levels of hCGβ (Figure 4.3 C). These data agree with studies 
that have shown elevated levels of hCGβ to be associated with chemoresistance 
[180, 280].  
Though downregulation of hCGβ seemed to sensitise A2780cis and HEY cells to 
cisplatin based drugs it had no effect on how cells responded to paclitaxel (Figure 
4.4). One likely explanation is that the paclitaxel and cisplatin have different cellular 
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targets (microtubules and DNA, respectively) hence different mechanisms of actions. 
hCGβ may be central to the mechanism of action of cisplatin and not microtubule 
targets agents. The possible mechanism of action of hCGβ in response to cisplatin 
treatment is investigated in Chapter 5.  
 
4.4.3 Effect of hCGβ downregulation on cell viability following treatment with 
other platinum-based drugs 
Downregulation of hCGβ significantly increased the sensitivity of A2780cis to 
carboplatin and oxaliplatin (Figure 4.5) which indicates that the increase in the 
sensitivity to cisplatin in these cells (discussed in section 4.4.2 above) could 
cross-over to other platinum-based drugs. Though both CGB_4 and CGB_5 siRNA 
showed a trend of decreased viability when HEY cells were exposed to carboplatin 
and oxaliplatin, only the use of CGB_4 siRNA caused a statistically significant 
increase in sensitivity to carboplatin (Figure 4.6 A). This suggests that the increased 
sensitivity to cisplatin may not necessarily cross-over to carboplatin and oxaliplatin 
in HEY cells.  It should also be noted that, although the use of CGB_4 siRNA 
showed a statistically significant increase in cisplatin and carboplatin sensitivity in 
A2780cis cells, the effect was not as marked as when CGB_5 siRNA was used. A 
possible reason (involving LHB) why the two siRNA were displaying functional 
differences despite showing similar level of hCGβ knockdown is discussed in section 
4.4.6. 
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4.4.4  Effect of hCGβ downregulation on cell survival 
Cell survival was significantly decreased when hCGβ was downregulated in 
A2780cis and HEY cells (Figure 4.7). This result agreed with data from the cell 
proliferation studies which showed that downregulation of hCGβ significantly 
decreased proliferation of HEY and A2780cis cells (Chapter 3, Figure 3.4). Indeed, 
cell survival and proliferation assays are different assays, but they are both reflective 
of how the cells are able to survive and proliferate.  
 
4.4.5 Effect of hCGβ downregulation on cell survival following cisplatin, 
carboplatin and oxaliplatin treatment 
Cell survival following hCGβ downregulation and treatment with cisplatin, 
carboplatin and oxaliplatin showed a trend of decreased sensitivity to the drugs in 
HEY and A2780cis cells (Figure 4.8 and Figure 4.9, respectively). However, only 
treatment with CGB_5 siRNA caused a significant increase in sensitivity to cisplatin 
and carboplatin in both A2780cis (Figure 4.8 B and C) and HEY cells (Figure 4.9 B 
and C), as well as an increase in sensitivity to oxaliplatin in A2780cis cells (Figure 
4.8 E).  
Carboplatin has a similar mode of action to cisplatin, supported by the fact that 
cross-resistance is commonly observed between these two drugs [192, 202, 211, 214, 
227]. Therefore it was not surprising that the increase in sensitivity to cisplatin 
following hCGβ downregulation was also observed following carboplatin treatment; 
however it was unexpected that cross-sensitivity to oxaliplatin was also observed as 
this is not often the case [214, 215]. Oxaliplatin forms similar DNA cross-links as 
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cisplatin however the mechanism of action of oxaliplatin seems to be different to that 
of cisplatin [215]. It is thought that the bulky 1,2-diaminocyclohexane (DACH) ring 
of oxaliplatin distorts the DNA in a manner which compromises binding the HMGB 
and MMR proteins [215]. MMR proteins seem to preferentially recognise and repair 
cisplatin-DNA adducts over oxaliplatin-DNA and therefore DNA lesions formed by 
oxaliplatin are bypassed [306].  It has also been suggested that other oxaliplatin 
interactions other than DNA-interactions may contribute to its mechanism of action 
[306, 307]. However, the increase in sensitivity following hCGβ downregulation 
suggests that hCGβ may play a direct or indirect role in common pathway shared by 
all three drugs which contributes to their cytotoxic effect. 
Although CGB_4 siRNA showed a trend of increased sensitivity to the platinum 
drugs, statistically significant results were achieved only in A2780cis cells after 
exposure to cisplatin and oxaliplatin (Figure 4.8 A and E). These results indicate that 
although hCGβ may be involved in sensitivity to platinum-based drugs; it could be 
more due to the different secondary effects of the siRNAs. A third siRNA targeting 
hCGβ (CGB_7) was used to test this theory. CGB_7 siRNA knocked down hCGβ at 
comparable levels to CGB_4 and CGB_5 siRNAs (60-70%) (Figure 4.11); however, 
this caused a significant decrease in cell survival in only A2780cis cells and not 
HEY cells following exposure to cisplatin and carboplatin (Figure 4.12). This 
suggested that the repeated increase in drug (in particular cisplatin and carboplatin) 
sensitivity observed by the CGB_5 siRNA in A2780cis is not due to a mere 
secondary effect of the siRNA. This result however, does not explain why HEY cells 
behaved differently with regards to drug sensitivity depending on the siRNA used to 
target hCGβ. The effects displayed by CGB_5 siRNA in HEY cells could be due to 
an off target effect, or perhaps due a compensatory effect of the related LHB gene. 
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The Taqman assay used to measure CGB gene downregulation does not distinguish 
between the different CGB genes and therefore cannot provide a representation of 
each individual gene product. The LHB gene could be detected and the results are 
discussed in below. 
 
4.4.6 Compensatory effect of LHβ subunit following hCGβ downregulation 
A compensatory effect of LHβ following hCGβ downregulation was studied in 
HEY and A2780cis cells in an attempt to explain: 1. the functional differences 
caused by the two siRNA used to target hCGβ (CGB_4 and CGB_5); and, 2. the 
different functional effects the siRNAs had on the two cell types (HEY and 
A2780cis cells). It was found that when CGB was downregulated using CGB_4 
siRNA, the LHB transcript level increased by 65 % and 30 % in HEY and A2780cis 
cells, respectively. This effect was not seen when CGB_5 siRNA was used (Figure 
4.13 A). This result could contribute to the functional differences observed using the 
two siRNAs. In particular, the significant changes in cell survival and viability after 
drug exposure observed with the use of CGB_5 siRNA may have been masked by 
increased LHB levels caused by the CGB_4 siRNA.  Interestingly, the LHB levels 
decreased following hCGβ downregulation with CGB_5 in HEY cells only. These 
results suggest that both LHB and CGB may need to be downregulated concurrently 
in these cells but not A2780cis cells in order to increase their sensitivity to platinum-
based drugs. In agreement with this theory it was observed that the use of CGB_7 
siRNA to downregulate hCGβ did not conclusively reduce the levels of the LHB 
gene in HEY cells. This may be a reason why an increase in cisplatin or carboplatin 
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sensitivity was not observed following hCGβ downregulation with CGB_7 siRNA 
(Figure 4.12).  
A study by Zhang et al. showed that in vitro exposure to exogenous LH could 
decrease the sensitivity of ovarian cancer cell lines to cisplatin [308]. As indicated in 
our data the α-subunit is expressed by both HEY and A2780cis cells (Chapter 3, 
Figure 3.2) which could potentially bind with the LHβ subunit thus forming the LH 
heterodimer and contributing to the response to cisplatin.  Interestingly, although 
HEY cells expressed up to 15 times more endogenous LHB compared to A2780cis 
(Figure 4.13 B) they are more sensitive to cisplatin. However it is still possible that 
when hCGβ is downregulated in HEY cells, LHB may contribute to the response of 
these cells to cisplatin.   
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4.4.7 Effect of hCGβ overexpression on cell viability and survival following 
exposure to cisplatin 
Overexpression of hCGβ in A2780 and A2780cis cells did not affect their 
response to cisplatin either in terms of cell viability (Figure 4.14) or cell survival 
(Figure 4.15). This result was not surprising in A2780 cells given that 
downregulation of hCGβ did not affect their response to cisplatin (Figure 4.3). It was 
however hypothesised that increased expression of hCGβ may decrease the 
sensitivity of A2780cis cells to cisplatin, since downregulation of hCGβ sensitised 
A2780cis to cisplatin (Figure 4.3). A possible explanation for this result is that 
increased expression of hCGβ beyond endogenous levels of hCGβ may not have 
influenced cisplatin sensitivity because a threshold level at which hCGβ has a 
protective effect to cisplatin had been reached. Another explanation, and one that is 
further investigated in the next chapter, is that there are additional factors which are 
altered only when hCGβ is downregulated thus contributing to its mechanism of 
action.  
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4.5 Conclusion 
Downregulation of hCGβ increased the sensitivity of the HGSC cells A2780cis 
and HEY to the drugs cisplatin, carboplatin and oxaliplatin, suggesting that hCGβ 
plays a role in sensitivity of HGSC towards platinum-based drugs. However, the 
effect may be dependent on several factors including a predisposition to drug 
resistance (or decreased sensitivity) as cisplatin sensitive A2780 cells did not seem to 
be affected by hCGβ downregulation. Furthermore, the discrepancies in the results 
shown by the use of two or three different siRNAs targeting hCGβ suggests that 
other unidentified factors e.g. LHβ, are required for the response of HGSC towards 
platinum-based drugs. These additional factors and the mechanism by which hCGβ 
is involved in the response of HGSC cells to cisplatin are further investigated in 
Chapter 5.  
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 Mechanism by which hCGβ may regulate Chapter 5
sensitivity of HGSC cells to cisplatin treatment 
 
5.1 Introduction 
In the previous chapter it was found that hCGβ may have a role in the response of 
HGSC cell lines to the platinum-based drugs cisplatin, carboplatin and oxaliplatin. 
However the mechanism by which hCGβ could be involved in this response needed 
to be understood. Therefore, further investigation into global protein changes that 
occur when hCGβ is downregulated following cisplatin treatment needed to be 
undertaken. To this end, quantitative proteomics using isobaric tags for relative and 
absolute quantitation (iTRAQ) labelling followed by tandem mass spectrometry 
(MS/MS) was used.  One of the advantages of using iTRAQ is that it allows 
multiplexing with the ability to analyse and compare 4 (4-plex) or 8 (8-plex) samples 
in a single MS/MS run.  
Briefly, protein samples from A2780cis cells with and without hCGβ 
downregulation in the absence or presence of cisplatin were extracted, digested with 
trypsin, iTRAQ labelled, pooled together, separated with liquid chromatography and 
peptides (correlating to whole proteins) quantified using tandem mass spectrometry. 
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5.1.1 iTRAQ labelling and quantitation of protein expression 
The iTRAQ label or tag consists of three groups: a N-methyl piperazine reporter, 
a carbonyl balance and a N-hydroxy succinimide ester peptide reactive group shown 
in Figure 5.1. 
 
Figure 5.1 Structure of the iTRAQ label 
Structure depicts the reporter group (114-117 Da), balance group (28-31 Da) and 
peptide reactive group. 
Figure extracted from  [309] 
 
The reporter group has a mass ranging from 114-117 Da and the weight of each 
reporter group is counter balanced with the balance group from  28-31 Da to yield an 
isobaric (equal mass) tag with a total mass of 145 Da. The isobaric tag is covalently 
linked to peptides through an amide bond at the N-terminus of the peptide or side 
amino group of lysine via the peptide reactive group [310]. Once the peptides are 
labelled they are pooled together and fractionated by liquid chromatography and then 
identified and quantified by tandem mass spectrometry. In the first MS round the 
peptides with different iTRAQ labels will appear as a single peak, however the 
second MS round will yield the peptide sequences as well as dissociate the reporter 
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group with a different mass thus allowing the quantitation of peptides from the 
different samples. The process of iTRAQ from protein extraction to identification 
and quantitation is outlined in Figure 5.2. 
 
 
Figure 5.2 iTRAQ coupled with LC-MS/MS for the quantification of global 
protein changes  
Flow of how protein samples are labelled using iTRAQ methodology and 
quantified using liquid chromatography coupled with tandem mass spectrometry. 
Figure extracted from  [309]  
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5.2 Materials and Methods 
5.2.1 Downregulation of hCGβ for proteomics 
A2780cis cells were used for the proteomic study as these cells showed a 
consistent differential response to cisplatin treatment after hCGβ was downregulated. 
CGB_5 was the siRNA chosen to knockdown hCGβ as this was the siRNA that 
showed significant and the most reproducible results in regards to increasing 
sensitivity of cells (both HEY and A2780cis cell lines) to cisplatin treatment. Refer 
to Appendix C Supplementary Figure 2 for quantification of downregulation of CGB 
in A2780cis cells used in the iTRAQ experiment. 
hCGβ was downregulated according to the method described in Chapter 2, 
section 2.8 with a few changes. A large amount of protein (2 mg) was required for 
the proteomics study hence approximately 1 x 10
7
 cells had to be transfected per 
treatment. Three lots of 3.5 x 10
6
 cells were transfected and pooled into a 15 cm petri 
dish in 15 mL of culture media. The transfections consisted of 2 dishes of cells 
receiving the negative non-silencing control siRNA, and 2 dishes of cells receiving 
the CGB_5 siRNA. The media was replaced with fresh media 24 h after transfection. 
 
5.2.2 Treatment with cisplatin for proteomic studies 
Forty-eight hours after transfection one plate of cells receiving the non-silencing 
control and the other receiving CGB_5 siRNA, were treated with 6.5 μM of cisplatin 
approximating an IC50 dose based on the cell viability data (Chapter 4, section 4.3.1), 
and incubated for 24 h.  
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5.2.3 Protein extraction for proteomic studies 
Twenty-four hours after drug treatment, the cells were washed with PBS twice, 
followed by the addition of 1 mL of protein lysis buffer (Table 5-1) on ice. Cells 
were scraped off with a cell scraper and the lysate transferred to a 15 mL tube. 
Table 5-1 Components of protein lysis buffer for iTRAQ 
Component Concentration 
Sodium dodecyl sulfate 0.15% 
HEPES, pH 7.5 20 mM 
Sodium chloride 150 mM 
Sodium fluoride 10 mM 
Sodium orthovanadate 1 mM 
EDTA 1 mM 
EGTA 1 mM 
 
The lysates were sonicated for 1 min in 30 s bursts, centrifuged for 5 min at 
500 g and the supernatant transferred to a 1.5 mL Eppendorf tube. The amount of 
protein was quantified using the BCA Protein Assay Kit colorimetric assay 
according to the manufacturer’s protocol. Briefly, 25 μl of the protein lysates 
(diluted 1:5 in lysis buffer) was assayed in duplicate against 25 μl of the BSA 
standard: 2, 1.5, 1, 0.75, 0.5, 0.25, 0.125, 0.025 and 0 (blank, lysis buffer) μg/mL in 
a 96 well plate, also in duplicate. Two hundred μl of working reagent (included in 
the kit) was added to the wells and incubated for 30 min at 37ºC. The absorbance 
was then measured at 560 nm on the Wallac Victor 1420 Multilabel Counter. A BSA 
protein standard curve of absorbance vs protein quantity was graphed and the protein 
concentrations were determined based on this curve.  
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5.2.4 iTRAQ labelling and proteomic analyses 
Once the protein concentrations were established, the samples were sent to the 
Australian Proteome Analysis Facility (APAF Ltd, Sydney, Australia) for iTRAQ 
labelling and proteomics analysis. As this process was outsourced on a fee-for-
service basis, only a summary of the method for analysis is outlined here.  Briefly, 
protein lysates were buffer exchanged to 0.25 M triethyl ammonium bicarbonate, 
0.05% SDS on a Vivaspin 2 5-kDa filter, and 100 μg of protein was then reduced 
with tris(2-carboxyethyl)phosphine, alkylated with methyl methanethiosulfonate and 
trypsin digested. The digested samples were isotope labelled using the iTRAQ® 
Reagent - 4plex system (AB Sciex). Labels assigned to protein samples are 
summarised (Table 5-2). 
 
Table 5-2 Labels assigned to samples for proteomic studies 
Sample/Treatment Isotope label 
Control siRNA 114 
Control siRNA + cisplatin 115 
CGB_5  siRNA 116 
CGB_5  siRNA + cisplatin 117 
 
The labelled samples were washed and fractionated by strong cation exchange 
high performance liquid chromatography (HPLC) followed by nanoflow liquid 
chromatography electrospray ionisation tandem mass spectrometry (nanoLC ESI 
MS/MS) with data acquisition using the Eksigent Ultra nanoLC system (Eksigent) 
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coupled with a Triple TOF 5600 mass spectrometer (AB Sciex). The data was then 
processed using ProteinPilot V4.2b (AB Sciex) against the SwissProt 2012 Human 
database.  
Protein changes were reported as iTRAQ ratios. Proteins were considered to be 
upregulated if the ratio was above 1.2 or downregulated if the ratio was below 0.85. 
The top 10 upregulated and downregulated proteins of the following comparisons 
were tabulated (Table 5-3).  
 
Table 5-3 Summary of sample labels and what they measure 
Indicated 
by 
Label Ratio Measures 
A 115:114 control siRNA + cisplatin : control siRNA  Effect of cisplatin 
B 116:114  CGB_5   siRNA : control siRNA  
Effect of hCGβ 
downregulation  
C 117:114  CGB_5   siRNA + cisplatin : control siRNA  
Effect of hCGβ 
downregulation and 
cisplatin together 
D 117:116 CGB_5   siRNA + cisplatin : CGB_5 siRNA 
Effect of  cisplatin 
when hCGβ was 
downregulated 
E 
115: 114
117: 116
 
 
Where 
115:114 
is close 
to 1 
control siRNA +  cisplatin ∶  control siRNA
CGB_5   siRNA +  cisplatin ∶  CGB_5   siRNA siRNA
 
 
Where “A” is close to 1 (0.9 > ratio <1.1) 
Proteins that were 
only responsive to 
cisplatin when 
hCGβ was 
downregulated (i.e. 
were resistant to 
cisplatin in the 
presence of hCGβ). 
 
Note that “E” indicates proteins that did not change in “A” (i.e. proteins that did 
not alter in response to cisplatin measured by a ratio close to 1, 0.9 > ratio <1.1) but 
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had changed when “A” was divided by “D”. This subset of proteins was indicative of 
proteins that had not changed when cells were treated with cisplatin alone but had 
changed in a cisplatin-dependent manner in cells where hCGβ was downregulated. 
In other words, this ratio allowed us to determine in a relative sense, the overall 
effect of cisplatin on cells where hCGβ was downregulated. 
 
5.2.5 Ingenuity® Pathway Analysis  
The protein changes (ratios) from the proteomic data were uploaded into 
Ingenuity® Pathway Analysis (IPA) software (Qiagen) and differentially regulated 
networks and pathways were generated. Note: Statistical significance of dysregulated 
pathways was determined by IPA software. 
 
5.2.6 Validation of proteomic protein changes by western blotting 
Changes in protein abundance from the proteomic data, based on “E” (i.e. 
proteins that became cisplatin-sensitive when hCGβ was downregulated) were 
validated using western blotting in A2780cis cells, as well as HEY cells. The 
proteins of interest for validation were chosen from the top 10 downregulated or 
upregulated proteins, and/or if they played a role in more than one biological 
pathway.  
 
For western blotting, hCGβ was downregulated in HEY and A2780cis cells by 
siRNA transfection and 1 x 10
5
 or 4 x 10
5 
cells, respectively, were plated into 
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12 well plates. After 24 h the media was replaced with 750 μl of fresh culture media 
and cells incubated for a further 24 h after which 250 μl of culture media, with or 
without cisplatin was added to cells. Cells were treated with IC50 concentrations 
(based on cell viability data) of cisplatin: 3.25 μM for HEYs and 6.5 μM for 
A2780cis, which was added at 4 x the concentration to take into account the dilution 
factor. After 24 h, protein lysates were extracted blotted and protein expression 
quantified (Chapter 2, section 2.7.2 for details on western blotting). Note: Protein 
expression is expressed as changes in the levels of the protein following the different 
treatments compared to control non-silencing siRNA treatment alone and then 
divided by the average ratios of protein expression compared to the control GAPDH.  
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5.3 Results 
5.3.1 Global changes after hCGβ downregulation and cisplatin treatment 
The changes in proteins from the proteomic study are presented as iTRAQ ratios. 
The top 10 proteins that were up regulated or downregulated in the following ratios: 
“A”, “B”, “C” and “E” are presented in Table 5-4 to Table 5-7. All proteins 
identified by iTRAQ are listed in the supplementary data. Refer to Appendix C 
Supplementary Figure 3 for the total number of identified proteins and proteins that 
were up- or down-regulated. 
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Table 5-4 Top 10 proteins upregulated and downregulated when A2780cis 
cells were treated with non-silencing siRNA and cisplatin “A” 
Protein A B C 
60S ribosomal protein L36a  3.477 2.289 3.326 
60S ribosomal protein L36a-like  3.367 1.484 2.437 
Cytochrome c oxidase subunit 6C  2.989 1.777 2.494 
Cytochrome b  2.809 1.857 2.657 
SAP30-binding protein  2.430 1.674 2.407 
Protein FAM98B  2.381 1.251 1.691 
Signal peptidase complex subunit 1  2.376 1.762 2.401 
V-type proton ATPase subunit G 1  2.368 1.288 1.751 
ADP/ATP translocase 2  2.279 1.244 2.091 
U6 snRNA-associated Sm-like protein LSm6 2.259 1.368 1.802 
HIG1 domain family member 1A   0.544 0.935 0.797 
E3 ubiquitin-protein ligase ZFP91     0.528 0.797 0.697 
Acyl-CoA dehydrogenase family member 9, mitochondrial  0.519 0.645 0.421 
Zinc transporter ZIP10 0.508 0.976 0.743 
Uncharacterised protein C10orf46  0.486 1.025 1.078 
Spermatogenesis-associated protein 5  0.446 0.745 0.690 
SH3 domain-binding glutamic acid-rich-like protein 3  0.439 0.841 0.800 
VPS33B-interacting protein  0.391 0.649 0.649 
Histone H1.2  0.389 0.907 0.274 
PCNA-interacting partner  0.302 0.833 0.585 
Data are shown as iTRAQ ratios. “A” is the effect of cisplatin treatment, “B” is the 
effect of hCGβ downregulation, and “C” is the effect of both treatments combined. 
Upregulated (  ) and downregulated proteins (  ). 
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Table 5-5 Top 10 proteins upregulated and downregulated when A2780cis 
cells were treated with CGB_5   siRNA alone “B”  
Protein A B C 
High mobility group protein HMGI 1.078 3.043 3.123 
Histone H2A type 2-A  1.674 2.841 3.908 
Protein S100-A13  1.256 2.671 3.090 
Interstitial collagenase  1.055 2.448 2.398 
Spermatid perinuclear RNA-binding protein 0.912 2.313 1.355 
60S ribosomal protein L36a  3.477 2.289 3.326 
Protein phosphatase 1 regulatory subunit 14B  1.813 2.211 2.533 
Protein S100-A4  0.940 2.118 1.989 
Phosphate carrier protein, mitochondrial  1.988 1.954 2.004 
Cytoskeleton-associated protein 2 0.901 0.552 1.024 
G patch domain-containing protein 1  0.990 0.549 0.517 
GC-rich sequence DNA-binding factor 2  0.546 0.537 0.568 
Telomeric repeat-binding factor 1  0.670 0.536 0.733 
ADP-ribosylation factor 6  1.024 0.535 0.517 
UPF0498 protein KIAA1191  0.646 0.529 0.619 
DNA repair protein RAD51 homolog 1  1.129 0.522 0.469 
Argininosuccinate lyase  0.864 0.518 0.776 
Mitochondrial import receptor subunit TOM34  1.084 0.480 0.588 
Branched-chain-amino-acid aminotransferase, mitochondrial  0.940 0.475 0.521 
Data are shown as iTRAQ ratios. “A” is the effect of cisplatin treatment, “B” is the 
effect of hCGβ downregulation, and “C” is the effect of both treatments combined. 
Upregulated (  ) and downregulated proteins (  ). 
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Table 5-6 Top 10 proteins upregulated and downregulated when A2780cis 
cells were treated with CGB_5   siRNA and cisplatin “C”  
Protein A B C 
Histone H2A type 2-A  1.674 2.841 3.908 
60S ribosomal protein L36a  3.477 2.289 3.326 
Keratin, type I cytoskeletal 10  1.289 1.274 3.266 
Keratin, type II cytoskeletal 1  0.953 1.175 3.181 
High mobility group protein HMGI-C  1.078 3.043 3.123 
Protein S100-A13  1.256 2.671 3.090 
Cytochrome b  2.809 1.857 2.657 
Protein phosphatase 1 regulatory subunit 14B  1.813 2.211 2.533 
Cytochrome c oxidase subunit 6C 2.989 1.777 2.494 
60S ribosomal protein L36a-like  3.367 1.484 2.437 
ATP-dependent RNA helicase DDX51  0.656 0.750 0.548 
Branched-chain-amino-acid aminotransferase, 
mitochondrial  
0.940 0.475 0.521 
ADP-ribosylation factor 6  1.024 0.535 0.517 
G patch domain-containing protein 1  0.990 0.549 0.517 
DNA repair protein RAD51 homolog 1 1.129 0.522 0.469 
52 kDa repressor of the inhibitor of the protein kinase  0.571 0.650 0.456 
Probable methyltransferase-like protein 15  0.697 0.927 0.552 
Acyl-CoA dehydrogenase family member 10  0.820 0.698 0.430 
Acyl-CoA dehydrogenase family member 9, mitochondrial  0.519 0.645 0.421 
Histone H1.2  0.389 0.907 0.274 
Data are shown as iTRAQ ratios. “A” is the effect of cisplatin treatment, “B” is the 
effect of hCGβ downregulation, and “C” is the effect of both treatments combined. 
Upregulated ( ) and downregulated proteins ( ). 
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Table 5-7 Top 10 proteins upregulated and downregulated when A2780cis 
cells were treated with CGB_5   siRNA and cisplatin compared to cells that 
received non-silencing siRNA and cisplatin “E” 
Protein A D E (A/D) 
Cytoskeleton-associated protein 2  0.901 1.855 2.058 
Galectin-related protein  0.910 1.587 1.743 
Glycerophosphodiester phosphodiesterase 1 0.906 1.563 1.724 
Dual specificity tyrosine-phosphorylation-regulated 
kinase 1A  
0.988 1.701 1.721 
CpG-binding protein 0.926 1.525 1.647 
Numb-like protein  1.072 1.714 1.599 
Melanoma-associated antigen D2  0.918 1.454 1.584 
Transmembrane protein 237  1.004 1.556 1.550 
LIM domain kinase 1  0.974 1.500 1.541 
Ras and Rab interactor 1 1.025 0.9221 1.539 
SWI/SNF-related matrix-associated actin-dependent regulator 
of chromatin subfamily D member 1  
1.028 0.728 0.708 
Wings apart-like protein homolog  0.931 0.645 0.692 
GDP-D-glucose phosphorylase C15orf58 1.007 0.697 0.692 
Glutathione S-transferase theta-1 1.077 0.743 0.689 
5-azacytidine-induced protein 1 1.075 0.737 0.685 
Signal peptidase complex catalytic subunit SEC11C  1.045 0.703 0.672 
UPF0614 protein C14orf102  1.085 0.706 0.651 
Spermatid perinuclear RNA-binding protein  0.912 0.587 0.644 
Collagen type IV alpha-3-binding protein  1.061 0.631 0.594 
Tripeptidyl-peptidase 1  1.067 0.627 0.588 
NAD-dependent deacetylase sirtuin-1 1.099 0.915 0.833 
Data are shown as iTRAQ ratios. Description of “A”, “D” and “E” are shown in 
Table 5-3. Upregulated (  ) and downregulated proteins (  ). Proteins chosen for 
validation experiments (  ). 
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5.3.2 Pathways affected by hCGβ downregulation and cisplatin treatment 
The top four to five pathways affected by “A”, “B”, “C” and “E” obtained from 
IPA analysis are presented in Table 5-8. Refer to Appendix C, Supplementary Figure 
4 to Figure 7 which show the top networks. 
Cisplatin treatment alone “A” affected the cell death and survival, cell cycle, 
DNA replication, recombination and repair, and RNA processing pathways. 
Interestingly, two out of the five top pathways affected in “A” were also affected by 
hCGβ siRNA treatment alone “B”: the DNA replication, recombination and repair 
pathway, and the RNA post-translational modification pathway. DNA repair appears 
to be increased in “A” and “B” however RNA post-transcriptional modification 
seems to be increased in “A” and decreased in “B”.  In addition to these pathways 
protein synthesis in general seems to be decreased when cells are treated with hCGβ 
siRNA alone “B”.  
The top four pathways affected in “A” and hCGβ siRNA + cisplatin treatment 
“C” were the same; however, the cellular processes within the pathways and some of 
molecules associated with the cellular processes were different. For example, though 
the cell death pathway was affected in “A” and “C” the cellular processes within the 
pathway were different. In “A” there was an increase in cell death, apoptosis and 
necrosis where as in “C” neither cell death nor apoptosis seemed to be 
downregulated or upregulated. Another example is the cell cycle pathway: “A” had 
an increase in senescence but “C” had a decrease in senescence. 
 “E” (i.e. pathways that became cisplatin-sensitive when hCGβ was 
downregulated) showed a decrease in DNA repair and cell cycle progression, and the 
cellular morphology compared to cisplatin treatment alone “A”. 
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Table 5-8 Top five pathways affected when A2780cells were treated with “A”, “B”, “C” or “E”  
Pathway Direction of regulation of cellular processes within the 
pathway 
Associated molecules 
Treatment “A” 
Cell death and survival 
p-value range = 3.95e-2  to 2.73 e-6 
anoikis CDKN2A, EPHA2,  FADD, PLK1, SMAD4, SRC 
cell death, apoptosis and survival, necrosis CDKN2A, BAX, AKT1, CDK2, EPHA2, FADD, PLK1, JAK1, 
ABL2, H2AFX, HNRNPK, EIF4EBP1, CCNB1 
Cell cycle 
p-value range = 3.95e-2  to 3.32 e-6 
G2 phase, mitosis spindle checkpoints AKT1, SMAD4, CCNB1, BAX, SRC, CDKN2A, SFN, TOP2A 
interphase, M-phase, senescence, cytokinesis CDKN2A, AKT1, EIF4EBP1, NOTCH3, RELA, CDK2, TOP1, 
PLK1 
DNA replication, recombination and repair  
p-value range = 3.95e-2  to 4.63e-6 
DNA repair  POLD1, CDK2, H2AFX, XPC, CDKN2A, PCNA 
damage BAX, H2AFX, PLK1, TOP1, TOP2A, CDKN2A 
RNA Post-transcriptional modification 
p-value range = 3.95e-2  to 1.77e-16 
Processing and splicing RPS17, PABPC4, HNRNPK 
Treatment “B” 
Free Radicle Scavenging 
p-value range = 3.43e-2  to 4.02e-5 
accumulation, production and synthesis TXN, HK2, FTL, LIMK1, MAP2K1, SRC 
Molecular transport 
p-value range = 3.43e-2  to 4.02e-5 
accumulation of oxygen reactive species CDKN2A, VIPAS39, PPT1 
DNA replication, recombination and repair 
p-value range = 3.43e-2  to 3.99e-5 
metabolism of DNA, segregation of chromosomes, 
recombination, aberrations of chromosomes 
TOP1, CCNB1, PPT1, CDKN2A, MCL1 
increased repair and checkpoints CDKN2A, PRKDC, WRN, CCNB1 
RNA post-transcription modification 
P VALUE=3.43e-2  to 1.88e5-5 
processing CDK7 
Protein Synthesis 
p-value range = 2.38e-2  to 1.17e-5 
translation, expression, proteolysis and catabolism CDKN2A, FADD, MMP1, AURKA 
Treatment “C” 
Cell death and survival 
p-value range = 3.85e-2  to 2.92e-9 
cell viability ADAM17, SRC, CASP3, EPHA2, PRKDC, STAT3, BAX, FADD, 
KIF11, PAK1, PTK2, SFN, TXN, CDKN2A, MCL1, CCNB1, PCNA 
cell death and apoptosis ABL2, ADAM17, AX, CAPS3, CDKN2A,  CCNB1, BCAP31, HSF1, 
IKBKG, FADD, CHUK, EPHA2 
anoikis MCL1, PTK2, CDKN2A, SRC, FADD 
Cell cycle 
p-value range = 4.11-2  to 6.12e-6 
mitosis, cytokinesis, M-phase, S-phase  KIF11, FADD, CCNB1, LMNA, RAB35, TXN, SRC, CDKN2A 
senescence YAP1, RELA, CDKN2A, EIF4EBP1 
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DNA replication, recombination and repair 
p-value range = 4.11e-2  to 3.50e-6 
fragmentation, damage, degradation, replication FADD, PAK1, BAX, CAPS3, CDKN2A, PPT1, PKT2, PRKDC, 
NQ01, PCNA, POLD1 
segregation of chromosome KIF11, LMNA, CCNB1 
RNA post-transcription modification 
p-value range = 3.27e-2  to 1.28e-6 
processing CDK7, HNRNPK 
p-value range = 3.85e-2  to 6.12e-6 
organisation of cytoskeleton and cytoplasm KRT18, STAT3, PAK1, PTK2, KIF11, SRC, CHUCK, CCNB1, 
EPHA2 
segregation of chromosomes and binding components of 
chromosomes 
KIF11, CCNB1, LMNA 
Treatment “E” 
Cell assembly and organisation 
p-value range = 3.36e-2  to 6.73e-6 
organisation of cytoskeleton and cytoplasm NRF1, EP300, LIMK1, VHL, SUN2, MPRIP, SHARPIN, NUMB, 
MAP9, CHD3, CIT 
microtubule dynamics NUMB, MAP9, LIMK1, RPS6KB1, CIT, NEDD1, VHL, EP300 
Cell cycle 
p-value range = 3.36e-2  to 2.69e-5 
cell cycle progression and interphase AATF, CKS2, SIRT1, EP300, CIT, ERCC1, RPS6KB1, WRN, 
SUN2, CAMP1, LIMK1, VHL, ORC3, CIT, CDK13, HMOX1 
CASP3, MAP9 
DNA replication, recombination and repair 
p-value range = 3.36e-2  to 2.69e-5 
metabolism, replication  ORC3, SIRT1, WAPAL, CKS2, LIG3, WRN, EP300, NRF1, ERCC1, 
WRNIP1, GTPBP4 
repair ERCC1, SIRT1, LIG3, WRN, HMOX1, MRE11A 
Cellular morphology 
p-value range = 3.04e-2  to 3.76e-4 
autophagy  SIRT1, CAMK1, NAF1, GNAS, RPS6KB1, EP300, MFN2 
morphology CASP3, LIMK1, SIRT1, ERCC1, EP300, GNAS, GSK3A, 
SHARPIN, NEDD1, MPRIP 
Description of “A”, “B”, “C” and “E” are shown in Table 5-3. Upregulated (  ) and downregulated cellular processes (  ).  
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5.3.3 Validation of iTRAQ results: effect of hCGβ downregulation and 
cisplatin on the protein expression level of WAPAL, LIMK1, and SIRT1 
LIM domain kinase 1 (LIMK1), wings apart-like homolog (WAPAL) and sirtuin 
1 (SIRT1) were chosen for validation by western blotting. LIMK1 and WAPAL 
were chosen as they not only appeared in the list of 10 top up- and downregulated 
proteins in “E” (Table 5-7) but also appeared in at least one pathway that was 
dysregulated in “E” (Table 5-8). SIRT1 was not part of the top ten downregulated 
proteins in “E” (although still represented in Table 5-7) but it was chosen for further 
validation as it appeared to be important in a number of pathways (Table 5-8) hence 
could be essential in the mechanism by which hCGβ confers cisplatin resistance. 
Both LIMK kinase and SIRT1 have been previously implicated in ovarian cancer 
[311-313] as well in response of cancer cells to cisplatin treatment [314-316]. 
According to the iTRAQ analysis, the levels of WAPAL and SIRT1 were 
downregulated and LIMK1 levels were upregulated when A2780cis cells were 
treated with cisplatin after hCGβ downregulation, “E”, but were unaffected by 
cisplatin treatment alone “A” (Table 5-7). In order to validate these results, hCGβ 
was downregulated in A2780cis as well as HEY cells using CGB_4 and CGB_5 
siRNAs, followed by cisplatin treatment (or no treatment for controls). Changes in 
the level of WAPAL, SIRT1 and LIMK1 were then assessed by western blotting. 
Western blots representing the levels of WAPAL protein, LIMK1 and SIRT1 in 
HEY and A2780cis cells after hCGβ downregulation and cisplatin treatment are 
shown in Figure 5.3. Interestingly, LIMK1 could not be detected by western blot in 
A2780cis cells despite these cells being used for the iTRAQ study. Quantitative 
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representations of the levels of WAPAL, SIRT1 and LIMK1 are shown in Figure 
5.4, Figure 5.5 and Figure 5.6, respectively.  
  
Chapter 5 
160 
 
A 
 
 
 
 
 
 
 
 
 
 B 
 
Figure 5.3 Effect of hCGβ downregulation and cisplatin on the expression 
levels of WAPAL, LIMK1 and SIRT1 
Protein levels of WAPAL, SIRT1 and LIMK1 levels in A2780cis (A), or HEY 
(B) cells following hCGβ downregulation and cisplatin treatment. LIMK1 was 
undetectable in A2780cis. 48 h post siRNA transfection: non-silencing control 
(C), CGB_4 and CGB_5. 
 
5.3.3.1 Effect of hCGβ downregulation and cisplatin on WAPAL expression  
In contrast to the iTRAQ results, WAPAL levels did not significantly decrease in 
A2780cis or HEY cells which were treated with cisplatin following hCGβ 
downregulation “D” compared to cells which were treated with cisplatin when hCGβ 
was not downregulated “A” (Figure 5.4 A and B, respectively). Treatment with 
cisplatin following downregulation of hCGβ with CGB_5 siRNA “D” significantly 
decreased the expression of WAPAL protein compared to the negative non-silencing 
siRNA, a result which was not shown by cells treated with cisplatin and the non-
silencing siRNA “A” as quantitated from western blots (Figure 5.4). Overall, this 
experiment was unable to confirm WAPAL as a protein whose regulation by 
cisplatin was dependent on the downregulation of hCGβ, although there was a trend 
towards this with CGB_5 siRNA in the HEY cells. 
Cisplatin   -    +    -    +     -   + 
siRNA    C   CGB_4  CGB_5  siRNA    C   CGB_4  CGB_5  
Cisplatin   -    +    -    +     -   + 
WAPAL 
SIRT1 
GAPDH 
WAPAL 
SIRT1 
LIMK1 
GAPDH 
Chapter 5 
161 
 
A 
 
 
 
B 
 
Figure 5.4 Effect of cisplatin treatment following hCGβ downregulation on 
WAPAL expression 
The effect of cisplatin treatment following hCGβ downregulation on the protein 
levels of WAPAL in A2780cis (A, N=4) and HEY cells (B, N=6), measured by 
western blotting, 48 h post siRNA transfection. Data are expressed as mean ± 
S.E.M. Statistical test: one-way ANOVA with LSD post hoc test. Statistical test: 
one-way ANOVA with LSD post hoc test, * P < 0.05, ** P < 0.005. Other 
differences were not significant 
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5.3.3.2  Effect of hCGβ downregulation and cisplatin on SIRT1 expression 
SIRTS levels did not significantly decrease in A2780cis or HEY cells which 
were treated with cisplatin following hCGβ downregulation “D” compared to cells 
which were treated with cisplatin when hCGβ was not downregulated “A” (Figure 
5.5 A and B, respectively). CGB_5 siRNA treatment alone compared to the non-
silencing control siRNA treatment alone caused a near significant (P=0.061) 
reduction of SIRT1 expression in A2780cis cells and a significant decrease in HEY 
cells (Figure 5.5 A and B, respectively). Overall, similar to WAPAL, this experiment 
was unable to confirm SIRT1 as a protein whose regulation by cisplatin was 
dependent on the downregulation of hCGβ although, again, there was a trend 
towards this with CGB_5 siRNA in the HEY cells. 
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Figure 5.5 Effect of cisplatin treatment following hCGβ downregulation on 
SIRT1 expression 
The effect of cisplatin treatment following hCGβ downregulation on the protein 
levels of SIRT1 in A2780cis (A) and HEY cells (B) measured by western 
blotting, 48 h post siRNA transfection. Statistical test: one-way ANOVA with 
LSD post hoc test, * P < 0.05, ** P < 0.005. 
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5.3.3.3 Effect of hCGβ downregulation and cisplatin on expression of LIMK1 
In Table 5-7, LIMK1 appeared upregulated by cisplatin when hCGβ was 
silenced. In contrast, in HEY cells the level of LIMK1 was significantly decreased in 
cells which were treated with cisplatin following hCGβ downregulation “D” as well 
as in cells which were treated with cisplatin alone “A” (Figure 5.6).  A significant 
decrease in LIMK1 was also observed with hCGβ downregulation alone or cisplatin 
treatment alone. As mentioned in section 5.3.3, LIMK1 could not be detected in 
A2780cis cells by western blot therefore data on LIMK1 expression following hCGβ 
downregulation and cisplatin treatment is not presented in Figure 5.6. 
 
 
Figure 5.6 Effect of cisplatin treatment following hCGβ downregulation on 
LIMK1 expression 
The effect of cisplatin treatment following hCGβ downregulation on the protein 
levels of LIMK1 in HEY cells measured by western blotting, 48 h post siRNA 
transfection. Data are expressed as mean ± S.E.M; (N=4). Statistical test: one-
way ANOVA with LSD post hoc test, * P < 0.05, ** P < 0.005. 
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5.3.4 Effect of SIRT1 downregulation on cisplatin sensitivity 
Of the three proteins validated by western blotting, SIRT1 showed the greatest 
promise as a protein whose levels might be significantly decreased in A2780cis and 
HEY cells when the cells were treated with cisplatin following downregulation of 
hCGβ with the CGB_5 siRNA (Figure 5.5). To further investigate whether a 
decrease in SIRT1 alone could be a possible mechanism by which CGB_5 or CGB_4 
siRNA could sensitise cells to cisplatin, SIRT1 was downregulated in A2780cis and 
HEY cells by siRNA transfection (Chapter 2, section 2.8) and the response of cells to 
cisplatin was assessed using the cell viability and clonogenic assays (Chapter 4, 
section 4.2.1).   
 
5.3.4.1 Downregulation of SIRT1 
SIRT1 was downregulated with both siRNAs directly targeting SIRT1 (SIRT1 
(2) and SIRT1 (3)) in both A2780cis and HEY cells by up to 90% (Figure 5.7).  
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Figure 5.7 Downregulation of SIRT1 in A2780cis and HEY cells 
Downregulation of SIRT1 in A2780cis and HEY cells 48h post siRNA 
transfection. Western blot showing levels of SIRT1 protein (A), quantification of 
SIRT1 knockdown (B). siRNAs: non-silencing control siRNA (C) two siRNAs 
targeting SIRT1: SIRT1 (2) and SIRT1 (3). Data are expressed as mean ± S.E.M; 
(N=3).  
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5.3.4.2 Effect of SIRT1 downregulation on cisplatin sensitivity determined by cell 
survival and viability 
In A2780cis cells, both siRNAs (SIRT1 (2) and SIRT1 (3)) targeting SIRT1 
showed a trend towards increased sensitivity to cisplatin treatment in terms of cell 
viability (Figure 5.8 A). However, this increase was statistically significant only 
when the SIRT 1(3) siRNA was used. This trend of increased cisplatin sensitivity 
was also evident in HEY cells but did not reach statistical significance (Figure 5.8 
B).  
The clonogenic assay showed that downregulation of SIRT1 in A2780cis cells 
significantly decreased cell survival following cisplatin treatment using both siRNAs 
targeting SIRT1 (Figure 5.9 A). However, SIRT1 downregulation in HEY cells did 
not affect cell survival following cisplatin treatment (Figure 5.9 B). 
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Figure 5.8 Effect of SIRT1 downregulation on the viability of A2780cis and 
HEY cells following cisplatin treatment  
Effect of SIRT1 downregulation on viability of A2780cis (A) and HEY (B) cells 
measured by the MTS assay in response to cisplatin treatment. 48 h post 
transfection with siRNAs: non-silencing control (C) ( ), SIRT1(2) ( ) 
and SIRT1(3) (  ). Data are expressed as mean ± S.E.M; (N=3). * P < 0.05.  
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Figure 5.9 Effect of SIRT1 downregulation on the survival of A2780cis and 
HEY cells following cisplatin treatment  
Effect of SIRT1 downregulation on survival of A2780cis (A) and HEY (B) cells 
measured using the clonogenic assay in response to cisplatin treatment. 24 h post 
transfection with siRNAs siRNAs: non-silencing control (C) ( ), SIRT1(2) 
( ) and SIRT1(3) ( ). Data are expressed as mean ± S.E.M; 
(N=3).  * P < 0.05, **P < 0.005. 
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Interestingly, a query of the online analysis software Kaplan Meier-plotter 
(KM-plotter) showed that SIRT1 was a negative prognostic marker of patient 
survival in ovarian cancer patients who received platinum treatment. Specifically 
high SIRT1 levels correlated with a lower rate of progress free survival in ovarian 
cancer patients who received platinum treatment (Figure 5.10). The KM-plotter is 
freely available online analysis software that enables the assessment of the 
prognostic value of a gene based on gene expression and clinical data from the Gene 
Expression Omnibus (Affymetrix microarrays only), European Genome-phenome 
Archive and The Cancer Genome Atlas archives [317].  
 
Figure 5.10 Kaplan-Meier Plot of SIRT1 levels and progress free survival in 
ovarian cancer patients who received platinum  therapy 
Assessment of the prognostic value of SIRT1 in ovarian cancer patients who 
received platinum therapy using data analysed by KM-Plotter. The cohort 
contained a total of 1185 patients, 320 patients expressed low SIRT1 and 865 
patients expressed high levels of SIRT1. Hazard ratio = 1.21 (1.04-1.41) and 
logrank P = 0.013. 
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5.4 Discussion 
5.4.1 iTRAQ protein changes 
Downregulation of hCGβ in A2780cis and HEY cells sensitised the cells to 
cisplatin treatment (Chapter 4, sections 4.3.3 and 4.3.6); however the mechanism by 
which hCGβ could be involved in the response to cisplatin needed to be understood. 
In order to do this the global protein changes that occurred when hCGβ was 
downregulated in A2780cis cells in the absence and presence of cisplatin were 
studied using iTRAQ. iTRAQ is a quantitative proteomic technique used to 
determine the relative abundance of specific proteins in one or more samples 
compared to a reference sample. One of the advantages of iTRAQ, and a reason why 
it was used in this study, is that it facilitates multiplexing, allowing comparison of up 
to 8 samples in one run. However the disadvantage of iTRAQ is that variability in 
labelling efficiencies and protein digestion could lead to discrepancies in the results.  
There are a number of other techniques which could have been used to overcome 
this problem. One example is use of the in vivo stable isotope labelling by amino 
acids (SILAC) technique, whereby “heavy” or “light” isotopes are used to label 
amino acids under different treatment conditions that are metabolically incorporated 
into cellular proteins causing a mass shift which can be quantified by MS-based 
techniques [318]. Specifically, two samples are grown in culture media containing 
either heavy (e.g. N
15
 and C
13
 L-lysine or Arginine) or light (naturally occurring) 
amino acids. The proteins are extracted and equal quantities of protein are pooled 
together before protein digestion and quantitation by MS-based techniques [319]. 
The disadvantage of SILAC is that it is relatively expensive and only two or three 
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samples can be compared in a single analysis [320, 321]. For these reasons, iTRAQ 
was deemed the most suitable technique for the current study. 
The 10 top upregulated and downregulated proteins when the A2780cis cells 
were treated with control non-silencing siRNA with cisplatin “A”, CGB_5 siRNA 
alone “B”, or CGB_5 siRNA with cisplatin “C” were different (Table 5-4, Table 5-5, 
Table 5-6, respectively). Interestingly, when all the protein changes which occurred 
in “A”, “B” and “C” were analysed by the IPA program, a number of pathways 
overlapped, in particular between “A” and “C” which was an unexpected result 
(Table 5-8). As mentioned earlier, hCGβ downregulation with CGB_5 siRNA 
significantly sensitised A2780cis cells to cisplatin; therefore it would be expected 
that different pathways would be dysregulated in these cells compared to cells which 
received cisplatin when hCGβ was not downregulated. However, even though the 
same pathways were affected in “A” and “C” the cellular processes and associated 
molecules within each pathway were different. For example the cell death pathway 
was affected in “A” and “C” but in “A” there was an increase in cell death, apoptosis 
and necrosis whereas in “C” neither cell death nor apoptosis seemed to be 
downregulated or upregulated. Another example is the cell cycle pathway: “A” had 
an increase in senescence and “C” had a decrease in senescence. It would be 
expected that “C” would have contained more cells that had undergone senescence 
because there seemed to be increased DNA fragmentation, damage and degradation 
in “C” and decreased DNA repair in “E” which could eventually lead to senescence 
[322]. A possible explanation is that cisplatin-induced senescence is dependent on 
the dose of cisplatin used to treat the cells [323]. Berndtsson et al. showed that DNA 
damage triggered by low cisplatin concentrations led to senescence of HCT116 
colon carcinoma cells whereas high cisplatin concentrations led to induction of 
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apoptosis by superoxide production [323]. Therefore it is possible that the cisplatin 
concentration used to treat the cells following hCGβ downregulation did not induce 
senescence. However it is also possible that given a longer exposure time these cells 
would have eventually undergone senescence.    
Interestingly DNA repair appears to be increased in “A” and “B”. This suggests 
that downregulation of hCGβ may have led to DNA damage in the cells and 
therefore the cells initiated DNA repair. Why would hCGβ downregulation lead to 
increased DNA damage or repair; could it have to do with additional secondary 
effects brought on by hCGβ downregulation? Indeed, one such effect is the impact of 
hCGβ downregulation on SIRT1 levels which has been shown to be involved in 
DNA repair [324] and is further discussed in section 5.4.2.2. It should be noted that 
the results in regards to either protein or pathway changes are based on a single 
iTRAQ experiment and therefore validation studies are important. Although the 
study of pathways affected by the different treatments was beyond the scope of this 
thesis we addressed some of the protein changes in sections 5.4.2 and 5.4.3. 
5.4.2 Validation of iTRAQ results 
Three proteins: WAPAL, SIRT1 and LIMK1, were chosen for validation 
experiments in A2780cis and HEY cells using western blot analysis. These proteins 
were chosen as they were either up- or downregulated following CGB_5 siRNA 
treatment in conjunction with cisplatin and not in cells that received non-silencing 
siRNA in conjunction with cisplatin (Table 5-7). They also appeared in more than 
one pathway or cellular process and may have had a potential role to play in how 
cells responded to cisplatin treatment.   
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5.4.2.1 WAPAL expression following hCGβ downregulation and cisplatin 
treatment 
In A2780cis and HEY cells, cisplatin treatment following downregulation of 
hCGβ did not significantly decrease the expression of WAPAL protein compared to 
cisplatin treatment alone, as quantitated from western blots (Figure 5.4). This data 
disagreed with the iTRAQ data which showed that WAPAL was decreased in a 
cisplatin-dependent manner in cells where hCGβ was downregulated “E” compared 
to cells which were treated with cisplatin alone “A” (Table 5-7). In other words the 
addition of siRNA targeting hCGβ did not increase cisplatin sensitivity. However, 
the data did show that treatment with cisplatin following downregulation of hCGβ 
with CGB_5 siRNA significantly decreased the expression of WAPAL compared to 
the cells treated with the negative non-silencing siRNA alone (Figure 5.4). This 
difference was not observed when cells were treated with the cisplatin in conjunction 
negative non-silencing siRNA compared to cells treated with the non-silencing 
siRNA alone. These data agree with the iTRAQ data which showed WAPAL levels 
were decreased in cells treated with cisplatin and CGB_5 siRNA “D” compared to 
cisplatin treatment alone “A” (Table 5-7). Not much is known about the WAPAL 
protein but it has been shown to be elevated in cervical cancer tissue [325]. Further, 
overexpression of WAPAL in NIH3T3 cells has been shown to make these cells 
tumorigenic in mice [325]. WAPAL is thought to be involved in mitosis by binding 
to cohesin which is involved in the timely separation of sister chromatids during 
mitosis [326]. Indeed, pathway analysis of the proteomic data suggests that 
segregation of chromosomes might be decreased when A2780cis were treated with 
both CGB_5 siRNA and cisplatin, “E”, which in turn could be a result of WAPAL 
(Table 5-8). Contrary to the results shown with the use of the CGB_5 siRNA, 
Chapter 5 
175 
 
cisplatin treatment following hCGβ downregulation by CGB_4 siRNA had no effect 
on WAPAL expression in either cell line. The manner in which both CGB_4 and 
CGB_5 regulate WAPAL in the presence of cisplatin suggest that WAPAL may be a 
secondary target of CGB_5 and this could account for the differences in the 
mechanism through which the two siRNAs sensitise cells to cisplatin treatment as 
seen in Chapter 4 (section 4.3.6). However, CGB_5 siRNA alone did not cause a 
decrease in WAPAL expression suggesting that WAPAL is not a direct off target 
effect of CGB_5 siRNA and therefore other downstream effects had occurred only 
when cells were treated with cisplatin in conjunction with CGB_5 siRNA. A search 
using the Blast® program confirmed that WAPAL was not a target of CGB_5 
siRNA however; it is possible that WAPAL levels in the presence of cisplatin could 
be indirectly altered due to the siRNA binding to alternative sequences.   
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5.4.2.2 SIRT1 expression following hCGβ downregulation and cisplatin treatment 
SIRT1 levels were not significantly downregulated when A2780cis and HEY 
cells were treated with cisplatin in conjunction with siRNAs targeting hCGβ 
compared to cells which were treated with cisplatin alone (Figure 5.5). This data 
disagrees with the iTRAQ data which showed that SIRT1 was decreased in a 
cisplatin-dependent manner in cells where hCGβ was downregulated “E” compared 
to cells which were treated with cisplatin alone “A” (Table 5 7). In other words the 
addition of siRNA targeting hCGβ did not increase cisplatin sensitivity. However, 
the data did show that treatment with cisplatin following downregulation of hCGβ 
with CGB_5 siRNA significantly decreased the expression of SIRT1 compared to 
the negative non-silencing siRNA, a result which was not shown by cells treated 
with cisplatin in conjunction with the negative non-silencing siRNA (Figure 5.5). 
These data agreed with the proteomics data where cisplatin treatment “A” alone did 
not affect levels of SIRT1 but cells treated with cisplatin and CGB_5 siRNA “D” 
showed a decrease in SIRT1 (Table 5-7). However, hCGβ downregulation using 
CGB_4 siRNA had no significant effect on SIRT1 levels in the presence or absence 
of cisplatin compared to the non-silencing control siRNA without cisplatin treatment 
Figure 5.5. As with the WAPAL expression levels, the manner in which both 
CGB_4 and CGB_5 regulate SIRT1in the presence of cisplatin could account for the 
differences in the mechanism through which the two siRNA sensitise cells to 
cisplatin treatment as seen in Chapter 4, section 4.3.6. Interestingly, SIRT1 
expression was also decreased by CGB_5 siRNA alone in both cell lines which 
suggests that indeed SIRT1 could be an off target effect of CGB_5 and could be an 
explanation of why CGB_5 siRNA treatment sensitises cells to cisplatin treatment. A 
search using the Blast® program however did not show that SIRT1 was a direct 
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target of CGB_5 siRNA however; it is possible that SIRT1 levels could be indirectly 
altered due to the siRNA binding to alternative sequences. Alternatively any effect of 
hCGβ downregulation by CGB_4 may have been offset by a compensatory increase 
in LHB (Figure 4.13).  The biological role of SIRT1 on cisplatin sensitivity is further 
discussed in section 5.4.3.   
 
5.4.2.3 LIMK1 expression following hCGβ downregulation and cisplatin treatment 
Changes in LIMK1 expression were detected by iTRAQ in A2780cis cells. 
However this result could not be validated in A2780cis as LIMK1 could not be 
detected in these cells, even after increasing the concentration of the LIMK1 primary 
antibody and using a more sensitive chemiluminescent (ECL) substrate for the HRP 
enzyme (SuperSignal™ West Femto Maximum). This could be due to low 
expression of the protein in A2780cis which could only be detected by MS/MS but 
not by western blot. In HEY cells, LIMK1 expression was decreased with cisplatin 
treatment alone “A” as well as hCGβ downregulation alone “B”, and cisplatin 
treatment in conjunction with hCGβ downregulation “D”. Interestingly, cisplatin 
treatment following hCGβ downregulation “D” caused a further decrease in LIMK1 
expression compared to cisplatin treatment alone “A”. These data disagree with the 
proteomic data attained from A2780cis cells which showed that LIMK1 expression 
increased with cisplatin and CGB_5 siRNA treatment, “E”, but was unchanged when 
cells were treated with cisplatin alone “A” (Table 5-7).  These differences between 
the two cell lines could be an indication of the different downstream effects of hCGβ 
downregulation and/or cisplatin treatment in HEY cells and A2780cis and could be a 
reason for differences in the way the cells respond in regards to response to drug 
treatment (Chapter 4, section 4.3.6).   
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LIMK1 is a Serine/Threonine kinase which phosphorylates cofilin, which binds 
actin filaments and thereby regulates the dynamics of the actin cytoskeleton [327]. 
LIMK1 has been associated with progression of a range of cancers including 
ovarian, breast and prostate cancer [311, 328, 329]. Both in vitro and in vivo data 
suggests that LIMK1 is mostly involved in invasion and migration of cancers and 
therefore potentially metastasis of cancer [311, 329-331]. Interestingly, Chen et al. 
showed that downregulation of LIMK1 can sensitise lung cancer cells to cisplatin 
[314]. In agreement with Chen et al. our data shows that the decrease in LIMK1 
levels by siRNA targeting hCGβ could be a mechanism by which hCGβ regulates 
cisplatin sensitivity.  
LIMK1 could have been chosen for further analysis to discover whether it had a 
role to play in cisplatin sensitivity independent of hCGβ and therefore could be a 
mechanism through which hCGβ confers cisplatin sensitivity; however, as LIMK1 
could not be detected in A2780cis cells this was not further investigated. Therefore 
results still need to be validated in A2780cis. This could be done by 
immunoprecipitating LIMK1 in order to concentrate it which may make it more 
visible on a western blot. 
5.4.3 Effect of SIRT1 downregulation on cisplatin sensitivity 
SIRT1 is a NAD-dependent deacetylase implicated in tumorigenesis and drug 
resistance [332]. It has a range of substrates including both histone proteins and 
non-histone proteins. These include transcription factors involved in apoptosis such 
as p53, and members of the forkhead transcription factors (FOXO) family [333, 
334].  SIRT1 levels have been found to be elevated in some epithelial cancers 
including colon [335, 336], prostate [337], breast [338] and ovarian [312]; however 
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its function as a tumour suppressor or promoter is still controversial [332]. 
Interestingly, higher expression of SIRT1 was observed in malignant serous ovarian 
carcinoma compared to the benign and borderline epithelial tumours, and it was 
associated with increased survival [312].  SIRT1 has been shown to be involved in 
inactivating p53 and hence preventing p53 driven apoptosis [339]. In vitro studies 
have shown that SIRT1 can be involved in drug resistance [316, 340]. A study by 
Zhang et al. found that patients with non-small cell lung cancer (NSCLC) whose 
tumours had high expression levels of SIRT1 were more likely to resist platinum-
based chemotherapy compared to patients whose tumours expressed low levels 
SIRT1. In the same study, it was also found that downregulation of SIRT1 in the 
NSCLC H292 cell line sensitised these cells to cisplatin treatment [315]. In prostate 
cancer cell lines it was found that pretreatment of PC3 and DU145 cells with sirtinol, 
an inhibitor of SIRT1, sensitised them to cisplatin by increasing apoptosis [340]. 
Chu et al. showed that cisplatin resistant IGROV and A2780cis cells had higher 
levels of SIRT1 compared to the parental chemosensitive cells [316]. Interestingly in 
this paper they also found that treatment of A2780 cells with a sub-lethal level of 
cisplatin induced expression of the cell cycle inhibitor p21/WAF1, therefore 
allowing the cells to adapt and survive the cytotoxic stress. Assessment of the 
prognostic value of SIRT1 using KM-plotter showed that ovarian cancer patients 
who received platinum-based therapy had a slightly lower rate of progress free 
survival when SIRT1 levels were high (Figure 5.10). This suggests that SIRT1 may 
be an indicator of patients’ response to platinum-based chemotherapy. 
In agreement with the involvement of SIRT1 in drug resistance, our data showed 
that downregulation of SIRT1 in A2780cis cells increased their sensitivity to 
cisplatin treatment (Figure 5.9 A). This result suggests that the decrease in SIRT1 
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expression following hCGβ downregulation by CGB_5 siRNA could be a 
mechanism by which hCGβ regulates sensitivity of A2780cis cells to cisplatin. 
However, CGB_4 siRNA did not cause a significant reduction in SIRT1 levels, 
again raising the possibility that SIRT1 could be an off target effect of CGB_5 
siRNA which results in the increased sensitivity to platinum-based drugs, a result 
which is not replicated by CGB_4 siRNA. However this does not explain why 
increased cisplatin sensitivity is not observed when SIRT1 is downregulated in HEY 
cells (Figure 5.9 B) despite CGB_5 siRNA increasing HEY cells sensitivity to 
cisplatin.  One explanation could be that although downregulation of hCGβ by 
CGB_5 siRNA decreases levels of SIRT1, it is not the mechanism through which 
hCGβ confers cisplatin sensitivity/resistance. Another explanation is that CGB_5 
siRNA confers cisplatin sensitivity in a SIRT1 dependent manner but the effect of 
SIRT1 on cisplatin sensitivity is cell type dependent. Lastly, it is possible that the 
effect of hCGβ on cisplatin sensitivity is independent of SIRT1 levels.  
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5.5 Conclusions 
Global protein changes detected by iTRAQ revealed a number of protein and 
pathway changes which occurred following hCGβ downregulation by 
CGB_5 siRNA and cisplatin treatment. Validation of changes in the expression of 
LIMK1, SIRT1 and WAPAL proteins by western blotting revealed that these 
proteins may be involved in the response of  A2780cis and HEY cells to cisplatin 
treatment following hCGβ downregulation, but the effect was dependent on the 
siRNA used to target hCGβ. Although changes in LIMK1 were mirrored by both 
siRNAs, changes in SIRT1 and WAPAL expression occurred only with the use of 
CGB_5 siRNA in the presence of cisplatin. This indicated that the two siRNAs 
worked by different mechanisms to confer cisplatin sensitivity. A possible 
compensatory effect of LHB upregulation by CBG_4 siRNA remains as another 
reason why the two siRNAs had different effects in some systems.   
SIRT1 expression was decreased following CGB_5 siRNA treatment alone. This 
may be an off target effect of CGB_5 siRNA which could have been responsible for 
the observed increase in cisplatin sensitivity of A2780cis and HEY cells.  Further 
investigation on the role SIRT1 on cisplatin sensitivity showed that it was indeed 
involved in cisplatin sensitivity but only in A2780cis cells and not HEY cells. This 
suggests that the effect of CGB_5 siRNA may be independent of SIRT1 levels and 
that the actual mechanism by which hCGβ downregulation confers cisplatin 
sensitivity has not yet been solved.  Despite the power of the quantitative proteomic 
analysis, it raised new questions requiring further exploration. 
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 General discussion Chapter 6
 
Ovarian cancer is the most lethal gynaecological disease in the developed world 
and although there have been great advancements in diagnosis, monitoring disease 
progress and treatment, it still remains a disease that is hard to fight. One of the main 
reasons it is such a challenging disease to combat is because even though a high 
percentage of cancers respond to conventional platinum-taxane based therapy, 
development of chemoresistance is common, leading to poor survival outcomes. 
Extensive research has focused on high throughput techniques aimed at 
understanding ovarian cancer at a molecular level. These techniques include 
proteomics, and whole genome and transcriptome sequencing which have 
undoubtedly added a tremendous amount of information to the field, but their impact 
on how the cancer is diagnosed and treated, and ultimately how this will translate to 
improved patient outcomes, is yet to be discovered. 
 
6.1 Focus of this thesis 
To gain a better understanding of high-grade serous ovarian carcinoma (HGSC) this 
thesis has taken a basic approach of studying the functional role of a single protein, 
hCGβ. hCGβ had been proposed as a useful prognostic marker for ovarian cancer  
[181, 182], but information on its functional role(s), if any, has not been well 
studied. The aim of this thesis was to determine the expression of hCGβ in HGSC 
cell lines and to explore the role of hCGβ in cellular processes including 
proliferation, migration and adhesion as well as in modulating the response of HGSC 
cells to platinum-based drugs. The power of proteomics was then employed to form 
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a global picture of the mechanisms by which hCGβ might be involved in the 
sensitivity and resistance of HGSC cells to cisplatin.  
The question may arise as to why we would investigate a protein which may not 
seem to play any role in ovarian cancer other than as a prognostic biomarker.  
Firstly, though the functional role of hCGβ has indeed been largely unknown, it is 
elevated in a number of cancers including ovarian cancer [134, 182-185]. This of 
course could imply that cancer cells simply produce hCGβ due to aberrant gene 
expression, but perhaps this is too simple an explanation. Secondly, hCGβ has been 
shown to have biological implications in terms of proliferation, migration and 
apoptosis in cancer cell line models other than ovarian cancer [155, 156, 180]. 
Thirdly, although the level of hCGβ has been shown to be associated with 
chemoresistance in small-cell lung cancer patients [180], a direct functional role of 
the molecule is still uncertain. This means that hCGβ has been a protein which has 
lingered in the background in the context of understanding ovarian cancer and 
chemoresistance, and therefore its functional significance needed to be investigated. 
 
6.2 Expression of hCGβ and its role in proliferation, migration and 
adhesion 
Firstly it had to be established that hCGβ was expressed in HGSC cell line 
models before its functional role could be investigated. It was demonstrated that 
CGB transcript and secreted hCGβ protein were expressed in all eight HGSC cell 
line models (SKOV-3, HEY, OV202, PEO-1, A2780, A2780cis, CaOV-3 and 
OVCAR-3) to varying degrees. Three cell line models – HEY, A2780 and A2780cis 
cells – expressing a varied range of CGB/hCGβ, were then selected for functional 
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studies. HEY cells were chosen as they expressed the highest level of hCGβ and the 
pair of cisplatin-sensitive and resistant cells, A2780 and A2780cis, respectively were 
chosen for drug response studies. hCGβ was then downregulated with at least two 
siRNAs, or its cDNA overexpressed with a plasmid vector to determine its effect on 
proliferation, migration, adhesion and response to platinum-based drugs.  
It was found that the effect of hCGβ on cell proliferation was cell type dependent 
as downregulation of hCGβ significantly decreased proliferation of A2780cis and 
HEY cells, but its effect on proliferation of A2780 cells was dependent on the 
siRNA used to downregulate hCGβ. This suggested that the two siRNAs targeting 
hCGβ may have some differences in their actions.  The influence of hCGβ 
downregulation on cell proliferation should be tested under low serum conditions, as 
growth factors in the serum may mask the effect of hCGβ. The addition of 
exogenous hCGβ or overexpression of hCGβ did not seem to affect cell proliferation, 
perhaps due to a threshold level of hCGβ being reached beyond which hCGβ had no 
influence. Furthermore, it has to be noted that the biological activity of exogenous 
recombinant hCGβ could not be easily determined prior to the study. 
Downregulation or overexpression of hCGβ did not seem to influence cell 
migration of the tested HGSC cells, contrary to published data by Wu and colleagues 
who showed that hCGβ increased the migratory characteristics of prostate cancer cell 
lines and the human glioblastoma cell line U87MG [156, 189, 190]. A possible 
explanation is that the influence of hCGβ on cell migration could be cell type 
dependent. As we only extensively studied cell migration in HEY cells which had a 
stronger potential to migrate compared to A2780 and A2780cis cells, it may be 
worthwhile testing for cell migration in a larger set of cell lines.  
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The role of hCGβ in HGSC cell adhesion has been investigated for the first time 
in this thesis. Cell adhesion is a means by which cells interact with their extracellular 
environment and has a number of implications on signalling pathways, which 
influence cell survival, apoptosis, migration and cancer metastasis [341]. Cell 
adhesion is regulated by integrins which are heterodimeric molecules composed of 
non-covalently associated α- and β- transmembrane glycoproteins which interact 
with extracellular matrix (ECM) proteins. There are up to 18 α- and 8 β- 
characterised subunits forming 24 different integrin combinations which bind to 
specific ECM proteins [341]. We found that downregulation of hCGβ resulted in a 
general increase in cell adhesion of HEY and A2780cis cells onto ECM proteins. 
This result raises the question of whether hCGβ could be regulating the different 
integrins within the cell, hence impacting on how the cells interact with ECM 
proteins. The influence of hCGβ on expression of integrins could be further 
investigated with integrin arrays, which is a high throughput technique which can 
determine the expression of a range of integrins on the cells surface [342].  Another 
possible explanation for the influence of hCGβ on cell adhesion is that it may be 
blocking cell adhesion, therefore downregulation of hCGβ could be eliminating this 
inhibitory effect on cell adhesion. The inhibitory effect of hCGβ should be further 
investigated by determining the impact of hCGβ overexpression or exogenous hCGβ 
on cell adhesion; however, this was not considered to be a cost-effective line of 
investigation to pursue for this thesis. 
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6.3 hCGβ and the cell response to chemotherapeutics 
Expression of hCGβ in epithelial cancers is often associated with aggressive 
disease with poor patient outcomes; however, the impact of hCGβ in 
chemoresistance has been largely unaddressed. Only two published papers were 
found to suggest that hCGβ may be involved in chemoresistance [180, 280]. 
Szturmowicz et al. found that patients with small-cell lung cancer who had elevated 
levels of hCGβ responded poorly to chemotherapy [180]. In vivo data published by 
Berman et al. found that small cell bronchial carcinoma xenografts which expressed 
hCGβ were resistant to the chemotherapeutic drug cyclophosphamide [280]. Both of 
these published studies were observational; therefore in this thesis, the functional 
role of hCGβ in the response of HGSC to platinum-based drugs has been a main 
focus. It was shown that hCGβ does in fact play a role in how HGSC cells respond to 
the platinum-based drugs cisplatin, carboplatin and oxaliplatin; a response that 
seemed to be specific to platinum-based drugs and not to the microtubule targeting 
agent paclitaxel. Downregulation of hCGβ increased the sensitivity of A2780cis and 
HEY cells to cisplatin; however, it had no influence on the response of cisplatin 
sensitive A2780 cells to the drug. The result suggests that the effect of hCGβ on drug 
response is cell type dependent. It could also be suggestive that cells need to have 
acquired resistance to platinum-based drugs; in this case A2780cis are cisplatin 
resistant and HEY have higher IC50 for cisplatin compared to A2780 cells.  
Whether the expression levels of hCGβ in tumour tissue or serum of patients with 
ovarian cancer (or other cancers) has a direct bearing on how patients respond to 
chemotherapy has to be further investigated. This could have future implications for 
determining which patients may benefit from platinum-based chemotherapy. As 
mentioned in Chapter 4, section 4.4.1 the absolute levels of hCGβ may not positively 
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correlate to drug response; however, it is possible that it is the absence (or lowered 
amount) of hCGβ that may determine how cells respond to drugs, particularly in 
cells that are already drug resistant. If indeed this is the case, then development of 
neutralising antibodies towards hCGβ, or other mechanisms of downregulating its 
expression or activity, could be a potential way of combating drug resistance in 
ovarian cancer.   
 
6.4 Potential role of LHβ in the response to platinum drugs 
It was observed that two hCGβ targeting siRNAs (CGB_4 and CGB_5) caused 
different biological effects in some experimental situations, despite a similar degree 
of hCGβ downregulation. In order to study whether a compensatory change in LHB 
could be a contributing factor to the different degrees of response of the two hCGβ 
siRNAs towards cisplatin, the LHB levels were determined following hCGβ 
downregulation. It was found that treatment with CGB_4 siRNA did in fact increase 
the levels of LHB but CGB_5 siRNA decreased its levels. These results were 
statistically significant in HEY cells compared to A2780cis cells, suggesting that in 
HEY cells both LHB and CGB may be an important determinant of the manner in 
which cells responded to cisplatin. Further to this point, a third siRNA (CGB_7) 
targeting hCGβ did not significantly affect the levels of LHB and did not influence 
how HEY cells responded to cisplatin treatment. This result demonstrated a potential 
link between LHB and response to cisplatin in some HGSC cells and maybe 
suggestive of some overlap of biological roles between LHβ and hCGβ. It was 
difficult to source a siRNA that specifically downregulated LHB independent of 
CGB levels. The manufacturer (Qiagen) who supplied our siRNAs, had a number of 
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siRNAs targeting LHB but these targeted identical sequences to CGB siRNAs. In 
future work, the role of LHB in response to cisplatin could be investigated by 
sourcing, or designing, siRNAs that specifically target LHB and by overexpressing 
LHB to determine whether it indeed has a role to play in drug response. Similarly, 
the expression of both LHβ and hCGβ (and/or LHB and CGB) in tumour tissue or 
serum from patients with ovarian cancer (or other cancers) could also be studied to 
determine whether their levels, together or independently, have an influence on how 
patients respond to chemotherapy.  
 
6.5 iTRAQ and the mechanism of action of hCGβ in response to 
cisplatin 
The quantitative proteomic technique of iTRAQ was used to determine the global 
protein changes that occurred when A2780cis cells were treated with cisplatin 
following hCGβ downregulation (with CGB_5 siRNA), in an attempt to understand 
the mechanism by which hCGβ regulates how HGSC cells respond to cisplatin. In 
the context of ovarian cancer, iTRAQ has been used to identify potential biomarkers 
[343] and differences between begin and malignant tumour tissue [344]; however, it 
had not been used to study chemoresistance. Multiple studies have been used iTRAQ 
and chemoresistance in two studies on mechanism of chemosensitivity or resistance 
in cancers such as head and neck carcinoma and colorectal cancer [345-347]; in 
these two studies, dysregulated proteins discovered by iTRAQ were validated using 
western blotting and the functional role of candidate proteins in chemosensitivity or 
resistance was investigated by gene silencing. This approach was followed in this 
thesis.  
Chapter 6 
189 
 
Pathway analysis of the protein changes from our iTRAQ study revealed that 
some pathways that were affected by cisplatin treatment in combination with hCGβ 
downregulation were also affected by cisplatin or hCGβ downregulation alone; 
however, the cellular processes and protein molecules involved in the overlapping 
pathways were different. This result was suggestive of the cells responding 
differently when treated with both cisplatin and hCGβ targeting siRNA compared to 
cisplatin or siRNA treatment alone, which was expected.  
Due to financial constraints, the iTRAQ experiment was conducted only once; 
and western blotting used to validate important protein changes. Specifically, 
changes in the levels of LIMK1, SIRT1 and WAPAL proteins were validated. SIRT1 
and WAPAL reflected the iTRAQ data; that is, their cellular abundance was altered 
by cisplatin treatment when hCGβ levels were decreased by siRNA, but not in the 
presence of normal hCGβ levels. This suggests that these proteins may be involved 
in the response of A2780cis and HEY cells to cisplatin treatment following hCGβ 
downregulation. However the results were dependent on the siRNA used to target 
hCGβ, indicative of different modes of action of the two siRNAs. Whether the 
differential responses related to differences in the compensatory induction of LHβ 
when hCGβ was downregulated, as discussed earlier, remains to be further explored. 
These findings meant that the actual mechanism by which hCGβ could be involved 
in drug response was not firmly established, although candidate proteins were 
identified. 
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6.5.1 Alternative strategy to iTRAQ 
iTRAQ has the advantage of multiplexing samples in a single experimental run; 
however, the results can be challenging to interpret due to differences in the labelling 
process of the individual samples. Therefore the list of deregulated proteins 
generated by iTRAQ in our single run may not provide a comprehensive reflection 
of the global protein changes that occurred when the cells were treated with cisplatin 
following hCGβ downregulation. In future work, the iTRAQ experiment could be 
repeated or used in conjunction with the label free technique Sequential Window 
Acquisition of all Theoretical Mass Spectra (SWATH) [348].  SWATH is a 
relatively new technique which allows for both relative and absolute quantitation of 
proteins in a precise and reproducible manner. It is operated in a data independent 
acquisition (DIA) mode whereby all precursor ions and product ions are detected and 
archived allowing for retrospective data analysis. Operation in DIA mode allows for 
a greater dynamic range, hence is more sensitive for low intensity ions which are 
often missed by data-dependent acquisition mode (whereby a precursor is selected in 
order for the product ion to be scanned) [349, 350]. The Australian Proteome 
Analysis Facility (APAF) has recently started to offer SWATH as an analytical 
option and in future this may be a more reliable method to study global protein 
changes. 
 
6.6 Approach of using antibodies to block effect of hCGβ 
Expression of both CGA and CGB by the all the HGSC cell lines suggests the 
whole hCG protein could be potentially expressed which in turn could contribute to 
some of the functional effects observed by free hCGβ. Use of an antibody that 
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specifically targets secreted hCGβ may have been a fruitful approach to studying the 
role of hCGβ independent of heterodimeric hCG. For this reason, the best means of 
studying the role of hCGβ was to overexpress and downregulate hCGβ; a means by 
which the role of hCGβ has been investigated in previously published studies [156, 
180, 191]. In future, antibodies against hCGβ could be developed to target free 
hCGβ allowing the study of hCGβ in culture independent of the whole hCG protein. 
Alternately, existing hCGβ antibodies designed for western blotting, for example, 
could also be tested to determine whether they could potentially be used to block 
hCGβ in culture. However, it is also possible that intracellular hCGβ may have a 
functional role in its own right which cannot be determined by antibodies directed at 
secreted hCGβ. Therefore the use of downregulation using siRNA, as employed in 
this thesis, is clearly a valuable experimental tool.  
 
6.7 Improving hCGβ downregulation 
hCGβ was downregulated by 50-60% using the highest amount of siRNA that 
could be used without theoretically introducing off target effects. Therefore a longer 
time course following siRNA transfection should be tested to determine whether a 
higher level of knockdown could be achieved. 
6.8 Validation of the on-target effects of hCGβ on response of cells 
to platinum-based drugs 
Validation of the increased sensitivity of the cells to platinum-based drugs following 
downregulation hCGβ can be done in two ways. 1. Addition of exogenous hCGβ 
following downregulation 2. Overexpressing hCGβ using a plasmid construct 
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containing a hCGβ gene insert (containing silent mutations) which is resistant to the 
siRNAs targeting hCGβ expressed by the cells [351, 352].  
 
6.9 Development of stable knockouts or overexpression 
In this thesis the functional role of hCGβ was studied using transient downregulation 
and overexpression systems. Although a lot of data has been generated using these 
systems, the development of stable systems could not only facilitate longer 
experiments but also in vivo experiments in animal models.  hCGβ could be stably 
downregulated using short hairpin RNA (shRNA) [353] and overexpressed using the 
same construct (pCI-neo-hCG) for transient overexpression, but by growing the cells 
under the selection of the antibiotic G418 [156]. It is possible that shRNA may result 
in better hCGβ knockdown compared to the use of siRNA. The disadvantage of 
stable downregulation of growth-regulatory proteins, which involves selection of 
clones or restricted cell populations, is that other cell markers may also inadvertently 
be selected, or that the selected populations may have upregulated mechanisms that 
compensate for the downregulated target protein. These disadvantages might in part 
be overcome by using an inducible vector to express the shRNA. 
 
6.10 SIRT1 and the response to cisplatin 
SIRT1 has been shown to be elevated in a number of cancers including ovarian 
cancer [312], however its role in tumorigenesis has not been established [332]. Our 
study shows that SIRT1 is potentially involved in the response to cisplatin of some 
HGSC cells, as downregulation of SIRT1 increased cisplatin sensitivity in A2780cis 
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cells but not HEY cells. In future work, the role of SIRT1 in the response to 
platinum-based drugs could be tested in different cell lines by downregulating or 
overexpressing SIRT1 or using an inhibitor of SIRT1, e.g. EX-527 (SEN0014196) 
[354].  
Expression of SIRT1 in tumour tissue of patients with ovarian cancer could also 
be studied to determine whether SIRT1 levels may be a prognostic marker of 
patients’ response to chemotherapy. Interestingly, a preliminary assessment of the 
prognostic value of SIRT1 using KM-Plotter showed that ovarian cancer patients 
who received platinum-based therapy had a slightly lower rate of progression free 
survival when SIRT1 levels were high. This suggests that SIRT1 could be a 
potentially valuable prognostic marker of patients’ response to chemotherapy. 
Further to this, if it is confirmed that SIRT1 has a functional role in chemosensitivity 
then a potential outcome could be the use of SIRT1 inhibitors alongside platinum-
taxane based therapy for the treatment of ovarian cancer. SIRT1 inhibitors have 
already been utilised in medical conditions such as diabetes and the neurological 
condition Huntington’s disease [355]. The selective SIRT1 inhibitor, Selisista (6-
chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide, SEN0014196, EX-527) is 
currently in Phase II clinical trials for the treatment of Huntington's disease [356].  
  
6.11 Changes in the field since undertaking this thesis 
One of the major changes in the field since the beginning of this thesis has been 
the characterisation of existing and new HGSC cell line models. Domcke et al. and 
Ince et al. deemed a number of cells lines, including SKOV-3 and A2780 cells that 
were used in this thesis, as potentially less suitable HGSC models as they did not 
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contain TP53 mutations or other genetic or molecular abnormalities characteristic of 
primary HGSC tumours [281, 282].  Ince et al. developed a method to isolate and 
propagate 25 ovarian cancer cells lines which were considered to be true 
representative models of the disease [282]. These cell lines not only reflected the 
histological, genotypic and molecular characteristics of the tumour cells they were 
derived from but these characteristics were maintained over successive passages.  
In the future, a panel of HGSC cell lines recommended by Domcke et al. and/or 
developed by Ince et al. should be used to confirm the functional role of hCGβ. As 
mentioned in Chapter 2, the A2780/A2780cis pair is a valuable model for studying 
drug resistance, however since Domcke et al. found that A2780 cells were not an 
optimum model for HGSC, cell lines resistant to cisplatin, carboplatin, oxaliplatin 
and paclitaxel could also be developed based on suitable HGSC models to allow the 
study of drug resistance in the context of hCGβ. This work would best be conducted 
in follow-up work, as development and testing of drug resistant cell lines can take up 
to 18 months [357]. Alternately, cell lines established by Ince and colleagues which 
are already resistant to platinum-taxane treatment could be used for drug based 
studies [282]. The advantage of using these cell lines is that they may be closer to a 
true representation of drug resistance as they are derived from chemoresistant 
tumours as opposed to having been artificially created in the lab. 
 
6.12 Concluding remarks 
This thesis has highlighted the potential role of hCGβ in cell proliferation, 
adhesion and response to platinum-based drugs in ovarian cancer cells. The LHβ, 
WAPAL and SIRT1 proteins were also discovered to be potentially involved in the 
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response to cisplatin and could have implications on how chemoresistance is 
managed in ovarian cancer. Future work on the mechanism by which hCGβ can 
regulate cellular response to platinum-based drugs needs to be established and may 
have implications for the management of chemoresistance in ovarian cancer. 
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Appendix A: Chapter 3 supplementary data 
 
Supplementary Figure 1: Standard curve for detection of hCGβ using the 
chorionic gonadotropin beta Human ELISA kit from Abam. Standard 
concentrations included 0, 2.5, 5, 10, 25 and 50 ng/mL of free hCGβ. 
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Appendix B: Chapter 4 supplementary data 
Supplementary Table 1: IC50 concentration of cisplatin derived from the cell 
viability assay for A2780cis and HEY cells 
Cisplatin 
 NS control CGB_4 CGB_5 
A2780cis 12.48 ± 1.14 12.49 ± 1.43 7.46 ± 0.54 
HEY 4.65 ± 0.26 4.07 ± 0.13 3.90 ± 0.25 
Carboplatin 
 NS control CGB_4 CGB_5 
A2780cis 99.92 ± 6.60 100.43 ± 7.27 73.10 ± 7.13 
HEY 38.36 ± 2.89 37.53 ± 0.81 36.59 ± 0.72 
Oxaliplatin 
 NS control CGB_4 CGB_5 
A2780cis 9.15 ± 0.79 8.03 ± 0.58 7.44 ± 0.38 
HEY 15.64 ± 1.41 17.91 ± 0.75 15.69 ± 2.57 
Taxol 
 NS control CGB_4 CGB_5 
A2780cis 14.17 ± 1.12 14.07 ± 0.79 13.73 ± 1.23 
HEY 17.84 ± 4.40 15.26 ± 1.00 17.9 5 ± 3.31 
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Supplementary Table 2: IC50 concentration of cisplatin derived from the 
cell survival (clonogenic) assay for A2780cis and HEY cells 
Cisplatin 
 NS control CGB_4 CGB_5 
A2780cis 2.07 ± 0.35 2.58 ±  0.26 4.34 ±  0.39 
HEY 1.28 ± 0.07 1.22 ± 0.18 0.73 ± 0.02 
Carboplatin 
 NS control CGB_4 CGB_5 
A2780cis 23.15 ±  4.57 19.96 ±  4.64 11.85 ±  1.36 
HEY 9.94 ± 2.95 9.83 ± 2.45 5.61 ± 1.36 
 NS control CGB_4 CGB_5 
Oxaliplatin 
A2780cis 0.38 ±  0.06 0.28 ±  0.03 0.25 ±  0.05 
HEY 0.31 ± 0.07 0.34 ± 0.04 0.35 ± 0.03 
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Appendix C: Chapter 5 supplementary data 
Refer to Compact Disk or attached file for complete iTRAQ data.  
 
Supplementary Figure 2: Downregulation on CGB gene for A2780cis cells 
undergoing iTRAQ. siRNAs: non-silencing control (ctr), and CGB_5 (hCG).  
Data normalised to negative non-silencing control siRNA. 
 
 
 
Supplementary Figure 3: “A” is the effect of cisplatin treatment  (ratio 115:114), 
“B” is the effect of hCGβ downregulation (ratio 116:114),  “C” is the effect of 
both treatments combined (ratio 117:114), “D” is the effect of  cisplatin when 
hCGβ was downregulated and “E” are proteins that were only responsive to 
cisplatin when hCGβ was downregulated ((115:114)/(117:115)).  
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Supplementary Figure 4: Effect of cisplatin treatment (ratio 115:114) on the cell 
death, survival, DNA replication, recombination and repair network. Indicated 
colours: RED: User input molecule that is upregulated, GREEN: user input 
molecule that is downregulated, GRAY: user input molecule that is neither up 
nor down-regulated, WHITE: molecule that is not user specified, but 
incorporated into the network through relationships with other molecules. 
Relationship and colour keys extracted from Ingenuity systems, IPA supporting 
documentation [358].  
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Supplementary Figure 5: Effect of hCGβ downregulation (ratio 116:114) on the 
cell morphology, cell death and survival network. Indicated colours: RED: User 
input molecule that is upregulated, GREEN: user input molecule that is 
downregulated, GRAY: user input molecule that is neither up nor down-
regulated, WHITE: molecule that is not user specified, but incorporated into the 
network through relationships with other molecules. Relationship and colour 
keys extracted from Ingenuity systems, IPA supporting documentation [358].  
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Supplementary Figure 6: Effect of cisplatin treatment followed by hCGβ 
downregulation (ratio 117:114) on the cell cycle, DNA replication, 
recombination and repair network. Indicated colours: RED: User input molecule 
that is upregulated, GREEN: user input molecule that is downregulated, GRAY: 
user input molecule that is neither up nor down-regulated, WHITE: molecule 
that is not user specified, but incorporated into the network through relationships 
with other molecules. Relationship and colour keys extracted from Ingenuity 
systems, IPA supporting documentation [358].  
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Supplementary Figure 7: Effect of a combination of cisplatin and hCGβ 
downregulation (ratio (115:114)/117:115) on the cell cycle, DNA replication, 
recombination and repair network. Indicated colours: RED: User input molecule 
that is upregulated, GREEN: user input molecule that is downregulated, GRAY: 
user input molecule that is neither up nor down-regulated, WHITE: molecule 
that is not user specified, but incorporated into the network through relationships 
with other molecules. Relationship and colour keys extracted from Ingenuity 
systems, IPA supporting documentation [358].  
 
 
 204 
 
References 
 
1. Dos Santos Silva, I., et al., Does ovarian stimulation increase the risk of 
ovarian cancer. Reproductive Medicine Review, 2002. 11(1): p. 57-66. 
2. Australian Institute of Health and Welfare & National Breast and Ovarian 
Cancer Center, Ovarian cancer in Australia: an overview  (AIHW, Canberra, 
2010). 2010. 
3. Ng, J.S., J.J.H. Low, and A. Ilancheran, Epithelial ovarian cancer. Best 
Practice & Research in Clinical Obstetrics & Gynaecology, 2012. 26(3): p. 
337-45. 
4. Heintz, A.P.M., et al., Carcinoma of the ovary. FIGO 26th Annual Report on 
the Results of Treatment in Gynecological Cancer. International Journal of 
Gynaecology & Obstetrics, 2006. 95 Suppl 1: p. S161-92. 
5. Bast, R.C., Jr., Early detection of ovarian cancer: new technologies in 
pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol 
Assoc, 2004. 115: p. 233-47; discussion 247-8. 
6. Jacobs, I.J. and U. Menon, Progress and challenges in ccreening for early 
detection of ovarian cancer. Molecular & Cellular Proteomics, 2004. 3: p. 
355-366. 
7. Ries, L.A., et al., SEER Cancer Statistics Review, 1975–2003. Bethesda, MD: 
National Institutes of Health, 2006  
8. Bast, R.C., Jr., B. Hennessy, and G.B. Mills, The biology of ovarian cancer: 
new opportunities for translation. Nature Reviews, 2009. Cancer. 9(6): p. 
415-28. 
9. Auersperg, N., et al., Ovarian surface epithelium: biology, endocrinology, 
and pathology. Endocrine Reviews, 2001. 22(2): p. 255-88. 
10. Vlahos, N.F., K.P. Economopoulos, and G. Creatsas, Fertility drugs and 
ovarian cancer risk: a critical review of the literature. Annals of the New 
York Academy of Sciences, 2010. 1205: p. 214-9. 
11. Eerola, H., et al., Familial breast cancer in southern Finland: how prevalent 
are breast cancer families and can we trust the family history reported by 
patients? European Journal of Cancer, 2000. 36(9): p. 1143-8. 
12. Claus, E.B., et al., The genetic attributable risk of breast and ovarian cancer. 
Cancer, 1996. 77(11): p. 2318-24. 
13. Struewing, J.P., et al., The Risk of Cancer Associated with Specific Mutations 
of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of 
Medicine, 1997. 336(20): p. 1401-1408. 
14. King, M.-C., et al., Breast and ovarian cancer risks due to inherited 
mutations in BRCA1 and BRCA2. Science, 2003. 302(5645): p. 643-6. 
15. Finch, A., G. Evans, and S.A. Narod, BRCA carriers, prophylactic salpingo-
oophorectomy and menopause: clinical management considerations and 
recommendations. Womens Health (Lond Engl), 2012. 8(5): p. 543-55. 
16. Ford, D., et al., Genetic Heterogeneity and Penetrance Analysis of the 
BRCA1 and BRCA2 Genes in Breast Cancer Families. The American Journal 
of Human Genetics, 1998. 62(3): p. 676-689. 
 205 
 
17. Risch, H.A., et al., Prevalence and penetrance of germline BRCA1 and 
BRCA2 mutations in a population series of 649 women with ovarian cancer. 
American Journal of Human Genetics, 2001. 68(3): p. 700-10. 
18. Finch, A.P.M., et al., Impact of oophorectomy on cancer incidence and 
mortality in women with a BRCA1 or BRCA2 mutation. Journal of Clinical 
Oncology, 2014. 32(15): p. 1547-53. 
19. Rebbeck, T.R., et al., Prophylactic Oophorectomy in Carriers of BRCA1 or 
BRCA2 Mutations. New England Journal of Medicine, 2002. 346(21): p. 
1616-1622. 
20. Malander, S., et al., The contribution of the hereditary nonpolyposis 
colorectal cancer syndrome to the development of ovarian cancer. 
Gynecologic Oncology, 2006. 101(2): p. 238-43. 
21. Geisler, J.P., et al., Mismatch repair gene expression defects contribute to 
microsatellite instability in ovarian carcinoma. Cancer, 2003. 98(10): p. 
2199-206. 
22. Havrilesky, L.J., et al., Oral contraceptive use for the primary prevention of 
ovarian cancer. Evidence Reports/Technology Assessments, 2013. 212: p. 1-
514. 
23. Rosenberg, L., et al., A case-control study of oral contraceptive use and 
invasive epithelial ovarian cancer. American Journal of Epidemiology, 1994. 
139(7): p. 654-61. 
24. Collaborative Group on Epidemiological Studies of Ovarian, C., Ovarian 
cancer and oral contraceptives: collaborative reanalysis of data from 45 
epidemiological studies including 23 257 women with ovarian cancer and 87 
303 controls. The Lancet, 2008. 371(9609): p. 303-314. 
25. Moorman, P.G., et al., Hormonal risk factors for ovarian cancer in 
premenopausal and postmenopausal women. American Journal of 
Epidemiology, 2008. 167(9): p. 1059-69. 
26. Grimbizis, G.F. and B.C. Tarlatzis, The use of hormonal contraception and 
its protective role against endometrial and ovarian cancer. Best Practice & 
Research in Clinical Obstetrics & Gynaecology, 2010. 24(1): p. 29-38. 
27. Tworoger, S.S., et al., Association of oral contraceptive use, other 
contraceptive methods, and infertility with ovarian cancer risk. Am J 
Epidemiol, 2007. 166(8): p. 894-901. 
28. Narod, S.A., et al., Oral contraceptives and the risk of hereditary ovarian 
cancer. Hereditary Ovarian Cancer Clinical Study Group. New England 
Journal of Medicine, 1998. 339(7): p. 424-8. 
29. Hankinson, S.E., et al., A prospective study of reproductive factors and risk 
of epithelial ovarian cancer. Cancer, 1995. 76(2): p. 284-90. 
30. Whittemore, A.S., R. Harris, and J. Itnyre, Characteristics relating to 
ovarian cancer risk: collaborative analysis of 12 US case-control studies. II. 
Invasive epithelial ovarian cancers in white women. Collaborative Ovarian 
Cancer Group. American Journal of Epidemiology, 1992. 136(10): p. 1184-
203. 
31. Bodelon, C., et al., Hormonal risk factors and invasive epithelial ovarian 
cancer risk by parity. British Journal of Cancer, 2013. 109(3): p. 769-76. 
32. Ness, R.B., et al., Infertility, fertility drugs, and ovarian cancer: a pooled 
analysis of case-control studies. American Journal of Epidemiology, 2002. 
155(3): p. 217-24. 
 206 
 
33. Fathalla, M.F., Incessant ovulation--a factor in ovarian neoplasia? Lancet, 
1971. 2(7716): p. 163. 
34. Cramer, D.W., et al., Determinants of ovarian cancer risk. I. Reproductive 
experiences and family history. Journal of the National Cancer Institute, 
1983. 71(4): p. 711-6. 
35. Stadel, B.V., Letter: The etiology and prevention of ovarian cancer. 
American Journal of Obstetrics & Gynecology, 1975. 123(7): p. 772-4. 
36. Smith, E.M. and B. Anderson, The effects of symptoms and delay in seeking 
diagnosis on stage of disease at diagnosis among women with cancers of the 
ovary. Cancer, 1985. 56(11): p. 2727-32. 
37. Goff, B.A., et al., Ovarian carcinoma diagnosis. Cancer, 2000. 89(10): p. 
2068-75. 
38. Goff, B.A., et al., Development of an ovarian cancer symptom index: 
possibilities for earlier detection. Cancer, 2007. 109(2): p. 221-7. 
39. Seki, K., et al., Increased serum CA 125 levels during the first trimester of 
pregnancy. Acta Obstet Gynecol Scand, 1986. 65(6): p. 583-5. 
40. Duffy, M.J., et al., CA125 in ovarian cancer: European Group on Tumor 
Markers guidelines for clinical use. International Journal of Gynecological 
Cancer, 2005. 15(5): p. 679-91. 
41. Sjovall, K., B. Nilsson, and N. Einhorn, The significance of serum CA 125 
elevation in malignant and nonmalignant diseases. Gynecologic Oncology, 
2002. 85(1): p. 175-8. 
42. Yamamoto, M., et al., Peritoneal lavage CEA/CA125 is a prognostic factor 
for gastric cancer patients. J Cancer Res Clin Oncol, 2007. 133(7): p. 471-6. 
43. Bairey, O., et al., Serum CA 125 as a prognostic factor in non-Hodgkin's 
lymphoma. Leuk Lymphoma, 2003. 44(10): p. 1733-8. 
44. Bast, R.C., Jr., et al., Prevention and early detection of ovarian cancer: 
mission impossible? Recent Results Cancer Res, 2007. 174: p. 91-100. 
45. Pignata, S., et al., Follow-up with CA125 after primary therapy of advanced 
ovarian cancer: in favor of continuing to prescribe CA125 during follow-up. 
Ann Oncol, 2011. 22 Suppl 8: p. viii40-viii44. 
46. Rustin, G.J., et al., Use of CA-125 in clinical trial evaluation of new 
therapeutic drugs for ovarian cancer. Clin Cancer Res, 2004. 10(11): p. 
3919-26. 
47. Santillan, A., et al., Risk of epithelial ovarian cancer recurrence in patients 
with rising serum CA-125 levels within the normal range. J Clin Oncol, 2005. 
23(36): p. 9338-43. 
48. Moore, R.G., et al., The use of multiple novel tumor biomarkers for the 
detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic 
Oncology, 2008. 108(2): p. 402-408. 
49. Escudero, J.M., et al., Comparison of serum human epididymis protein 4 with 
cancer antigen 125 as a tumor marker in patients with malignant and 
nonmalignant diseases. Clin Chem, 2011. 57(11): p. 1534-44. 
50. Montagnana, M., et al., The utility of serum human epididymis protein 4 
(HE4) in patients with a pelvic mass. Journal of Clinical Laboratory 
Analysis, 2009. 23(5): p. 331-5. 
51. Moore, R.G., et al., Evaluation of the diagnostic accuracy of the risk of 
ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol, 
2011. 118(2 Pt 1): p. 280-8. 
 207 
 
52. Moore, R.G., et al., A novel multiple marker bioassay utilizing HE4 and 
CA125 for the prediction of ovarian cancer in patients with a pelvic mass. 
Gynecol Oncol, 2009. 112(1): p. 40-6. 
53. Van Gorp, T., et al., HE4 and CA125 as a diagnostic test in ovarian cancer: 
prospective validation of the Risk of Ovarian Malignancy Algorithm. British 
Journal of Cancer, 2011. 104(5): p. 863-70. 
54. J., A., OVA1 test for preoperative assessment of ovarian cancer. Community 
Oncol., 2010. 7: p. 249–251. 
55. Miller, R.W., et al., Performance of the American College of Obstetricians 
and Gynecologists' Ovarian Tumor Referral Guidelines With a Multivariate 
Index Assay. Obstetrics & Gynecology, 2011. 117(6): p. 1298-1306. 
56. Ueland, F.R., et al., Effectiveness of a Multivariate Index Assay in the 
Preoperative Assessment of Ovarian Tumors. Obstetrics & Gynecology, 
2011. 117(6): p. 1289-1297. 
57. Prat, J., Ovarian, fallopian tube and peritoneal cancer staging: Rationale 
and explanation of new FIGO staging 2013. Best Practice & Research 
Clinical Obstetrics & Gynaecology, 2015(0). 
58. Prat, J., Staging classification for cancer of the ovary, fallopian tube, and 
peritoneum. International Journal of Gynecology & Obstetrics, 2014. 124: p. 
1-5. 
59. Li, J., et al., Ovarian serous carcinoma: recent concepts on its origin and 
carcinogenesis. Journal of hematology & oncology, 2012. 5: p. 8. 
60. Prat, J., Ovarian carcinomas: five distinct diseases with different origins, 
genetic alterations, and clinicopathological features. Virchows Archiv, 2012. 
460(3): p. 237-49. 
61. Lee, Y., et al., A candidate precursor to serous carcinoma that originates in 
the distal fallopian tube. The Journal of Pathology, 2007. 211(1): p. 26-35. 
62. Patch, A.M., et al., Whole-genome characterization of chemoresistant 
ovarian cancer. Nature, 2015. 521(7553): p. 489-94. 
63. Gilks, C.B. and J. Prat, Ovarian carcinoma pathology and genetics: recent 
advances. Human Pathology, 2009. 40(9): p. 1213-1223. 
64. Vang, R., M. Shih Ie, and R.J. Kurman, Ovarian low-grade and high-grade 
serous carcinoma: pathogenesis, clinicopathologic and molecular biologic 
features, and diagnostic problems. Adv Anat Pathol, 2009. 16(5): p. 267-82. 
65. Kurman, R.J. and I.-M. Shih, Molecular pathogenesis and extraovarian 
origin of epithelial ovarian cancer—Shifting the paradigm. Human 
Pathology, 2011. 42(7): p. 918-931. 
66. Kurman, R.J., Origin and molecular pathogenesis of ovarian high-grade 
serous carcinoma. Ann Oncol, 2013. 24 Suppl 10: p. x16-21. 
67. Gershenson, D.M., et al., Recurrent low-grade serous ovarian carcinoma is 
relatively chemoresistant. Gynecologic Oncology, 2009. 114(1): p. 48-52. 
68. Schmeler, K.M., et al., Neoadjuvant chemotherapy for low-grade serous 
carcinoma of the ovary or peritoneum. Gynecologic Oncology, 2008. 108(3): 
p. 510-514. 
69. Hart, W.R., Mucinous tumors of the ovary: a review. Int J Gynecol Pathol, 
2005. 24(1): p. 4-25. 
70. Fujii, K., et al., Ovarian mucinous tumors arising from mature cystic 
teratomas—a molecular genetic approach for understanding the cellular 
origin. Human Pathology, 2014. 45(4): p. 717-724. 
 208 
 
71. Bowtell, D.D.L., The genesis and evolution of high-grade serous ovarian 
cancer. Nature Reviews, 2010. Cancer. 10(11): p. 803-8. 
72. Ness, R.B., Endometriosis and ovarian cancer: thoughts on shared 
pathophysiology. Am J Obstet Gynecol, 2003. 189(1): p. 280-94. 
73. Bell, D.A., Origins and molecular pathology of ovarian cancer. Mod Pathol, 
2005. 18 Suppl 2: p. S19-32. 
74. Crotzer, D.R., et al., Lack of effective systemic therapy for recurrent clear 
cell carcinoma of the ovary. Gynecol Oncol, 2007. 105(2): p. 404-8. 
75. Takano, M., H. Tsuda, and T. Sugiyama, Clear cell carcinoma of the ovary: 
is there a role of histology-specific treatment? J Exp Clin Cancer Res, 2012. 
31: p. 53. 
76. Cancer Genome Atlas Research, N., Integrated genomic analyses of ovarian 
carcinoma.[Erratum appears in Nature. 2012 Oct 11;490(7419):298]. 
Nature, 2011. 474(7353): p. 609-15. 
77. Cho, K.R. and I.-M. Shih, Ovarian cancer. Annual review of pathology, 
2009. 4: p. 287-313. 
78. Ruscito, I., et al., BRCA1 gene promoter methylation status in high-grade 
serous ovarian cancer patients--a study of the tumour Bank ovarian cancer 
(TOC) and ovarian cancer diagnosis consortium (OVCAD). Eur J Cancer, 
2014. 50(12): p. 2090-8. 
79. Singer, G., et al., Mutations in BRAF and KRAS characterize the 
development of low-grade ovarian serous carcinoma. J Natl Cancer Inst, 
2003. 95(6): p. 484-6. 
80. Sieben, N.L., et al., In ovarian neoplasms, BRAF, but not KRAS, mutations 
are restricted to low-grade serous tumours. J Pathol, 2004. 202(3): p. 336-
40. 
81. Landen, C.N., Jr., M.J. Birrer, and A.K. Sood, Early events in the 
pathogenesis of epithelial ovarian cancer. J Clin Oncol, 2008. 26(6): p. 995-
1005. 
82. Wiegand, K.C., et al., ARID1A mutations in endometriosis-associated 
ovarian carcinomas. N Engl J Med, 2010. 363(16): p. 1532-43. 
83. Merritt, M.A. and D.W. Cramer, Molecular pathogenesis of endometrial and 
ovarian cancer. Cancer Biomark, 2010. 9(1-6): p. 287-305. 
84. Willner, J., et al., Alternate molecular genetic pathways in ovarian 
carcinomas of common histological types. Human Pathology, 2007. 38(4): p. 
607-613. 
85. Schuijer, M. and E.M. Berns, TP53 and ovarian cancer. Hum Mutat, 2003. 
21(3): p. 285-91. 
86. Shelling, A.N., I.E. Cooke, and T.S. Ganesan, The genetic analysis of 
ovarian cancer. British Journal of Cancer, 1995. 72(3): p. 521-7. 
87. Chien, J., et al., TP53 mutations, tetraploidy and homologous recombination 
repair defects in early stage high-grade serous ovarian cancer. Nucleic 
Acids Res, 2015. 
88. Leitao, M.M., et al., Mutation and expression of the TP53 gene in early stage 
epithelial ovarian carcinoma. Gynecologic Oncology, 2004. 93(2): p. 301-
306. 
89. Crum, C.P., et al., The distal fallopian tube: a new model for pelvic serous 
carcinogenesis. Curr Opin Obstet Gynecol, 2007. 19(1): p. 3-9. 
90. Kurman, R.J., et al., Early detection and treatment of ovarian cancer: 
shifting from early stage to minimal volume of disease based on a new model 
 209 
 
of carcinogenesis. American Journal of Obstetrics & Gynecology, 2008. 
198(4): p. 351-6. 
91. Singer, G., et al., Diverse tumorigenic pathways in ovarian serous 
carcinoma. Am J Pathol, 2002. 160(4): p. 1223-8. 
92. Vivanco, I. and C.L. Sawyers, The phosphatidylinositol 3-Kinase AKT 
pathway in human cancer. Nat Rev Cancer, 2002. 2(7): p. 489-501. 
93. Cheaib, B., A. Auguste, and A. Leary, The PI3K/Akt/mTOR pathway in 
ovarian cancer: therapeutic opportunities and challenges. Chinese Journal of 
Cancer, 2015. 34(1): p. 4-16. 
94. Obata, K., et al., Frequent PTEN/MMAC mutations in endometrioid but not 
serous or mucinous epithelial ovarian tumors. Cancer Research, 1998. 
58(10): p. 2095-7. 
95. Saito, M., et al., Allelic imbalance and mutations of the PTEN gene in 
ovarian cancer. International Journal of Cancer, 2000. 85(2): p. 160-165. 
96. Bellacosa, A., et al., Molecular alterations of the AKT2 oncogene in ovarian 
and breast carcinomas. Int J Cancer, 1995. 64(4): p. 280-5. 
97. Shayesteh, L., et al., PIK3CA is implicated as an oncogene in ovarian 
cancer. Nat Genet, 1999. 21(1): p. 99-102. 
98. Reisman, D., S. Glaros, and E.A. Thompson, The SWI/SNF complex and 
cancer. Oncogene, 2009. 28(14): p. 1653-68. 
99. Geisler, J.P., et al., Frequency of BRCA1 dysfunction in ovarian cancer. J 
Natl Cancer Inst, 2002. 94(1): p. 61-7. 
100. Hilton, J.L., et al., Inactivation of BRCA1 and BRCA2 in ovarian cancer. J 
Natl Cancer Inst, 2002. 94(18): p. 1396-406. 
101. Alsop, K., et al., BRCA mutation frequency and patterns of treatment 
response in BRCA mutation-positive women with ovarian cancer: a report 
from the Australian Ovarian Cancer Study Group. J Clin Oncol, 2012. 
30(21): p. 2654-63. 
102. Dubeau, L., The cell of origin of ovarian epithelial tumors and the ovarian 
surface epithelium dogma: does the emperor have no clothes? Gynecol 
Oncol, 1999. 72(3): p. 437-42. 
103. Schildkraut, J.M., E. Bastos, and A. Berchuck, Relationship between lifetime 
ovulatory cycles and overexpression of mutant p53 in epithelial ovarian 
cancer. J Natl Cancer Inst, 1997. 89(13): p. 932-8. 
104. Purdie, D.M., et al., Ovulation and risk of epithelial ovarian cancer. Int J 
Cancer, 2003. 104(2): p. 228-32. 
105. Hildreth, N.G., et al., An epidemiologic study of epithelial carcinoma of the 
ovary. Am J Epidemiol, 1981. 114(3): p. 398-405. 
106. Modan, B., et al., Cancer incidence in a cohort of infertile women. American 
Journal of Epidemiology, 1998. 147(11): p. 1038-42. 
107. Choi, J.-H., et al., Gonadotropins and ovarian cancer. Endocrine Reviews, 
2007. 28(4): p. 440-61. 
108. Riman, T., I. Persson, and S. Nilsson, Hormonal aspects of epithelial ovarian 
cancer: review of epidemiological evidence. Clinical Endocrinology, 1998. 
49(6): p. 695-707. 
109. Hartge, P., et al., A case-control study of epithelial ovarian cancer. Am J 
Obstet Gynecol, 1989. 161(1): p. 10-6. 
110. Rossing, M.A., et al., Ovarian tumors in a cohort of infertile women. New 
England Journal of Medicine 1994. 331: p. 771-776. 
 210 
 
111. Sanner, K., et al., Ovarian epithelial neoplasia after hormonal infertility 
treatment: long-term follow-up of a historical cohort in Sweden. Fertility & 
Sterility, 2009. 91(4): p. 1152-8. 
112. Dor, J., et al., Cancer incidence in a cohort of infertile women who 
underwent in vitro fertilization. Fertility & Sterility, 2002. 77(2): p. 324-7. 
113. Fleming, J.S., et al., Incessant ovulation, inflammation and epithelial ovarian 
carcinogenesis: Revisiting old hypotheses. Molecular and Cellular 
Endocrinology, 2006. 247(1–2): p. 4-21. 
114. Vang, R., M. Shih Ie, and R.J. Kurman, Fallopian tube precursors of ovarian 
low- and high-grade serous neoplasms. Histopathology, 2013. 62(1): p. 44-
58. 
115. Karst, A.M. and R. Drapkin, The new face of ovarian cancer modeling: 
better prospects for detection and treatment. F1000 Med Rep, 2011. 3: p. 22. 
116. Folkins, A.K., et al., A candidate precursor to pelvic serous cancer (p53 
signature) and its prevalence in ovaries and fallopian tubes from women with 
BRCA mutations. Gynecologic Oncology, 2008. 109(2): p. 168-173. 
117. Shih, I.-M. and R.J. Kurman, Ovarian tumorigenesis: A proposed model 
based on morphological and molecular genetic analysis. The American 
Journal of Pathology, 2004. 164(5): p. 1511-1518. 
118. Romero, I. and R.C. Bast, Jr., Minireview: human ovarian cancer: biology, 
current management, and paths to personalizing therapy. Endocrinology, 
2012. 153(4): p. 1593-602. 
119. Koshiyama, M., N. Matsumura, and I. Konishi, Recent concepts of ovarian 
carcinogenesis: Type I and Type II. BioMed Research International, 2014. 
2014: p. 11. 
120. Bristow, R.E. and D.S. Chi, Platinum-based neoadjuvant chemotherapy and 
interval surgical cytoreduction for advanced ovarian cancer: a meta-
analysis. Gynecologic Oncology, 2006. 103(3): p. 1070-6. 
121. Schorge, J.O., C. McCann, and M.G. Del Carmen, Surgical Debulking of 
Ovarian Cancer: What Difference Does It Make? Reviews in Obstetrics and 
Gynecology, 2010. 3(3): p. 11-117. 
122. van der Burg, M.E., et al., The effect of debulking surgery after induction 
chemotherapy on the prognosis in advanced epithelial ovarian cancer. 
Gynecological Cancer Cooperative Group of the European Organization for 
Research and Treatment of Cancer. New England Journal of Medicine, 1995. 
332(10): p. 629-34. 
123. Vergote, I., et al., Primary surgery or neoadjuvant chemotherapy followed by 
interval debulking surgery in advanced ovarian cancer. European Journal of 
Cancer, 2011. 47 Suppl 3: p. S88-92. 
124. Oza, A.M., et al., Olaparib combined with chemotherapy for recurrent 
platinum-sensitive ovarian cancer: a randomised phase 2 trial.[Erratum 
appears in Lancet Oncol. 2015 Feb;16(2):e55], [Erratum appears in Lancet 
Oncol. 2015 Jan;16(1):e6]. Lancet Oncology, 2015. 16(1): p. 87-97. 
125. Heffner, L.J. and D.J. Schust, The Reproductive System at a Glance 2010. 
3rd Edition: p. 46-48. 
126. Shi, Q.J., et al., Novel role of human chorionic gonadotropin in 
differentiation of human cytotrophoblasts. Endocrinology, 1993. 132(3): p. 
1387-95. 
 211 
 
127. Berndt, S., et al., Angiogenic activity of human chorionic gonadotropin 
through LH receptor activation on endothelial and epithelial cells of the 
endometrium. FASEB Journal, 2006. 20(14): p. 2630-2. 
128. Morgan, F.J., S. Birken, and R.E. Canfield, The amino acid sequence of 
human chorionic gonadotropin. The alpha subunit and beta subunit. Journal 
of Biological Chemistry, 1975. 250(13): p. 5247-58. 
129. Bahl, O.P., et al., Human chorionic gonadotropin: Amino acid sequence of 
the α and β subunits. Biochemical and Biophysical Research 
Communications, 1972. 48(2): p. 416-422. 
130. Fiddes, J.C. and H.M. Goodman, The cDNA for the beta-subunit of human 
chorionic gonadotropin suggests evolution of a gene by readthrough into the 
3'-untranslated region. Nature, 1980. 286(5774): p. 684-7. 
131. Pierce, J.G. and T.F. Parsons, Glycoprotein hormones: structure and 
function. Annual Review of Biochemistry, 1981. 50: p. 465-95. 
132. Lapthorn, A.J., et al., Crystal structure of human chorionic gonadotropin. 
Nature, 1994. 369(6480): p. 455-61. 
133. Choi, J. and J. Smitz, Luteinizing hormone and human chorionic 
gonadotropin: Origins of difference. Molecular and Cellular Endocrinology, 
2014. 383(1–2): p. 203-213. 
134. Stenman, U.-H., H. Alfthan, and K. Hotakainen, Human chorionic 
gonadotropin in cancer. Clinical Biochemistry, 2004. 37(7): p. 549-61. 
135. Casarini, L., et al., LH and hCG action on the same receptor results in 
quantitatively and qualitatively different intracellular signalling. PLoS ONE 
[Electronic Resource], 2012. 7(10): p. e46682. 
136. Matzuk, M.M., et al., The biological role of the carboxyl-terminal extension 
of human chorionic gonadotropin [corrected] beta-subunit. Endocrinology, 
1990. 126(1): p. 376-83. 
137. Simula, A.P., et al., Luteinizing hormone/chorionic gonadotropin bioactivity 
in the common marmoset (Callithrix jacchus) is due to a chorionic 
gonadotropin molecule with a structure intermediate between human 
chorionic gonadotropin and human luteinizing hormone. Biol Reprod, 1995. 
53(2): p. 380-9. 
138. Rahman, N.A. and C.V. Rao, Recent progress in luteinizing hormone/human 
chorionic gonadotrophin hormone research. Molecular Human 
Reproduction, 2009. 15(11): p. 703-711. 
139. Cole, L.A., New discoveries on the biology and detection of human chorionic 
gonadotropin. Reproductive Biology & Endocrinology, 2009. 7: p. 8. 
140. Ryan, R.J., et al., The glycoprotein hormones: recent studies of structure-
function relationships. Faseb j, 1988. 2(11): p. 2661-9. 
141. Toll, H., et al., Glycosylation patterns of human chorionic gonadotropin 
revealed by liquid chromatography-mass spectrometry and bioinformatics. 
Electrophoresis, 2006. 27(13): p. 2734-46. 
142. Vitt, U.A., S.Y. Hsu, and A.J. Hsueh, Evolution and classification of cystine 
knot-containing hormones and related extracellular signaling molecules. 
Mol Endocrinol, 2001. 15(5): p. 681-94. 
143. Cole, L.A., Biological functions of hCG and hCG-related molecules. 
Reproductive Biology & Endocrinology, 2010. 8: p. 102. 
144. Alam, V., E. Altieri, and F. Zegers-Hochschild, Preliminary results on the 
role of embryonic human chorionic gonadotrophin in corpus luteum rescue 
 212 
 
during early pregnancy and the relationship to abortion and ectopic 
pregnancy. Hum Reprod, 1999. 14(9): p. 2375-8. 
145. Morley, L.C., N. Simpson, and T. Tang, Human chorionic gonadotrophin 
(hCG) for preventing miscarriage. Cochrane Database Syst Rev, 2013. 1: p. 
Cd008611. 
146. Rao, C.V., Uphill battle: The saga of hCG research that led to a paradigm 
shift. The Indian Journal of Medical Research, 2014. 140(Suppl 1): p. S3-S5. 
147. Licht, P., et al., Is human chorionic gonadotropin directly involved in the 
regulation of human implantation? Molecular and Cellular Endocrinology, 
2007. 269(1–2): p. 85-92. 
148. Androutsopoulos, G., P. Gkogkos, and G. Decavalas, Mid-Trimester 
Maternal Serum hCG and Alpha Fetal Protein Levels: Clinical Significance 
and Prediction of Adverse Pregnancy Outcome. Int J Endocrinol Metab, 
2013. 11(2): p. 102-6. 
149. Lei, Z.M., E. Reshef, and V. Rao, The expression of human chorionic 
gonadotropin/luteinizing hormone receptors in human endometrial and 
myometrial blood vessels. J Clin Endocrinol Metab, 1992. 75(2): p. 651-9. 
150. Zygmunt, M., et al., Characterization of human chorionic gonadotropin as a 
novel angiogenic factor. J Clin Endocrinol Metab, 2002. 87(11): p. 5290-6. 
151. Zygmunt, M., et al., Invasion of cytotrophoblastic JEG-3 cells is stimulated 
by hCG in vitro. Placenta, 1998. 19(8): p. 587-93. 
152. Bahado-Singh, R.O., et al., The role of hyperglycosylated hCG in trophoblast 
invasion and the prediction of subsequent pre-eclampsia. Prenat Diagn, 
2002. 22(6): p. 478-81. 
153. Hameed, A., et al., Frequent expression of beta-human chorionic 
gonadotropin (beta-hCG) in squamous cell carcinoma of the cervix. 
International Journal of Gynecological Pathology, 1999. 18(4): p. 381-6. 
154. Gillott, D.J., R.K. Iles, and T. Chard, The effects of beta-human chorionic 
gonadotrophin on the in vitro growth of bladder cancer cell lines. British 
Journal of Cancer, 1996. 73(3): p. 323-6. 
155. Butler, S.A., et al., The increase in bladder carcinoma cell population 
induced by the free beta subunit of human chorionic gonadotrophin is a 
result of an anti-apoptosis effect and not cell proliferation. British Journal of 
Cancer, 2000. 82(9): p. 1553-6. 
156. Wu, W. and A.M. Walker, Human chorionic gonadotropin beta (HCGbeta) 
down-regulates E-cadherin and promotes human prostate carcinoma cell 
migration and invasion. Cancer, 2006. 106(1): p. 68-78. 
157. Cole, L.A., Immunoassay of human chorionic gonadotropin, its free subunits, 
and metabolites. Clinical Chemistry, 1997. 43(12): p. 2233-43. 
158. Franchimont, P., et al., Polymorphism of protein and polypeptide hormones. 
Clinical Endocrinology, 1972. 1(4): p. 315-336. 
159. Boorstein, W.R., N.C. Vamvakopoulos, and J.C. Fiddes, Human chorionic 
gonadotropin beta-subunit is encoded by at least eight genes arranged in 
tandem and inverted pairs. Nature, 1982. 300(5891): p. 419-22. 
160. Hallast, P., K. Rull, and M. Laan, The evolution and genomic landscape of 
CGB1 and CGB2 genes. Mol Cell Endocrinol, 2007. 260-262: p. 2-11. 
161. Talmadge, K., N.C. Vamvakopoulos, and J.C. Fiddes, Evolution of the genes 
for the beta subunits of human chorionic gonadotropin and luteinizing 
hormone. Nature, 1984. 307(5946): p. 37-40. 
 213 
 
162. Bo, M. and I. Boime, Identification of the transcriptionally active genes of 
the chorionic gonadotropin beta gene cluster in vivo. Journal of Biological 
Chemistry, 1992. 267(5): p. 3179-84. 
163. Dirnhofer, S., et al., Expression of the human chorionic gonadotropin-beta 
gene cluster in human pituitaries and alternate use of exon 1. Journal of 
Clinical Endocrinology & Metabolism, 1996. 81(12): p. 4212-7. 
164. Jameson, J.L. and A.N. Hollenberg, Regulation of chorionic gonadotropin 
gene expression. Endocrine Reviews, 1993. 14(2): p. 203-21. 
165. Aldaz-Carroll, L., et al., Specific detection of type II human chorionic 
gonadotropin beta subunit produced by trophoblastic and neoplastic cells. 
Clin Chim Acta, 2015. 444: p. 92-100. 
166. Bellet, D., et al., Malignant transformation of nontrophoblastic cells is 
associated with the expression of chorionic gonadotropin beta genes 
normally transcribed in trophoblastic cells. Cancer Res, 1997. 57(3): p. 516-
23. 
167. Giovangrandi, Y., et al., Analysis of the human CGB/LHB gene cluster in 
breast tumors by real-time quantitative RT-PCR assays. Cancer Letters, 
2001. 168(1): p. 93-100. 
168. Hotakainen, K., et al., Expression Of Human Chorionic Gonadotropin β-
Subunit Type I Genes Predicts Adverse Outcome In Renal Cell Carcinoma. 
The Journal of molecular diagnostics : JMD, 2006. 8(5): p. 598-603. 
169. Newlands, E.S., The management of recurrent and drug-resistant gestational 
trophoblastic neoplasia (GTN). Best Practice & Research in Clinical 
Obstetrics & Gynaecology, 2003. 17(6): p. 905-23. 
170. Utsuki, S., et al., Long-term outcome of intracranial germinoma with hCG 
elevation in cerebrospinal fluid but not in serum. Acta Neurochirurgica, 
2002. 144(11): p. 1151-4; discussion 1154-5. 
171. Bagshawe, K.D., Choriocarcinoma. A model for tumour markers. Acta 
Oncol, 1992. 31(1): p. 99-106. 
172. Iles, R.K., et al., Urinary concentration of human chorionic gonadotrophin 
and its fragments as a prognostic marker in bladder cancer. Br J Urol, 1996. 
77(1): p. 61-9. 
173. Halim, A.B., et al., Urinary beta-HCG in benign and malignant urinary tract 
diseases. Dis Markers, 1995. 12(2): p. 109-15. 
174. Crawford, R.A., et al., The prognostic significance of beta human chorionic 
gonadotrophin and its metabolites in women with cervical carcinoma. J Clin 
Pathol, 1998. 51(9): p. 685-8. 
175. Louhimo, J., et al., Serum HCG beta and CA 72-4 are stronger prognostic 
factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology, 
2004. 66(2): p. 126-31. 
176. Iles, R.K., P.J. Delves, and S.A. Butler, Does hCG or hCGbeta play a role in 
cancer cell biology? Molecular & Cellular Endocrinology, 2010. 329(1-2): p. 
62-70. 
177. Acevedo, H.F. and R.J. Hartsock, Metastatic phenotype correlates with high 
expression of membrane-associated complete beta-human chorionic 
gonadotropin in vivo. Cancer, 1996. 78(11): p. 2388-99. 
178. Sheaff, M.T., et al., beta hCG as a prognostic marker in adenocarcinoma of 
the prostate. Journal of Clinical Pathology, 1996. 49(4): p. 329-32. 
179. Jenkins, B.J., et al., Prediction of response to radiotherapy in invasive 
bladder cancer. British Journal of Urology, 1990. 65(4): p. 345-8. 
 214 
 
180. Szturmowicz, M., et al., The role of human chorionic gonadotropin beta 
subunit elevation in small-cell lung cancer patients. Journal of Cancer 
Research & Clinical Oncology, 1995. 121(5): p. 309-12. 
181. Vartiainen, J., et al., Combination of serum hCG beta and p53 tissue 
expression defines distinct subgroups of serous ovarian carcinoma. 
International Journal of Cancer, 2008. 122(9): p. 2125-9. 
182. Vartiainen, J., et al., Preoperative serum concentration of hCGbeta as a 
prognostic factor in ovarian cancer. Int J Cancer, 2001. 95(5): p. 313-316. 
183. Nowak-Markwitz, E., et al., Expression of beta-human chorionic 
gonadotropin in ovarian cancer tissue. European Journal of Gynaecological 
Oncology, 2004. 25(4): p. 465-9. 
184. Grossmann, M., et al., Measurement of human chorionic gonadotropin-
related immunoreactivity in serum, ascites and tumour cysts of patients with 
gynaecologic malignancies. European Journal of Clinical Investigation, 
1995. 25(11): p. 867-73. 
185. Ind, T., et al., Serum concentrations of cancer antigen 125, placental alkaline 
phosphatase, cancer-associated serum antigen and free beta human 
chorionic gonadotrophin as prognostic markers for epithelial ovarian 
cancer. British Journal of Obstetrics & Gynaecology, 1997. 104(9): p. 1024-
9. 
186. Lenhard, M., et al., Human chorionic gonadotropin and its relation to grade, 
stage and patient survival in ovarian cancer. BMC Cancer, 2012. 12: p. 2. 
187. Jankowska, A., et al., Reduction of human chorionic gonadotropin beta 
subunit expression by modified U1 snRNA caused apoptosis in cervical 
cancer cells. Molecular Cancer, 2008. 7: p. 26. 
188. Butler, S.A., et al., The beta-subunit of human chorionic gonadotrophin 
exists as a homodimer. Journal of Molecular Endocrinology, 1999. 22(2): p. 
185-92. 
189. Li, Z., et al., Human chorionic gonadotropin beta induces migration and 
invasion via activating ERK1/2 and MMP-2 in human prostate cancer 
DU145 cells. PLoS One, 2013. 8(2): p. e54592. 
190. Li, Z., et al., Human chorionic gonadotropin beta induces cell motility via 
ERK1/2 and MMP-2 activation in human glioblastoma U87MG cells. J 
Neurooncol, 2013. 111(3): p. 237-44. 
191. Guo, X., et al., Overexpression of the beta subunit of human chorionic 
gonadotropin promotes the transformation of human ovarian epithelial cells 
and ovarian tumorigenesis. American Journal of Pathology, 2011. 179(3): p. 
1385-93. 
192. Rabik, C.A. and M.E. Dolan, Molecular mechanisms of resistance and 
toxicity associated with platinating agents. Cancer Treatment Reviews, 2007. 
33(1): p. 9-23. 
193. McWhinney, S.R., R.M. Goldberg, and H.L. McLeod, Platinum 
Neurotoxicity Pharmacogenetics. Molecular cancer therapeutics, 2009. 8(1): 
p. 10-16. 
194. McGuire, W.P., et al., Cyclophosphamide and cisplatin versus paclitaxel and 
cisplatin: a phase III randomized trial in patients with suboptimal stage 
III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol, 
1996. 23(5 Suppl 12): p. 40-7. 
 215 
 
195. du Bois, A., et al., A randomized clinical trial of cisplatin/paclitaxel versus 
carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer 
Inst, 2003. 95(17): p. 1320-9. 
196. Raja, F.A., N. Chopra, and J.A. Ledermann, Optimal first-line treatment in 
ovarian cancer. Ann Oncol, 2012. 23 Suppl 10: p. 118-27. 
197. The International Collaborative Ovarian Neoplasm, G., Paclitaxel plus 
carboplatin versus standard chemotherapy with either single-agent 
carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with 
ovarian cancer: the ICON3 randomised trial. The Lancet, 2002. 360(9332): 
p. 505-515. 
198. Turner, A. and L. Mascorda, Particle-water interactions of platinum-based 
anticancer drugs in river water and estuarine water. Chemosphere, 2014. 
119: p. 415-422. 
199. Ciarimboli, G., Membrane Transporters as Mediators of Cisplatin Effects 
and Side Effects. Scientifica, 2012. 2012: p. 18. 
200. Andrews, P.A., et al., cis-Diamminedichloroplatinum(II) accumulation in 
sensitive and resistant human ovarian carcinoma cells. Cancer Res, 1988. 
48(1): p. 68-73. 
201. Blair, B.G., et al., Copper transporter 2 regulates the cellular accumulation 
and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res, 2009. 
15(13): p. 4312-21. 
202. Larson, C.A., et al., The role of the mammalian copper transporter 1 in the 
cellular accumulation of platinum-based drugs. Mol Pharmacol, 2009. 75(2): 
p. 324-30. 
203. Katano, K., et al., Acquisition of resistance to cisplatin is accompanied by 
changes in the cellular pharmacology of copper. Cancer Res, 2002. 62(22): 
p. 6559-65. 
204. Samimi, G., et al., Increase in expression of the copper transporter ATP7A 
during platinum drug-based treatment is associated with poor survival in 
ovarian cancer patients. Clinical Cancer Research, 2004. 9(16 Pt 1): p. 5853-
9. 
205. Borst, P., et al., A family of drug transporters: the multidrug resistance-
associated proteins. J Natl Cancer Inst, 2000. 92(16): p. 1295-302. 
206. Eckstein, N., Platinum resistance in breast and ovarian cancer cell lines. 
Journal of Experimental & Clinical Cancer Research, 2011. 30: p. 91. 
207. Zhu, C., J. Raber, and L.A. Eriksson, Hydrolysis process of the second 
generation platinum-based anticancer drug cis-
amminedichlorocyclohexylamineplatinum(II). J Phys Chem B, 2005. 
109(24): p. 12195-205. 
208. Basu, A. and S. Krishnamurthy, Cellular Responses to Cisplatin-Induced 
DNA Damage. Journal of Nucleic Acids, 2010. 2010: p. 16. 
209. Umapathy, P., The chemical and biochemical consequences of the binding of 
the antitumour drug cisplatin and other platinum group metal complexes to 
DNA. Coordination Chemistry Reviews, 1989. 95(2): p. 129-181. 
210. Henkels, K.M. and J.J. Turchi, Induction of Apoptosis in Cisplatin-sensitive 
and -resistant Human Ovarian Cancer Cell Lines. Cancer Research, 1997. 
57(20): p. 4488-4492. 
211. Lokich, J. and N. Anderson, Carboplatin versus cisplatin in solid tumors: an 
analysis of the literature. Ann Oncol, 1998. 9(1): p. 13-21. 
 216 
 
212. Woynarowski, J.M., et al., Oxaliplatin-induced damage of cellular DNA. 
Molecular Pharmacology, 2000. 58(5): p. 920-7. 
213. Saris, C.P., et al., In vitro formation of DNA adducts by cisplatin, lobaplatin 
and oxaliplatin in calf thymus DNA in solution and in cultured human cells. 
Carcinogenesis, 1996. 17(12): p. 2763-9. 
214. Raymond, E., et al., Cellular and Molecular Pharmacology of Oxaliplatin1. 
Molecular Cancer Therapeutics, 2002. 1(3): p. 227-235. 
215. Ahmad, S., Platinum-DNA interactions and subsequent cellular processes 
controlling sensitivity to anticancer platinum complexes. Chemistry & 
Biodiversity, 2010. 7(3): p. 543-66. 
216. Mukhopadhyay, A., et al., PARP inhibitors and epithelial ovarian cancer: an 
approach to targeted chemotherapy and personalised medicine. Bjog, 2011. 
118(4): p. 429-32. 
217. Agarwal, R. and S.B. Kaye, Ovarian cancer: strategies for overcoming 
resistance to chemotherapy. Nat Rev Cancer, 2003. 3(7): p. 502-16. 
218. Hennessy, B.T., R.L. Coleman, and M. Markman, Ovarian cancer. The 
Lancet, 2009. 374(9698): p. 1371-1382. 
219. Siddik, Z.H., Cisplatin: mode of cytotoxic action and molecular basis of 
resistance. Oncogene, 2003. 22(47): p. 7265-79. 
220. Wang, D. and S.J. Lippard, Cellular processing of platinum anticancer 
drugs. Nature Reviews. Drug Discovery, 2005. 4(4): p. 307-20. 
221. Johnson, S.W., et al., Increased platinum-DNA damage tolerance is 
associated with cisplatin resistance and cross-resistance to various 
chemotherapeutic agents in unrelated human ovarian cancer cell lines. 
Cancer Research, 1997. 
222. Chu, G., Cellular responses to cisplatin. The roles of DNA-binding proteins 
and DNA repair. Journal of Biological Chemistry, 1994. 269(2): p. 787-90. 
223. Godwin, A.K., et al., High resistance to cisplatin in human ovarian cancer 
cell lines is associated with marked increase of glutathione synthesis. 
Proceedings of the National Academy of Sciences of the United States of 
America, 1992. 89(7): p. 3070-4. 
224. Ishikawa, T. and F. Ali-Osman, Glutathione-associated cis-
diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from 
leukemia cells. Molecular characterization of glutathione-platinum complex 
and its biological significance. Journal of Biological Chemistry, 1993. 
268(27): p. 20116-20125. 
225. Smyth, J.F., et al., Glutathione reduces the toxicity and improves quality of 
life of women diagnosed with ovarian cancer treated with cisplatin: results of 
a double-blind, randomised trial. Annals of Oncology, 1997. 8(6): p. 569-73. 
226. Gately, D.P. and S.B. Howell, Cellular accumulation of the anticancer agent 
cisplatin: a review. British Journal of Cancer, 1993. 67(6): p. 1171-1176. 
227. Holzer, A.K., G.H. Manorek, and S.B. Howell, Contribution of the major 
copper influx transporter CTR1 to the cellular accumulation of cisplatin, 
carboplatin, and oxaliplatin. Molecular Pharmacology, 2006. 70(4): p. 1390-
4. 
228. Lee, Y.Y., et al., Prognostic value of the copper transporters, CTR1 and 
CTR2, in patients with ovarian carcinoma receiving platinum-based 
chemotherapy. Gynecol Oncol, 2011. 122(2): p. 361-5. 
 217 
 
229. van den Berghe, P.V., et al., Human copper transporter 2 is localized in late 
endosomes and lysosomes and facilitates cellular copper uptake. Biochem J, 
2007. 407(1): p. 49-59. 
230. Safaei, R., et al., The role of copper transporters in the development of 
resistance to Pt drugs. Journal of Inorganic Biochemistry, 2004. 98(10): p. 
1607-1613. 
231. Safaei, R., et al., Abnormal lysosomal trafficking and enhanced exosomal 
export of cisplatin in drug-resistant human ovarian carcinoma cells. 
Molecular Cancer Therapeutics, 2005. 4(10): p. 1595-604. 
232. Gottesman, M.M. and V. Ling, The molecular basis of multidrug resistance 
in cancer: the early years of P-glycoprotein research. FEBS Lett, 2006. 
580(4): p. 998-1009. 
233. Yang, L., et al., Altered microRNA expression in cisplatin-resistant ovarian 
cancer cells and upregulation of miR-130a associated with MDR1/P-
glycoprotein-mediated drug resistance. Oncology Reports, 2012. 28: p. 592-
600. 
234. Ren, L., L. Xiao, and J. Hu, MDR1 and MDR3 genes and drug resistance to 
cisplatin of ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci, 
2007. 27(6): p. 721-4. 
235. Taniguchi, K., et al., A human canalicular multispecific organic anion 
transporter (cMOAT) gene is overexpressed in cisplatin-resistant human 
cancer cell lines with decreased drug accumulation. Cancer Res, 1996. 
56(18): p. 4124-9. 
236. Kool, M., et al., Analysis of expression of cMOAT (MRP2), MRP3, MRP4, 
and MRP5, homologues of the multidrug resistance-associated protein gene 
(MRP1), in human cancer cell lines. Cancer Res, 1997. 57(16): p. 3537-47. 
237. Guminski, A.D., et al., MRP2 (ABCC2) and cisplatin sensitivity in 
hepatocytes and human ovarian carcinoma. Gynecologic Oncology, 2006. 
100(2): p. 239-246. 
238. Materna, V., et al., RNA expression of MDR1/P-glycoprotein, DNA-
topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with 
chemotherapeutic response. Gynecol Oncol, 2004. 94(1): p. 152-60. 
239. Arts, H.J.G., et al., Drug Resistance-associated Markers P-Glycoprotein, 
Multidrug Resistance-associated Protein 1, Multidrug Resistance-associated 
Protein 2, and Lung Resistance Protein as Prognostic Factors in Ovarian 
Carcinoma. Clinical Cancer Research, 1999. 5(10): p. 2798-2805. 
240. Surowiak, P., et al., ABCC2 (MRP2, cMOAT) can be localized in the nuclear 
membrane of ovarian carcinomas and correlates with resistance to cisplatin 
and clinical outcome. Clin Cancer Res, 2006. 12(23): p. 7149-58. 
241. Galluzzi, L., et al., Molecular mechanisms of cisplatin resistance. Oncogene, 
2012. 31(15): p. 1869-83. 
242. Lomonaco, S.L., X.S. Xu, and G. Wang, The Role of Bcl-x(L) Protein in 
Nucleotide Excision Repair–Facilitated Cell Protection Against Cisplatin-
Induced Apoptosis. DNA Cell Biol, 2009. 28(6): p. 285-94. 
243. Bellacosa, A., Functional interactions and signaling properties of 
mammalian DNA mismatch repair proteins. Cell Death Differ, 2001. 8(11): 
p. 1076-92. 
244. Brown, R., et al., hMLH1 expression and cellular responses of ovarian 
tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 1997. 
15(1): p. 45-52. 
 218 
 
245. Aebi, S., et al., Loss of DNA mismatch repair in acquired resistance to 
cisplatin. Cancer Res, 1996. 56(13): p. 3087-90. 
246. Fink, D., et al., The role of DNA mismatch repair in platinum drug 
resistance. Cancer Res, 1996. 56(21): p. 4881-6. 
247. Colton, S.L., et al., The Involvement of Ataxia-telangiectasia Mutated Protein 
Activation in Nucleotide Excision Repair-facilitated Cell Survival with 
Cisplatin Treatment. Journal of Biological Chemistry, 2006. 281(37): p. 
27117-27125. 
248. Li, Q., et al., Association between the level of ERCC-1 expression and the 
repair of cisplatin-induced DNA damage in human ovarian cancer cells. 
Anticancer Research, 2000. 20(2A): p. 645-52. 
249. Saldivar, J.S., et al., Nucleotide excision repair pathway review I: 
implications in ovarian cancer and platinum sensitivity. Gynecologic 
Oncology, 2007. 107(1 Suppl 1): p. S56-71. 
250. Masuda, H., et al., Increased DNA repair as a mechanism of acquired 
resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer 
cell lines. Cancer Research, 1988. 48(20): p. 5713-6. 
251. Masuda, H., et al., Increased removal of DNA-bound platinum in a human 
ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). 
Cancer Research, 1990. 50(6): p. 1863-6. 
252. Dabholkar, M., et al., Messenger RNA levels of XPAC and ERCC1 in ovarian 
cancer tissue correlate with response to platinum-based chemotherapy. 
Journal of Clinical Investigation, 1994. 94(2): p. 703-8. 
253. Saldivar, J.S., et al., Moving toward individualized therapy based on NER 
polymorphisms that predict platinum sensitivity in ovarian cancer patients. 
Gynecologic Oncology, 2007. 107(1, Supplement): p. S223-S229. 
254. Shirota, Y., et al., ERCC1 and thymidylate synthase mRNA levels predict 
survival for colorectal cancer patients receiving combination oxaliplatin and 
fluorouracil chemotherapy. Journal of Clinical Oncology, 2001. 19(23): p. 
4298-304. 
255. Olaussen, K.A., et al., DNA repair by ERCC1 in non-small-cell lung cancer 
and cisplatin-based adjuvant chemotherapy. New England Journal of 
Medicine, 2006. 355(10): p. 983-91. 
256. Dabholkar, M., et al., ERCC1 and ERCC2 expression in malignant tissues 
from ovarian cancer patients. Journal of the National Cancer Institute, 1992. 
84(19): p. 1512-7. 
257. Steffensen, K.D., M. Waldstrom, and A. Jakobsen, The relationship of 
platinum resistance and ERCC1 protein expression in epithelial ovarian 
cancer. International Journal of Gynecological Cancer, 2009. 19(5): p. 820-5. 
258. Steffensen, K.D., et al., Prediction of response to chemotherapy by ERCC1 
immunohistochemistry and ERCC1 polymorphism in ovarian cancer. 
International Journal of Gynecological Cancer, 2008. 18(4): p. 702-10. 
259. Qi, B.-l., et al., Polymorphisms of ERCC1 gene and outcomes in epithelial 
ovarian cancer patients with platinum-based chemotherapy. Chinese Journal 
of Obstetrics & Gynecology, 2013. 48(11): p. 847-52. 
260. Kang, S., et al., Association between excision repair cross-complementation 
group 1 polymorphism and clinical outcome of platinum-based 
chemotherapy in patients with epithelial ovarian cancer. Exp Mol Med, 
2006. 38(3): p. 320-4. 
 219 
 
261. Moggs, J.G., et al., Differential human nucleotide excision repair of paired 
and mispaired cisplatin-DNA adducts. Nucleic Acids Research, 1997. 25(3): 
p. 480-91. 
262. Zamble, D.B., et al., Repair of cisplatin--DNA adducts by the mammalian 
excision nuclease. Biochemistry, 1996. 35(31): p. 10004-13. 
263. Dann, R.B., et al., BRCA1/2 mutations and expression: response to platinum 
chemotherapy in patients with advanced stage epithelial ovarian cancer. 
Gynecologic Oncology, 2012. 125(3): p. 677-682. 
264. Ashworth, A., Drug resistance caused by reversion mutation. Cancer 
Research, 2008. 68(24): p. 10021-3. 
265. Sakai, W., et al., Secondary mutations as a mechanism of cisplatin resistance 
in BRCA2-mutated cancers. Nature, 2008. 451(7182): p. 1116-20. 
266. Suh, D.H., et al., Epigenetic Therapies as a Promising Strategy for 
Overcoming Chemoresistance in Epithelial Ovarian Cancer. J Cancer Prev, 
2013. 18(3): p. 227-34. 
267. Borley, J. and R. Brown, Epigenetic mechanisms and therapeutic targets of 
chemotherapy resistance in epithelial ovarian cancer. Annals of Medicine, 
2015. 47(5): p. 1-11. 
268. Wang, Y.Q., et al., Aberrant methylation of breast and ovarian cancer 
susceptibility gene 1 in chemosensitive human ovarian cancer cells does not 
involve the phosphatidylinositol 3'-kinase-Akt pathway. Cancer Sci, 2010. 
101(7): p. 1618-23. 
269. Strathdee, G., et al., A role for methylation of the hMLH1 promoter in loss of 
hMLH1 expression and drug resistance in ovarian cancer. Oncogene, 1999. 
18(14): p. 2335-41. 
270. Zeller, C., et al., Candidate DNA methylation drivers of acquired cisplatin 
resistance in ovarian cancer identified by methylome and expression 
profiling. Oncogene, 2012. 31(42): p. 4567-76. 
271. Gifford, G., et al., The Acquisition of hMLH1 Methylation in Plasma DNA 
after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients. 
Clinical Cancer Research, 2004. 10(13): p. 4420-4426. 
272. Mamenta, E.L., et al., Enhanced replicative bypass of platinum-DNA adducts 
in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Research, 
1994. 54(13): p. 3500-5. 
273. Paul, I., et al., Acquired differential regulation of caspase-8 in cisplatin-
resistant non-small-cell lung cancer. Cell Death Dis, 2012. 3: p. e449. 
274. Johnstone, R.W., A.A. Ruefli, and S.W. Lowe, Apoptosis: A Link between 
Cancer Genetics and Chemotherapy. Cell, 2002. 108(2): p. 153-164. 
275. Olivier, M., M. Hollstein, and P. Hainaut, TP53 Mutations in Human 
Cancers: Origins, Consequences, and Clinical Use. Cold Spring Harb 
Perspect Biol, 2010. 2(1). 
276. Han, J.Y., et al., The relationship between cisplatin-induced apoptosis and 
p53, bcl-2 and bax expression in human lung cancer cells. Korean J Intern 
Med, 1999. 14(1): p. 42-52. 
277. Katayama, H., et al., Phosphorylation by aurora kinase A induces Mdm2-
mediated destabilization and inhibition of p53. Nature Genetics, 2004. 36(1): 
p. 55-62. 
278. Iles, R.K., Ectopic hCGbeta expression by epithelial cancer: malignant 
behaviour, metastasis and inhibition of tumor cell apoptosis. Molecular & 
Cellular Endocrinology, 2007. 260-262: p. 264-70. 
 220 
 
279. Berman, R. and G.G. Steel, Induced and inherent resistance to alkylating 
agents in human small-cell bronchial carcinoma xenografts. British Journal 
of Cancer, 1984. 49(4): p. 431-436. 
280. Berman, R., B. Gusterson, and G.G. Steel, Resistance to alkylating agents 
and tumour differentiation in xenografts of small cell lung cancer. British 
Journal of Cancer, 1985. 51(5): p. 653-8. 
281. Domcke, S., R. Sinha, and D.A. Levine, Evaluating cell lines as tumour 
models by comparison of genomic profiles. Nature communications, 2013. 4: 
p. 2126. 
282. Ince, T.A. and A.D. Sousa, Characterization of twenty-five ovarian tumour 
cell lines that phenocopy primary tumours. Nat Commun, 2015. 6: p. 7419. 
283. Hamilton, T.C., R.C. Young, and R.F. Ozols, Experimental model systems of 
ovarian cancer: applications to the design and evaluation of new treatment 
approaches. Semin Oncol, 1984. 11(3): p. 285-98. 
284. Behrens, B.C., et al., Characterization of a cis-
diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and 
its use in evaluation of platinum analogues. Cancer Res, 1987. 47(2): p. 414-
8. 
285. Stordal, B., et al., BRCA1/2 mutation analysis in 41 ovarian cell lines reveals 
only one functionally deleterious BRCA1 mutation. Molecular Oncology, 
2013. 7(3): p. 567-579. 
286. Yaginuma, Y. and H. Westphal, Abnormal structure and expression of the 
p53 gene in human ovarian carcinoma cell lines. Cancer Res, 1992. 52(15): 
p. 4196-9. 
287. Conover, C.A., et al., Biological characterization of human epithelial 
ovarian carcinoma cells in primary culture: the insulin-like growth factor 
system. Experimental Cell Research, 1998. 238(2): p. 439-49. 
288. Hamilton, T.C., et al., Characterization of a human ovarian carcinoma cell 
line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res, 
1983. 43(11): p. 5379-89. 
289. Fogh, J., W.C. Wright, and J.D. Loveless, Absence of HeLa cell 
contamination in 169 cell lines derived from human tumors. J Natl Cancer 
Inst, 1977. 58(2): p. 209-14. 
290. Fogh, J., J.M. Fogh, and T. Orfeo, One hundred and twenty-seven cultured 
human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst, 
1977. 59(1): p. 221-6. 
291. Langdon, S.P., et al., Characterization and properties of nine human ovarian 
adenocarcinoma cell lines. Cancer Res, 1988. 48(21): p. 6166-72. 
292. Cooke, S.L., et al., Genomic analysis of genetic heterogeneity and evolution 
in high-grade serous ovarian carcinoma. Oncogene, 2010. 29(35): p. 4905-
13. 
293. Buick, R.N., R. Pullano, and J.M. Trent, Comparative properties of five 
human ovarian adenocarcinoma cell lines. Cancer Res, 1985. 45(8): p. 3668-
76. 
294. Hagopian, G.S., et al., Expression of p53 in cisplatin-resistant ovarian 
cancer cell lines: modulation with the novel platinum analogue (1R, 2R-
diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV). Clin Cancer 
Res, 1999. 5(3): p. 655-63. 
 221 
 
295. Shih, I.-M., et al., Assessing tumors in living animals through measurement 
of urinary [beta]-human chorionic gonadotropin. Nat Med, 2000. 6(6): p. 
711-714. 
296. Nowak-Markwitz, E., et al., Localization of human chorionic gonadotropin 
beta subunit transcripts in ovarian cancer tissue. Folia Histochemica et 
Cytobiologica, 2004. 42(2): p. 123-6. 
297. Cory, A.H., et al., Use of an aqueous soluble tetrazolium/formazan assay for 
cell growth assays in culture. Cancer Commun, 1991. 3(7): p. 207-12. 
298. Huang, K.T., Y.H. Chen, and A.M. Walker, Inaccuracies in MTS assays: 
major distorting effects of medium, serum albumin, and fatty acids. 
Biotechniques, 2004. 37(3): p. 406, 408, 410-2. 
299. Nemansky, M., et al., Human endometrial stromal cells generate 
uncombined alpha-subunit from human chorionic gonadotropin, which can 
synergize with progesterone to induce decidualization. J Clin Endocrinol 
Metab, 1998. 83(2): p. 575-81. 
300. Moy, E., et al., Glycoprotein hormone alpha-subunit functions synergistically 
with progesterone to stimulate differentiation of cultured human endometrial 
stromal cells to decidualized cells: a novel role for free alpha-subunit in 
reproduction. Endocrinology, 1996. 137(4): p. 1332-9. 
301. Blithe, D.L., R.G. Richards, and M.C. Skarulis, Free alpha molecules from 
pregnancy stimulate secretion of prolactin from human decidual cells: a 
novel function for free alpha in pregnancy. Endocrinology, 1991. 129(4): p. 
2257-9. 
302. Persons, D.L., et al., Cisplatin-induced activation of mitogen-activated 
protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-
regulated kinase activity increases sensitivity to cisplatin. Clinical Cancer 
Research, 1999. 5(5): p. 1007-14. 
303. O'Toole, S.A., et al., The MTS assay as an indicator of 
chemosensitivity/resistance in malignant gynaecological tumours. Cancer 
Detection & Prevention, 2003. 27(1): p. 47-54. 
304. Gan, P.P., E. Pasquier, and M. Kavallaris, Class III beta-tubulin mediates 
sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer 
Res, 2007. 67(19): p. 9356-63. 
305. Yan, X., et al., Increased expression of annexin A3 is a mechanism of 
platinum resistance in ovarian cancer. Cancer Res, 2010. 70(4): p. 1616-24. 
306. Chaney, S.G., et al., Recognition and processing of cisplatin- and 
oxaliplatin-DNA adducts. Crit Rev Oncol Hematol, 2005. 53(1): p. 3-11. 
307. Faivre, S., et al., DNA strand breaks and apoptosis induced by oxaliplatin in 
cancer cells. Biochemical Pharmacology, 2003. 66(2): p. 225-237. 
308. Zhang, Z., et al., Luteinizing hormone upregulates survivin and inhibits 
apoptosis in ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol, 
2011. 155(1): p. 69-74. 
309. https://www.broadinstitute.org/scientific-
community/science/platforms/proteomics/itraq, 2015. 
310. Ross, P.L., et al., Multiplexed protein quantitation in Saccharomyces 
cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell 
Proteomics, 2004. 3(12): p. 1154-69. 
311. Zhang, W., N. Gan, and J. Zhou, Immunohistochemical investigation of the 
correlation between LIM kinase 1 expression and development and 
 222 
 
progression of human ovarian carcinoma. J Int Med Res, 2012. 40(3): p. 
1067-73. 
312. Jang, K.Y., et al., Expression and prognostic significance of SIRT1 in 
ovarian epithelial tumours. Pathology, 2009. 41(4): p. 366-71. 
313. Yuan, H., L. Su, and W.Y. Chen, The emerging and diverse roles of sirtuins 
in cancer: a clinical perspective. Onco Targets Ther, 2013. 6: p. 1399-416. 
314. Chen, Q., et al., Downregulation of LIMK1 level inhibits migration of lung 
cancer cells and enhances sensitivity to chemotherapy drugs. Oncol Res, 
2013. 20(11): p. 491-8. 
315. Zhang, T., et al., SIRT1 expression is associated with the chemotherapy 
response and prognosis of patients with advanced NSCLC. PLoS One, 2013. 
8(11): p. e79162. 
316. Chu, F., et al., Control of multidrug resistance gene mdr1 and cancer 
resistance to chemotherapy by the longevity gene sirt1. Cancer Res, 2005. 
65(22): p. 10183-7. 
317. Gyorffy, B., et al., Online survival analysis software to assess the prognostic 
value of biomarkers using transcriptomic data in non-small-cell lung cancer. 
PLoS One, 2013. 8(12). 
318. Wasinger, V.C., M. Zeng, and Y. Yau, Current Status and Advances in 
Quantitative Proteomic Mass Spectrometry. International Journal of 
Proteomics, 2013. 2013: p. 12. 
319. Ong, S.-E. and M. Mann, A practical recipe for stable isotope labeling by 
amino acids in cell culture (SILAC). Nat. Protocols, 2007. 1(6): p. 2650-
2660. 
320. Elliott, M.H., et al., Current trends in quantitative proteomics. Journal of 
Mass Spectrometry, 2009. 44(12): p. 1637-1660. 
321. Thelen, J.J., Quantitative Proteomics in Plants: Choices in Abundance. Plant 
Cell, 2007. 19(11): p. 3339–3346. 
322. Lou, Z. and J. Chen, Cellular senescence and DNA repair. Experimental Cell 
Research, 2006. 312(14): p. 2641-2646. 
323. Berndtsson, M., et al., Acute apoptosis by cisplatin requires induction of 
reactive oxygen species but is not associated with damage to nuclear DNA. 
Int J Cancer, 2007. 120(1): p. 175-80. 
324. Jeong, J., et al., SIRT1 promotes DNA repair activity and deacetylation of 
Ku70. Exp Mol Med, 2007. 39(1): p. 8-13. 
325. Oikawa, K., et al., Expression of a novel human gene, human wings apart-
like (hWAPL), is associated with cervical carcinogenesis and tumor 
progression. Cancer Res, 2004. 64(10): p. 3545-9. 
326. Gandhi, R., P. Gillespie, and T. Hirano, Human Wapl Is a Cohesin-binding 
Protein that Promotes Sister Chromatid Resolution in Mitotic Prophase. Curr 
Biol, 2006. 16(24): p. 2406-17. 
327. Arber, S., et al., Regulation of actin dynamics through phosphorylation of 
cofilin by LIM-kinase. Nature, 1998. 393(6687): p. 805-9. 
328. McConnell, B.V., K. Koto, and A. Gutierrez-Hartmann, Nuclear and 
cytoplasmic LIMK1 enhances human breast cancer progression. Mol Cancer, 
2011. 10: p. 75. 
329. Davila, M., et al., LIM kinase 1 is essential for the invasive growth of 
prostate epithelial cells: implications in prostate cancer. J Biol Chem, 2003. 
278(38): p. 36868-75. 
 223 
 
330. Tapia, T., R. Ottman, and R. Chakrabarti, LIM kinase1 modulates function of 
membrane type matrix metalloproteinase 1: implication in invasion of 
prostate cancer cells. Mol Cancer, 2011. 10: p. 6. 
331. Yoshioka, K., et al., A role for LIM kinase in cancer invasion. Proc Natl 
Acad Sci U S A, 2003. 100(12): p. 7247-52. 
332. Deng, C.X., SIRT1, Is It a Tumor Promoter or Tumor Suppressor? Int J Biol 
Sci, 2009. 5(2): p. 147-52. 
333. Hori, Y.S., et al., Regulation of FOXOs and p53 by SIRT1 modulators under 
oxidative stress. PLoS One, 2013. 8(9): p. e73875. 
334. Motta, M.C., et al., Mammalian SIRT1 Represses Forkhead Transcription 
Factors. Cell, 2004. 116(4): p. 551-563. 
335. Chen, X., et al., High levels of SIRT1 expression enhance tumorigenesis and 
associate with a poor prognosis of colorectal carcinoma patients. Sci Rep, 
2014. 4: p. 7481. 
336. Stunkel, W., et al., Function of the SIRT1 protein deacetylase in cancer. 
Biotechnol J, 2007. 2(11): p. 1360-8. 
337. Huffman, D.M., et al., SIRT1 is significantly elevated in mouse and human 
prostate cancer. Cancer Res, 2007. 67(14): p. 6612-8. 
338. Holloway, K.R., et al., SIRT1 positively regulates breast cancer associated 
human aromatase (CYP19A1) expression. Mol Endocrinol, 2013. 27(3): p. 
480-90. 
339. Luo, J., et al., Negative control of p53 by Sir2alpha promotes cell survival 
under stress. Cell, 2001. 107(2): p. 137-48. 
340. Kojima, K., et al., A role for SIRT1 in cell growth and chemoresistance in 
prostate cancer PC3 and DU145 cells. Biochemical and Biophysical 
Research Communications, 2008. 373(3): p. 423-428. 
341. Desgrosellier, J.S. and D.A. Cheresh, Integrins in cancer: biological 
implications and therapeutic opportunities. Nature reviews. Cancer, 2010. 
10(1): p. 9-22. 
342. Dedes, P.G., et al., Expression of matrix macromolecules and functional 
properties of breast cancer cells are modulated by the bisphosphonate 
zoledronic acid. Biochimica et Biophysica Acta (BBA) - General Subjects, 
2012. 1820(12): p. 1926-1939. 
343. Boylan, K.L.M., et al., Quantitative proteomic analysis by iTRAQ(® )for the 
identification of candidate biomarkers in ovarian cancer serum. Proteome 
Science, 2010. 8: p. 31-31. 
344. Waldemarson, S., et al., Protein expression changes in ovarian cancer during 
the transition from benign to malignant. J Proteome Res, 2012. 11(5): p. 
2876-89. 
345. Wu, W., et al., Unbiased Proteomic and Transcript Analyses Reveal that 
Stathmin-1 Silencing Inhibits Colorectal Cancer Metastasis and Sensitizes to 
5-Fluorouracil Treatment. Molecular Cancer Research, 2014. 12(12): p. 
1717-1728. 
346. Syed, N., et al., Silencing of high-mobility group box 2 (HMGB2) modulates 
cisplatin and 5-fluorouracil sensitivity in head and neck squamous cell 
carcinoma. PROTEOMICS, 2015. 15(2-3): p. 383-393. 
347. Nishimura, K., et al., Identification of chemoresistant factors by protein 
expression analysis with iTRAQ for head and neck carcinoma. Br J Cancer, 
2014. 111(4): p. 799-806. 
 224 
 
348. Gillet, L.C., et al., Targeted Data Extraction of the MS/MS Spectra 
Generated by Data-independent Acquisition: A New Concept for Consistent 
and Accurate Proteome Analysis. Molecular & Cellular Proteomics, 2012. 
11(6). 
349. Michalski, A., J. Cox, and M. Mann, More than 100,000 Detectable Peptide 
Species Elute in Single Shotgun Proteomics Runs but the Majority is 
Inaccessible to Data-Dependent LC−MS/MS. Journal of Proteome Research, 
2011. 10(4): p. 1785-1793. 
350. Bourassa, S., et al., Evaluation of iTRAQ and SWATH-MS for the 
Quantification of Proteins Associated with Insulin Resistance in Human 
Duodenal Biopsy Samples. PLoS ONE, 2015. 10(5): p. e0125934. 
351. Morita, E., et al., Attenuated Protein Expression Vectors for Use in siRNA 
Rescue Experiments. BioTechniques, 2012. 0(0): p. 1-5. 
352. Lassus, P., J. Rodriguez, and Y. Lazebnik, Confirming specificity of RNAi in 
mammalian cells. Sci STKE, 2002. 2002(147): p. pl13. 
353. Wang, Z., et al., RNA Interference and Cancer Therapy. Pharmaceutical 
Research, 2011. 28(12): p. 2983-2995. 
354. Solomon, J.M., et al., Inhibition of SIRT1 Catalytic Activity Increases p53 
Acetylation but Does Not Alter Cell Survival following DNA Damage. 
Molecular and Cellular Biology, 2006. 26(1): p. 28-38. 
355. Yang, S.J., et al., Nicotinamide improves glucose metabolism and affects the 
hepatic NAD-sirtuin pathway in a rodent model of obesity and type 2 
diabetes. J Nutr Biochem, 2014. 25(1): p. 66-72. 
356. Süssmuth, S.D., et al., An exploratory double-blind, randomized clinical trial 
with selisistat, a SirT1 inhibitor, in patients with Huntington's disease. 
British Journal of Clinical Pharmacology, 2015. 79(3): p. 465-476. 
357. McDermott, M., et al., In vitro Development of Chemotherapy and Targeted 
Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case 
Studies. Front Oncol, 2014. 4: p. 40. 
358. http://www.biolreprod.org/content/suppl/2010/09/29/ 
biolreprod.110.085910.DC1/biolreprod.110.085910-3.pdf, 2016. 
 
